



(86) Date de dépôt PCT/PCT Filing Date: 2005/09/28
(87) Date publication PCT/PCT Publication Date: 2006/04/06
(85) Entrée phase nationale/National Entry: 2007/03/09
(86) N° demande PCT/PCT Application No.: EP 2005/054893
(87) N° publication PCT/PCT Publication No.: 2006/035051
(30) Priorités/Priorities: 2004/09/28 (EP04104720.0);
2004/10/20 (US60/620,500)

(51) Cl.Int./Int.Cl. *C07K 14/35* (2006.01),
A61K 31/00 (2006.01), *C12N 15/31* (2006.01),
C12N 15/52 (2006.01), *G01N 33/50* (2006.01)
(71) Demandeur/Applicant:
JANSSEN PHARMACEUTICA N.V., BE
(72) Inventeurs/Inventors:
ANDRIES, KOENRAAD JOZEF LODEWIJK MARCEL,
BE;
GOEHLMANN, HINRICH WILHELM HELMUT, BE;
NEEFS, JEAN-MARC EDMOND FERNAND MARIE, BE;
VERHASSELT, PETER KAREL MARIA, BE;
WINKLER, JOHANN, BE;
DE JONGE, MARC RENE, BE;
KOYMANS, LUCIEN MARIA HENRICUS, BE

(54) Titre : DOMAINE DE LIAISON D'ATP SYNTASE BACTERIENNE
(54) Title: A BACTERIAL ATP SYNTHASE BINDING DOMAIN

(57) **Abrégé/Abstract:**

This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.



(21) **2 579 971**

(13) **A1**

(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 April 2006 (06.04.2006)

PCT

(10) International Publication Number
WO 2006/035051 A1

(51) International Patent Classification:

C07K 14/35 (2006.01) **G01N 33/50** (2006.01)
C12N 15/31 (2006.01) **A61K 31/00** (2006.01)
C12N 15/52 (2006.01)

(21) International Application Number:

PCT/EP2005/054893

(22) International Filing Date:

28 September 2005 (28.09.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

04104720.0 28 September 2004 (28.09.2004) EP
60/620,500 20 October 2004 (20.10.2004) US

(71) Applicant (*for all designated States except US*):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ANDRIES, Koenraad, Jozef, Lodewijk, Marcel** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **GÖHLMANN, Hinrich, Wilhelm, Helmut** [DE/NL]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **NEEFS, Jean-Marc, Edmond, Fernand, Marie** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VERHASSELT, Peter, Karel, Maria** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **WINKLER, Johann** [AT/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **DE JONGE, Marc, René** [NL/NL]; MolMo Services BVBA, Campus Blairon 424, B-2300 Turnhout (BE). **KOYMANS, Lucien, Maria, Henricus** [NL/BE]; MolMo Services BVBA, Campus Blairon 424, B-2300 Turnhout (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A BACTERIAL ATP SYNTHASE BINDING DOMAIN

(57) Abstract: This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.



WO 2006/035051 A1

-1-

A BACTERIAL ATP SYNTHASE BINDING DOMAIN

This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also
5 provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial
10 agent, even more particular for treating tuberculosis in a subject.

BACKGROUND OF THE INVENTION

After AIDS, tuberculosis (TB) is the leading cause of adult mortality (2–3 million deaths per year) in the world and is a critical impediment to alleviating global poverty
15 and suffering (1). Factors contributing to the resurgence of the disease include difficulties in implementing anti-TB programs in many countries, the dramatic increase in the number of immunosuppressed individuals—due mainly to HIV infection—and the movement of people through and from areas where TB is endemic. The TB and HIV epidemics fuel one another in co-infected people—currently 11 million adults—
20 increasing both morbidity and mortality (2, 3). In addition, TB is the leading cause of death in HIV-infected people (4).

Although first-line anti-TB drug regimens can achieve more than 90% efficacy rates, their complexity can lead to poor compliance when adequate medical support and TB
25 treatment programs are not available and, in turn, to the emergence of resistance (5). Multidrug-resistant (MDR) strains of TB complicate treatment substantially (6). The Global Alliance for TB Drug Development has recommended that any new treatment should offer at least one of the following three advantages over existing therapies: shortening or simplifying effective treatment of TB; increasing efficacy against MDR-
30 TB; and improving treatment of the latent form of TB infection. Such a new drug would greatly improve patient compliance, thereby reducing the cost of TB treatment programs like the World Health Organization (WHO)'s Directly Observed Treatment Short-course (DOTs) strategy (7).

35 Newer anti-TB candidates currently in preclinical and clinical development tend to be either from existing families of drugs (such as moxifloxacin), or analogs of first-line drugs such as MJH-98-1-81 (from isoniazid), the oxazolidinones, and rifapentine (a

-2-

close analog of rifampin) (8). Although these new drugs may be potent, analog compounds provide only temporary solutions to resistance (9), as they rely on the same mechanism of action as the existing families of drugs.

Antibiotics in general usually inhibit bacterial replication by inhibiting bacterial metabolism through a specific mechanism. For example, isoniazid interferes with the enzymatic machinery that synthesizes mycolic acids, necessary components of the cell wall, while rifampicin interferes with the bacterial machinery for transcribing RNA from DNA. It is accordingly of interest to explore novel methods to identify anti-TB compounds that target different mycobacterial specific aspects of cell growth and replication compared to the known agents.

SUMMARY OF THE INVENTION

This invention provides for isolated mutant atpE proteins, in particular encoded by the amino acid sequences selected from (SEQ ID No.1), (SEQ ID No.2), (SEQ ID No.3), (SEQ ID No.4) and (SEQ ID No.5), an isolated nucleic acid encoding said mutant atpE proteins, in particular selected from the group consisting of (SEQ ID No.6), (SEQ ID No.7), (SEQ ID No.8), (SEQ ID No.9) and (SEQ ID No.10) and a vector comprising the instant nucleic acid. In a particular embodiment the mutant atpE protein is encoded by SEQ ID No.2 and the isolated nucleic acid sequence encoding said protein consists of SEQ ID No.7.

This invention further provides a host-vector system comprising a host cell having therein the instant expression vector.

This invention further provides an isolated cell comprising a mutant atpE protein, wherein said protein induces anti-microbial resistance in the cell.

This invention further provides a method for identifying an anti-microbial compound said method comprising the steps of

- (a) contacting a cell expressing an atpE protein with a test compound under physiological conditions;
- (b) determining whether the test compound interacts with the atpE protein.

This invention further provides a method for evaluating the potential of a test compound to interact with an atpE protein said method comprising;

- (a) using molecular modeling techniques to generate a three-dimensional structure of the atpE protein;

-3-

- (b) employing computational means to perform a fitting operation between the test compound and the three-dimensional structure of the atpE protein; and
- (c) analyzing the results of said fitting operation to quantify the association of the test compound with the three dimensional structure of the atpE protein.

5

It is also an object of the present invention to provide a binding site of an F₀ part of an ATPase comprising at least the amino acids Ala²⁴, Gly²⁷, Phe⁵³, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴ and Phe⁶⁵ of one C subunit; the amino acids Ser¹⁸², Leu¹⁸³, Ser¹⁸⁴, Leu¹⁸⁵, and Arg¹⁸⁶ of one A subunit and said amino acids having the atomic coordinates of any of

10 Tables 3, 4 or 5.

In a further object, the present invention provides the use of the aforementioned binding domain in a method to identify compounds that interact with the F₀ part of an ATPase and to their potential as anti-microbial compounds, in particular in a method to identify

15 anti-mycobacterial compounds.

It is accordingly, an object of the present invention to provide a method of treating a subject with a microbially-based infection, comprising administering to the subject a compound that interacts with the F₀ part of an ATPase, in particular with an atpE

20 protein at the resistance-conferring mutation sites or with the binding site of the present invention. This invention further provides a method for treating a subject afflicted with tuberculosis comprising administering to the subject an agent that interacts with an atpE protein using any of the aforementioned screening methods. In the methods of treatment comprising the use of a compound that interacts with the F₀ part of an ATPase, in

25 particular with an atpE protein, compounds previously known to interact with the F₀ part of an ATPase, and in particular with an atpE protein are to be excluded. More in particular the use of the DARQ J compounds described in (11) in any of the disclosed method of treatments is to be excluded.

30 This invention further provides for a pharmaceutical composition comprising an agent that interacts with an atpE protein in a cell, and a pharmaceutically acceptable carrier. Finally, this invention provides for an article of manufacture comprising a packaging and a pharmaceutical agent, wherein (a) the pharmaceutical agent interacts with an atpE protein in a cell, and (b) the packaging comprises a label indicating the use of the agent

35 for treating a bacterial infection in a subject. In a particular embodiment the present invention provides the use of DARQ J in the manufacture of an anti-microbial medicine.

This and further aspects of the present invention will be discussed in more detail hereinafter.

5 BRIEF DESCRIPTION OF THE DRAWING

- Table. 1 The minimum inhibitory concentrations (MICs) of the lead DARQ compound (J), that inhibited 90% of the growth of different mycobacterial species. the number of strains tested were n=1, unless otherwise indicated.
- Table. 2 The amino acids surrounding the binding site for the DARQ J compound.
- Table. 3 The atomic coordinates for the amino acids surrounding the binding site for the DARQ J compound derived from both the wild type and DARQ J mutant *M. tuberculosis* strain.
- Table 4. The atomic coordinates for the binding site for the DARQ J compound in the wild type *M. tuberculosis*.
- Table 5. The atomic coordinates for the binding site for the DARQ J compound in the DARQ J mutant *M. tuberculosis* strain.
- Table 6. The atomic coordinates for the mutant atpE protein (SEQ ID No.2) of *M. tuberculosis*.
- Table 7. The atomic coordinates for the wild type atpE protein (SEQ ID No.1) of *M. tuberculosis*.
- Fig.1 Absolute configuration of R207910, hereinafter also referred to as J or DARQ J.
- Fig. 2 atpE protein sequence alignments for *M. tuberculosis* and *M. smegmatis* mutants. Mtb_S: drug-sensitive strain of *M. tuberculosis* H37Rv, atpE (1-81). Accession number: Swiss-Prot Q10598 (SEQ ID No.1). Mtb_R: drug-resistant strain of *M. tuberculosis* BK12, atpE (1-81) (SEQ ID

-5-

No.2). Msm_S: drug-sensitive strain of *M. smegmatis*, atpE (1–86). Sequence obtained by the Institute for Genome Research (SEQ ID No.3). Msm_R09 (SEQ ID No.4) and R10 (SEQ ID No.5): drug-resistant strains of *M. smegmatis* atpE (1–86). Sequences obtained in-house.

5 Human: *Homo sapiens*, ATP5G3 (66–142). Accession number: Ensembl ENSP00000284727. Top numbering: *M. tuberculosis* and *M. smegmatis* atpE. Bottom numbering: *H sapiens* ATP5G3 (66-142)

10 Shading indicates amino acid similarity using BLOSUM62 matrix (black = high, grey = medium). Arrows indicate the positions of the point mutations observed in the resistant strains.

Fig. 3 Total cellular ATP-measurement of *M. tuberculosis* in presence of DARQ J, Isoniazid & DCCD. Relative Luminescence Units of Oxyluciferin measured at 526 nm, both in wild type *M. tuberculosis* and DARQ J mutant *M. tuberculosis*.

15

Fig. 4. Ribbon representation of the three C-subunits (A Chain, K Chain and L Chain) and the A subunit (M chain) which form together the binding site for the DARQ J compound.

20

DETAILED DESCRIPTION

Definitions

As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below.

25

"atpE protein" shall mean the C chain of the F₀ subunit of ATPase complex as represented by SwissProt entry Q10598 for *M. tuberculosis*, or a protein having at least 70, 80, 90, 95, 97 or 99% sequence identity to said *M. tuberculosis* sequence.

"F₁F₀ ATPase" also referred to as ATPase, ATP synthase or F₀F₁ ATP ase shall mean a large-multisubunit complex that catalyses the synthesis or hydrolysis of ATP. F₀F₁ ATPases are composed of two domains: an F₁ part, which is extrinsic to the membrane and contains the catalytic sites and an F₀ part which spans the bilayer and contains a proton pore. The ATP ases are found in the plasma membrane of bacteria, the thylakoid membrane of chloroplasts, and the inner membrane of mitochondria where they use the energy of a proton electrochemical gradient to drive ATP synthesis.

30

35

-6-

"Administering" shall mean delivering in a manner, which is effected or performed using any of the various methods and delivery systems known to those skilled in the art. Administering can be performed, for example, topically, intravenously, pericardially, orally, via implant, transmucosally, transdermally, intramuscularly, subcutaneously, intraperitoneally, intrathecally, intralymphatically, intralesionally, or epidurally. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.

"Host cells" include, but are not limited to, bacterial cells, yeast cells, fungal cells, insect cells, and mammalian cells. Bacterial cells can be transfected by methods well-known in the art such as calcium phosphate precipitation, electroporation and microinjection.

"Isolated", with respect to atpE protein, shall mean an atpE protein-containing membrane fragment preparation or other suitable preparation wherein atpE retains its natural function and is free from some or all of the other proteins in its native milieu. It is meant to include membrane preparations comprising the F₀ part of an F₀F₁ ATPase, in particular an F₀ part comprising the mutant atpE proteins of the present invention.

"Bacterial cell" shall mean any bacterial cell. Bacterial cells include, without limitation, cells which are normal, abnormal and transformed, and are exemplified by mycobacteria, in particular *Mycobacterium tuberculosis* and *Mycobacterium smegmatis*, corynebacteria, nocardia, gram-positive bacteria such as for example streptococcus, staphylococcus and enterococcus or gram negative bacteria such as for example *Escherichia coli*, *Haemophilus influenzae* and *Helicobacter pylori*.

The terms "nucleic acid" and "polynucleotide" are used interchangeably herein, and each refers to a polymer of deoxyribonucleotides and/or ribonucleotides. The deoxyribonucleotides and ribonucleotides can be naturally occurring or synthetic analogues thereof.

The term "physiological conditions" shall mean, with respect to a given cell, such conditions, which would normally constitute the cell's biochemical milieu. The cell's biochemical milieu includes, without limitation some or all the proteases to which the cell is normally exposed. Such conditions include, but are not limited, to in vivo conditions.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein, and each means a polymer of amino acid residues. The amino acid residues can be naturally occurring or chemical analogues thereof. Polypeptides, peptides and proteins can also

-7-

include modifications such as glycosylation, lipid attachment, sulfation, hydroxylation, and ADP- ribosylation.

"Subject" shall mean any animal, such as a mammal or a bird, including, without limitation, a cow, a horse, a sheep, a pig, a dog, a cat, a rodent such as a mouse or rat, a
5 turkey, a chicken and a primate. In the preferred embodiment, the subject is a human being.

"Treating" shall include, without limitation, eliminating, reversing the course of, slowing the progression of, reducing the symptoms of, or otherwise ameliorating, a disease in a subject.

10 "Vector" shall mean any nucleic acid vector known in the art. Such vectors include, but are not limited to, plasmid vectors, cosmid vectors, and bacteriophage vectors.

The terms "Candidate substance" and "Test compound" are used interchangeably and refer to a substance that is believed to interact with another moiety, i.e. the atpE protein, as a biological response modifier. For example a representative candidate substance is
15 believed to interact with an atpE protein and is believed to modify the ATPase activity. Exemplary candidate substances that can be investigated using the methods of the present invention include, but are not restricted to peptides, enzymes, enzyme substrates, co-factors, sugars, oligonucleotides, chemical compounds small molecules and monoclonal antibodies.

20 "Modulate" shall mean an increase, decrease or other alteration of any or all chemical and biological activities or properties of a wild type or mutant atpE protein.

"Interact" shall mean detectable interactions between molecules, including "binding" interactions between molecules. Interactions can, for example, be protein-protein or protein-nucleic acid in nature. Such interactions can be detected using art know
25 procedures, for example, yeast two-hybrid assay, immunoprecipitation, SPA-assay or filter binding assays.

As used herein, the term "atomic coordinates" or "structure coordinates" refers to mathematical coordinates that describe the positions of atoms in Protein Data Bank (PDB) format, including X, Y, Z and B for each atom. Those of skilled in the art
30 understand that a set of structure coordinates determined by X-ray crystallography is not without standard error. For the purpose of this invention, any set of structure coordinates for ATPsynthase from any source having a root mean square deviation of non-hydrogen atoms of less than 1.5Å when superimposed on the non-hydrogen atom position of the corresponding atomic coordinates of Tables 3, 4, 5, 6 or 7 are considered
35 substantially identical or homologous. In a more preferred embodiment, any set of

-8-

structure coordinates for ATPsynthase from any source having a root mean square deviation of non-hydrogen atoms of less than 0.75Å when superimposed on the non-hydrogen atom position of the corresponding atomic coordinates of Tables 3, 4, 5, 6 or 7 are considered substantially identical.

5

Embodiments of the Invention

Mutant atpE proteins

This invention provides for isolated mutant atpE proteins, in particular bacterial atpE proteins, more particular mycobacterial atpE proteins, even more particular *M. tuberculosis* or *M. smegmatis* atpE proteins. The mutation is selected from single point mutations, insertions or deletions. In one embodiment of the invention the mutation consist of at least one point mutation located in any one of amino acids 20 to 40, in particular 30 to 40, preferable in amino acid 34 or of amino acids 60 to 75, in particular 62 to 73, preferably in amino acid 69 as shown in the sequence alignment of Fig.2. In a further embodiment the isolated mutant atpE proteins are selected from Mtb_R (SEQ ID No.2), Msm_R09 (SEQ ID No.4) and Msm_R10 (SEQ ID No.5) as shown in Fig.2 or of an amino acid sequence having at least 70, 80, 90, 95, 97 or 98% sequence identity to any of the aforementioned amino acid sequences.

20

This invention further provides an isolated nucleic acid encoding said mutant atpE proteins. In one embodiment said nucleic acid sequence consists of all genes that encode an F₀ part, such as for example described in *J.Biol.Chem*, 1994, Vol.269(10),p.7285-7289, wherein said genes are transcribed from a single promoter and comprise the nucleic acid sequence encoding the mutant atpE protein of the present invention. The nucleic acid can be DNA or RNA, and preferably DNA and are in a further embodiment selected from the nucleic acid sequences encoding Mtb_R (SEQ ID No. 7) Msm_R09 (SEQ ID No.9), Msm_R10 (SEQ ID No.10) or a nucleic acid sequence having at least 70, 80, 90, 95, 97 or 98% sequence identity to any of the aforementioned nucleic acid sequences.

30

The percentage identity of nucleic acid and polypeptide sequences can be calculated using commercially available algorithms which compare a reference sequence with a query sequence. The following programs (provided by the National Center for Biotechnology Information) may be used to determine homologies/identities: BLAST, gapped BLAST, BLASTN and PSI-BLAST, which may be used with default parameters.

35

-9-

The algorithm GAP (Genetics Computer Group, Madison, WI) uses the Needleman and Wunsch algorithm to align two complete sequences that maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used,
5 with a gap creation penalty = 12 and gap extension penalty = 4.

Another method for determining the best overall match between a nucleic acid sequence or a portion thereof, and a query sequence is the use of the FASTDB computer program based on the algorithm of Brutlag et al (Comp. App. Biosci., 6; 237-
10 245 (1990)). The program provides a global sequence alignment. The result of said global sequence alignment is in percent identity. Suitable parameters used in a FASTDB search of a DNA sequence to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, and Window Size=500 or
15 query sequence length in nucleotide bases, whichever is shorter. Suitable parameters to calculate percent identity and similarity of an amino acid alignment are: Matrix=PAM 150, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, and Window
Size=500 or query sequence length in nucleotide bases, whichever is shorter.

20

This invention further provides a vector comprising the instant nucleic acid. In one embodiment the vector is a plasmid vector.

This invention further provides a host-vector system comprising a host cell having
25 therein the instant plasmid vector. The cell can be prokaryotic or eukaryotic, in one embodiment the host cell is a bacterial cell, in particular a mycobacterial cell such as for example *M.tuberculosis* or *M. smegmatis*.

This invention further provides an isolated cell comprising a mutant atpE protein,
30 which protein induces anti-microbial resistance in the cell. In one embodiment the isolated cell consists of a *M. smegmatis* cell transformed with a mutant mycobacterial atpE protein, in particular transformed with a mutant mycobacterial atpE protein wherein the mutation consist of at least one point mutation located in any one of amino acids 20 to 40, in particular 30 to 40, preferable in amino acid 34 or of amino acids 60
35 to 75, in particular 62 to 73, preferably in amino acid 69 as shown in the sequence alignment of Fig.2.

-10-

Screening methods

This invention further provides a method for identifying an anti-microbial compound said method comprising the steps of

- 5 (a) contacting a cell expressing an atpE protein with a test compound under physiological conditions;
(b) determining whether the test compound interacts with the atpE protein.

In one embodiment the atpE protein used in the aforementioned method, consist of a
10 bacterial atpE protein, in particular a mycobacterial protein and is meant to include both the wild type atpE proteins as well as the mutant atpE proteins as described hereinbefore. In a further embodiment of the present invention, the mycobacterial atpE protein used in the aforementioned method consists of a mutant mycobacterial atpE protein according to the invention. In a particular embodiment of the aforementioned
15 assay a host cell transformed with a mutant atpE protein of the invention is used and the interaction of the test compound with said atpE protein is assessed by determining the possible inhibition of the enzymatic activity of the F₁Fo-ATPase comprising said mutant atpE protein. Inhibition of the F₁Fo-ATPase activity is determined using art known procedures, such as for example by adding the substance to a system comprising
20 the F₁Fo-ATPase and ATP as a substrate, with detection of the enzymatic activity by coupling the production of ADP to the oxidation of NADH via pyruvate kinase and lactate hydrogenase reactions.

In one embodiment of the assay, the atpE protein may be employed in a binding assay.
25 Binding assays may be competitive or non-competitive. Such an assay can accommodate the rapid screening of a large number of compounds to determine which compounds, if any, are capable of binding to the polypeptides.

Within this context, the present invention provides a method to identify whether a test compound binds to an isolated atpE protein of the present invention, and is thus a
30 potential anti-microbial compound, said method comprising;

- a) contacting cells expressing the atpE protein wherein such cells do not normally express said atpE protein, with the test compound in the presence and absence of a compound known to bind the atpE protein,
b) determine the binding of the test compound to the atpE protein using the
35 compound known to bind to the atpE protein as a reference.

-11-

Binding of the test compound or of the compound known to bind to the atpE protein, hereinafter also referred to as reference compound, is assessed using art-known methods for the study of protein-ligand interactions. For example, such binding can be measured by employing a labeled substance or reference compound. The test
5 compound or reference compound, in particular compound J (Fig.1) can be labeled in any convenient manner known in the art, *e.g.* radioactively, fluorescently or enzymatically. In a particular embodiment of the aforementioned method, the compound known to bind to the atpE protein, also known as the reference compound is detectably labeled, and . Said label is used to determine the binding of the test
10 compound to the atpE protein. Said reference compound being labeled using a radiolabel, a fluorescent label or an enzymatic label, more preferably a radiolabel.

In an alternative embodiment of the present invention, the aforementioned binding assays are performed on a cellular composition, *i.e.* a cellular extract, a cell fraction or
15 cell organelles comprising an atpE protein as defined hereinbefore. More in particular, the aforementioned binding assays are performed on a cellular composition, *i.e.* a membrane preparation comprising an atpE protein as defined hereinbefore, wherein said cellular composition, *i.e.* membrane preparation is obtained from a *M. smegmatis* cell transformed with a mutant mycobacterial atpE protein, in particular transformed
20 with a mutant mycobacterial atpE protein wherein the mutation consist of at least one point mutation located in any one of amino acids 20 to 40, in particular 30 to 40, preferable in amino acid 34 or of amino acids 60 to 75, in particular 62 to 73, preferably in amino acid 69 as shown in the sequence alignment of Fig.2. Taking the numbering of Mtb_S (SEQ ID No.1) or of Mtb_R (SEQ ID No.2) as a reference, the
25 aforementioned regions correspond to amino acids 14 to 34, in particular 24 to 34, preferably in amino acid 28 or to amino acids 54 to 69, in particular 56 to 67, preferably to amino acid 63.

In one embodiment the binding assays are performed using membrane preparations.
30 These membrane preparations can be used in conventional filter-binding assays (*eg.* Using Brandel filter assay equipment) or in high throughput Scintillation Proximity type binding assays (SPA and Cytostar-T flashplate technology; Amersham Pharmacia Biotech) to detect binding of radio-labelled atpE ligands (including ³H labelled DARQs) and displacement of such radio-ligands by competitors for the binding site.
35 Radioactivity can be measured with Packard Topcount, or similar instrumentation, capable of making rapid measurements from 96-, 384-, 1536- microtitre well formats. SPA/Cytostar-T technology is particularly amenable to high throughput screening and

-12-

therefore this technology is suitable to use as a screen for compounds able to displace standard ligands.

Another approach to study binding of ligands to atpE protein in an environment approximating the native situation makes use of a surface plasmon resonance effect exploited by the Biacore instrument (Biacore). atpE protein in membrane preparations or whole cells could be attached to the biosensor chip of a Biacore and binding of ligands examined in the presence and absence of compounds to identify competitors of the binding site.

Molecular Modeling

This invention further provides a method for evaluating the potential of a test compound to interact with an atpE protein said method comprising;

- (a) using molecular modeling techniques to formulate a three dimensional structure of the atpE protein;
- (b) employing computational means to perform a fitting operation between the test compound and the three-dimensional structure of the atpE protein; and
- (c) analyzing the results of said fitting operation to quantify the association of the test compound with the three dimensional structure of the atpE protein.

Molecular modeling techniques are known in the art, including both hardware and software appropriate for creating and utilizing models of receptors and enzyme conformations.

Numerous computer programs are available and suitable for the processes of computer modeling, model building and computationally identifying, selecting and evaluating potential atpE interacting compounds in the methods described herein. These include for example, GRID (available from Oxford University, UK), MCSS (available from Accelrys, Inc., San Diego, CA), AUTODOCK (available from Oxford Molecular Group), FLEX X (available from Tripos, St. Louis, MO), DOCK (available from University of California, San Francisco, CA), CAVEAT (available from University of California, Berkeley), HOOK (available from Accelrys, Inc., San Diego, CA) and 3D database systems such as MACCS-3D (available from MDL Information Systems, San Leandro, CA), UNITY (available from Tripos, St. Louis, MO) and CATALYST (available from Accelrys, Inc., San Diego, CA). Potential candidate substances may also be computationally designed "*de novo*" using software packages as LUDI (available from Biosym Technologies, San Diego, CA), LEGEND (available from

-13-

Accelrys, Inc, San Diego, CA) and LEAPFROG (available from Tripos, St. Louis.MO). Compound deformation energy and electrostatic repulsion, may be analysed using programs such as GAUSSIAN 92, AMBER, QUANTA/CHARMM and INSIGHT II/DISCOVER. These computer evaluation and modeling techniques may be performed
5 on any suitable hardware including for example, workstations available from Silicon Graphics, Sun Microsystems and others. These modeling techniques, methods, hardware and software packages are representative and are not intended to be a comprehensive listing. Other modeling techniques known in the art may also be employed in accordance with this invention. See for example, N.C. Cohen, *Molecular*
10 *Modeling in Drug Design*, Academic Press (1996).

In one embodiment of the present invention, the three-dimensional structure of the atpE protein is generated using the atomic coordinates of the Ile28, Glu61 and Ile63 of *E. coli* (Protein Database 1Q01) +/- a root mean square deviation of the backbone atoms
15 of said amino acids of not more than 10Å, preferably not more than 5 Å.

As provided in the examples hereinafter, it has been an object of the present invention to provide the three-dimensional structure of the atpE protein. Tables 6 and 7 provide the atomic coordinates for the mutant and wild type atpE protein with SEQ ID No.2 and
20 SEQ ID No.1. Thus, in one embodiment the three-dimensional structure of the atpE protein is generated using the atomic coordinates of Tables 6 or 7. In a particular embodiment the three-dimensional structure of the atpE protein is generated using the atomic coordinates of Table 7. The DARQ J compound inhibits the interaction of Arg¹⁸⁶ of the A subunit with Glu⁶¹ of the C-subunit in its deprotonated form. It is
25 accordingly an object of the present invention to provide the use of the atomic coordinates of Tables 6 or 7 in a method to evaluate the potential of a test compound to interact with an atpE protein.

Binding Site

30 In another embodiment the present invention provides the characterization of a binding site in the F₀ part of an ATPase. This binding site, identified as being capable of binding the DARQ J compound, was found to coincide with the regions identified hereinbefore, as the resistance-conferring mutation sites in the atpE proteins of
35 *M.tuberculosis* and *M. smegmatis* (17). Hence, the present invention provides a binding site in the F₀ part of an ATPase characterised in that it comprises the resistance-conferring mutation sites of an atpE protein. The resistance-conferring mutation sites

-14-

as used herein refer to amino acids 14 to 34, in particular 24 to 34 and to amino acids 53 to 69, in particular 56 to 67 of an atpE protein, taking the numbering of Mtb_S (SEQ ID No.1) or of Mtb_R (SEQ ID No.2) as a reference.

5 In a further embodiment the binding site comprises at least the amino acids Ala²⁴, Gly²⁷, Phe⁵³, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴ and Phe⁶⁵ of one C subunit and the amino acids Ser¹⁸², Leu¹⁸³, Leu¹⁸⁵, and Arg¹⁸⁶ of one A subunit (having for the A subunit, the codes Ser 206 – Leu 207 – Leu 209 and Arg 210 in Tables 3, 4 and 5), wherein said amino acids have the atomic coordinates of any of Tables 3, 4 or 5 or homologous structure
10 coordinates comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å, preferably not more than 0.75 Å, when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Tables 3, 4 or 5. In a particular embodiment the binding site comprises amino acids Ala²¹, Gly²⁵ of a first C subunit; amino acids Ala²⁴, Gly²⁷, Phe⁵³, Phe⁵⁴, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴, Phe⁶⁵
15 of a second C subunit; amino acids Met¹⁷, Gly¹⁹, Gly²⁰, Ala²¹, Ile²², Gly²³, Ala²⁴, Gly²⁵, Ile²⁶, Gly²⁷, Asp²⁸, Gly²⁹, Ala³¹, Phe⁵³, Thr⁵⁶, Val⁵⁷, Gly⁵⁸, Leu⁵⁹, Val⁶⁰, Glu⁶¹, Ala⁶², Ala⁶³/Pro⁶³, Tyr⁶⁴, Phe⁶⁵ of a third C subunit and amino acids Leu¹⁸³, Leu¹⁸⁵ and Arg¹⁸⁶ of an A subunit; wherein said amino acids have the atomic coordinates of any of Tables 3, 4 or 5 or homologous structure coordinates comprising a root mean square deviation
20 of non-hydrogen atoms of less than about 1.5 Å, preferably not more than 0.75 Å, when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Tables 3, 4 or 5. In an even more particular embodiment the binding site consists of the amino acids Ala²¹, Gly²⁵ of a first C subunit; amino acids Ala²⁴, Gly²⁷, Phe⁵³, Phe⁵⁴, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴, Phe⁶⁵ of a second C subunit; amino acids Met¹⁷, Gly¹⁹, Gly²⁰, Ala²¹, Ile²², Gly²³, Ala²⁴, Gly²⁵, Ile²⁶, Gly²⁷, Asp²⁸, Gly²⁹, Ala³¹, Phe⁵³,
25 Thr⁵⁶, Val⁵⁷, Gly⁵⁸, Leu⁵⁹, Val⁶⁰, Glu⁶¹, Ala⁶², Ala⁶³/Pro⁶³, Tyr⁶⁴, Phe⁶⁵ of a third C subunit and amino acids Leu¹⁸³, Leu¹⁸⁵, and Arg¹⁸⁶ of an A subunit; wherein said amino acids have the atomic coordinates of any of Tables 3, 4 or 5. In a most particular embodiment the binding site consists of the amino acids Ala²¹, Gly²⁵ of a first C
30 subunit; amino acids Ala²⁴, Gly²⁷, Phe⁵³, Phe⁵⁴, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴, Phe⁶⁵ of a second C subunit; amino acids Met¹⁷, Gly¹⁹, Gly²⁰, Ala²¹, Ile²², Gly²³, Ala²⁴, Gly²⁵, Ile²⁶, Gly²⁷, Asp²⁸, Gly²⁹, Ala³¹, Phe⁵³, Thr⁵⁶, Val⁵⁷, Gly⁵⁸, Leu⁵⁹, Val⁶⁰, Glu⁶¹, Ala⁶², Ala⁶³/Pro⁶³, Tyr⁶⁴, Phe⁶⁵ of a third C subunit and amino acids Leu¹⁸³, Leu¹⁸⁵ and Arg¹⁸⁶ of an A subunit; wherein said amino acids have the atomic coordinates of Table 3.

35

It is accordingly an object of the present invention to evaluate the potential of a test compound to interact with an atpE protein using the atomic coordinates as outlined

-15-

above, in computational screening programs. In one embodiment, the present invention provides a method to evaluate the potential of a test compound to interact with an atpE protein, said method comprising; - molecular modeling techniques to generate the three-dimensional structure of a binding site of an F₀ part of an ATPase; - employing
 5 computational means to perform a fitting operation between the test compound and the three-dimensional structure of the binding site; and - analyzing the results of said fitting operation to quantify the association of the test compound with the three-dimensional structure of the binding site. In a further embodiment of the present invention, the three-dimensional structure of the binding site is generated using the
 10 atomic coordinates of Tables 3, 4 or 5 or homologous structure coordinates comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å, preferably not more than 0.75 Å, when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Tables 3, 4 or 5. In a particular embodiment the three-dimensional structure is generated using the atomic coordinates of the amino
 15 acids Ala²¹, Gly²⁵ of the A Chain of any of Tables 3, 4 or 5; the amino acids Ala²⁴, Gly²⁷, Phe⁵³, Phe⁵⁴, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴, Phe⁶⁵ of the K Chain of any of Tables 3, 4 or 5; the amino acids Met¹⁷, Gly¹⁹, Gly²⁰, Ala²¹, Ile²², Gly²³, Ala²⁴, Gly²⁵, Ile²⁶, Gly²⁷, Asp²⁸, Gly²⁹, Ala³¹, Phe⁵³, Thr⁵⁶, Val⁵⁷, Gly⁵⁸, Leu⁵⁹, Val⁶⁰, Glu⁶¹, Ala⁶², Ala⁶³/Pro⁶³, Tyr⁶⁴, Phe⁶⁵ of the L Chain of any of Tables 3, 4 or 5; and the amino acids Ser²⁰⁶,
 20 Leu²⁰⁷, Leu²⁰⁷, and Arg²¹⁰ of the M Chain of any of Tables 3, 4 or 5.

In this screening, the quality of fit of such compounds to the binding site may be judged either by shape complementarity or by estimated interaction energy (Meng, E.C. et al., J. Coma.Chem 13:505-524 (1992)).

25

Use of Binding Site

The design of compounds that bind to, promote or inhibit the functional activity of atpE according to this invention generally involves consideration of two factors. First, the
 30 compound must be capable of physically and structurally associating with atpE. Non-covalent molecular interactions important in the association of atpE with the compound, include hydrogen bonding, van der Waals and hydrophobic interactions. Second, the compound must be able to assume a conformation that allows it to associate with atpE. Although certain portions of the compound may not directly
 35 participate in the association with atpE, those portions may still influence the overall conformation of the molecule. This, in turn, may have a significant impact on binding affinities, therapeutic efficacy, drug-like qualities and potency. Such conformational

-16-

requirements include the overall three-dimensional structure and orientation of the chemical entity or compound in relation to all or a portion of the active site or other region of atpE or the spacing between functional groups of a compound comprising several chemical entities that directly interact with atpE.

5

The potential, predicted, inhibitory agonist, antagonist or binding effect of a ligand or other compound on atpE may be analyzed prior to its actual synthesis and testing by the use of computer modeling techniques. If the theoretical structure of the given compound suggests insufficient interaction and association between it and atpE,

10

synthesis and testing of the compound may be obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to interact with atpE. In this manner, synthesis of inoperative compounds may be avoided. In some cases, inactive compounds are synthesized predicted on modeling and then tested to develop a SAR (structure-activity

15

relationship) for compounds interacting with a specific region of atpE.

One skilled in the art may use one of several methods to screen chemical entities fragments, compounds, or agents for their ability to associate with atpE and more particularly with the individual binding pockets or active sites of atpE. This process may begin by visual inspection of, for example, the active site on the computer screen based on the atomic coordinates of atpE or atpE complexed with a ligand. Selected chemical entities, compounds, or agents may then be positioned in a variety of orientations, or docked within an individual binding pocket of atpE. Docking may be accomplished using software such as Quanta and Sybyl, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.

25

Specialized computer programs may also assist in the process of selecting chemical entities. These include but are not limited to: GRID (Goodford, P. J., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules," *J. Med. Chem.* 28:849-857 (1985), available from Oxford University, Oxford, UK); MCSS (Miranker, A. and M. Karplus, "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method." *Proteins: Structure, Function and Genetics* 11: 29-34 (1991), available from Molecular Simulations, Burlington, Mass.); AUTODOCK (Goodsell, D. S. and A. J. Olsen, "Automated Docking of Substrates to Proteins by Simulated Annealing" *Proteins: Structure, Function, and Genetics* 8:195-202 (1990), available from Scripps Research Institute, La Jolla, Calif.); and DOCK (Kuntz, I. D. et al., "A Geometric Approach to

30

35

-17-

Macromolecule-Ligand Interactions," *J.-Mol. Biol.* 161:269-288 (1982), available from University of California, San Francisco, Calif.).

5 The use of software such as GRID, a program that determines probable interaction sites between probes with various functional group characteristics and the macromolecular surface, is used to analyze the surface sites to determine structures of similar inhibiting proteins or compounds. The GRID calculations, with suitable inhibiting groups on molecules (e.g., protonated primary amines) as the probe, are used to identify potential hotspots around accessible positions at suitable energy contour levels. The program
10 DOCK may be used to analyze an active site or ligand binding site and suggest ligands with complementary steric properties.

Once suitable chemical entities, compounds, or agents have been selected, they can be assembled into a single ligand or compound or inhibitor or activator. Assembly may
15 proceed by visual inspection of the relationship of the fragments to each other on the three-dimensional image. This may be followed by manual model building using software such as Quanta or Sybyl.

Useful programs to aid in connecting the individual chemical entities, compounds, or
20 agents include but are not limited to: CAVEAT (Bartlett, P. A. et al., "CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules." In *Molecular Recognition in Chemical and Biological Problems*, Special Pub., Royal Chem. Soc., 78, pp. 82-196 (1989)); 3D Database systems such as MACCS-3D (MDL Information Systems, San Leandro, Calif. and Martin, Y.C., "3D Database Searching in
25 Drug Design", *J. Med. Chem.* 35: 2145-2154 (1992); and HOOK (available from Molecular Simulations, Burlington, Mass.).

Several methodologies for searching three-dimensional databases to test pharmacophore hypotheses and select compounds for screening are available. These include the program CAVEAT (Bacon et al., *J. Mol. Biol.* 225:849-858 (1992)). For
30 instance, CAVEAT uses databases of cyclic compounds which can act as "spacers" to connect any number of chemical fragments already positioned in the active site. This allows one skilled in the art to quickly generate hundreds of possible ways to connect the fragments already known or suspected to be necessary for tight binding.

Instead of proceeding to build an inhibitor activator, agonist or antagonist of atpE in a
35 step-wise fashion one chemical entity at a time as described above, such compounds may be designed as a whole or "de novo" using either an empty active site or optionally including some portion(s) of a known molecules. These methods include: LUDI

-18-

(Bohm, H.-J., "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors", *J. ComR. Aid. Molec. Design*, 6, pp. 61-78 (1992), available from Biosym Technologies, San Diego, Calif.); LEGEND (Nishibata, Y. and A. Itai, *Tetrahedron* 47:8985 (1991), available from Molecular Simulations, Burlington, Mass.); and LeapFrog (available from Tripos Associates, St. Louis, Mo.).

For instance, the program LUDI can determine a list of interaction sites into which to place both hydrogen bonding and hydrophobic fragments. LUDI then uses a library of linkers to connect up to four different interaction sites into fragments. Then smaller "bridging" groups such as -CH₂- and -COO- are used to connect these fragments.

For example, for the enzyme DHFR, the placements of key functional groups in the well-known inhibitor methotrexate were reproduced by LUDI. See also, Rotstein and Murcko, *J. Med. Chem.* 36: 1700-1710 (1992).

Other molecular modeling techniques may also be employed in accordance with this invention. See, e.g., Cohen, N. C. et al., "Molecular Modeling Software and Methods for Medicinal Chemistry, *J. Med. Chem.* 33:883-894 (1990). See also, Navia, M. A. and M. A. Murcko, "The Use of Structural Information in Drug Design," *Current Opinions in Structural Biology*, 2, pp. 202-210 (1992).

Once a compound has been designed or selected by the above methods, the affinity with which that compound may bind or associate with atpE may be tested and optimized by computational evaluation and/or by testing biological activity after synthesizing the compound. Inhibitors or compounds may interact with the atpE in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy of the free compound and the average energy of the conformations observed when the compound binds to atpE.

A compound designed or selected as binding or associating with atpE may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with atpE. Such non-complementary (e.g., electrostatic) interactions include repulsive charge-charge, dipole-dipole and charge-dipole interactions. Specifically, the sum of all electrostatic interactions between the inhibitor and atpE when the inhibitor is bound, preferably make a neutral or favorable contribution to the enthalpy of binding. Weak binding compounds will also be designed by these methods so as to determine SAR. See, for example, U. S. Appl. Nos. 60/275,629; 60/331,235; 60/379,617; and, 10/097,249.

-19-

Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interaction. Examples of programs designed for such uses include: Gaussian 92, revision C (M. J. Frisch, Gaussian, Inc., Pittsburgh, Pa.,
5 COPYRGT 1992); AMBER, version 4.0 (P. A. Kollman, University of California at San Francisco, COPYRGT 1994); QUANTA/CHARMM (Molecular Simulations, Inc., Burlington, Mass. COPYRGT 1994); and Insight II/Discover (Biosym Technologies Inc., San Diego, Calif. COPYRGT 1994). Other hardware systems and software packages will be known to those skilled in the art.

10

Once a compound that associates with atpE has been optimally selected or designed, as described above, substitutions may then be made in some of its atoms or side groups in order to improve or modify its binding properties. Generally, initial substitutions are conservative, i.e., the replacement group will have approximately the same size, shape,
15 hydrophobicity and charge as the original group. It should, of course, be understood that components known in the art to alter conformation may be avoided. Such substituted chemical compounds may then be analyzed for efficiency of fit to atpE by the same computer methods described in detail, above.

20

The present invention further provides systems, particularly computer-based systems, which contain the sequence and/or structure coordinates described herein. Such systems are designed to do structure determination and rational drug design for atpE or for the binding site in the F_0 part of the ATPase. The computer-based systems refer to the hardware means, software means and data storage means used to analyze the
25 sequence and/or structure coordinates of the present invention in any of the computer methods described in detail, above. The minimum hardware means of the computer-based system of the present invention comprises a central processing unit (CPU), input means, output means and data storage means. A skilled person can readily appreciate which of the currently available computer-based systems are suitable for use in the
30 present invention.

It is accordingly an object of the present invention to provide computer readable data storage medium containing the structure coordinates described herein. As used herein, "computer readable data storage medium" refers to any medium which can be read or
35 accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy disks, hard disc storage media and magnetic tape; optical

-20-

storage media such as optical discs or CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetical/optical storage media.

Methods of Treatment

5

As already mentioned hereinbefore, it is also an object of the present invention to provide the use of compounds identified using any of the aforementioned screening methods in a method of treating a subject with a microbially-based infection. In general, bacterial pathogens may be classified as either gram-positive or gram-negative pathogens. Antimicrobial compounds with activity against both gram-positive and gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as active against gram-positive and/or gram-negative bacterial pathogens. In particular, the present compounds are active against at least one gram-positive bacterium, preferably against several gram-positive bacteria, more preferably against one or more gram-positive bacteria and/or one or more gram-negative bacteria.

10

15

Examples of gram-positive and gram-negative aerobic and anaerobic bacteria, include Staphylococci, for example *S. aureus*; Enterococci, for example *E. faecalis*; Streptococci, for example *S. pneumoniae*, *S. mutans*, *S. pyogenes*; Bacilli, for example *Bacillus subtilis*; Listeria, for example *Listeria monocytogenes*; Haemophilus, for example *H. influenza*; Moraxella, for example *M. catarrhalis*; Pseudomonas, for example *Pseudomonas aeruginosa*; and Escherichia, for example *E. coli*.

20

Gram-positive pathogens, for example Staphylococci, Enterococci and Streptococci are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from for example a hospital environment once established. Examples of such strains are methicillin resistant *Staphylococcus aureus* (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant *Streptococcus pneumoniae* and multiple resistant *Enterococcus faecium*.

25

30

The compounds of the present invention also show activity against resistant bacterial strains.

The compounds of the present invention are especially active against those bacteria of which the viability depends on proper functioning of F_1F_0 ATP synthase. Without being bound to any theory, it is taught that the activity of the present compounds lies in inhibition of the F_1F_0 ATP synthase, in particular the inhibition of the F_0 complex of the

35

-21-

F₁F₀ ATP synthase, more in particular the inhibition of the proton transfer from Arg186 of the A subunit to Glu61 of the C subunit of the F₀ complex of the F₁F₀ ATP synthase, leading to killing of the bacteria by depletion of the cellular ATP levels of the bacteria. The compounds identified using any of the aforementioned screening methods are particularly active against Gram-positive bacteria, more particular mycobacteria, and most particular against infections caused by *M. africanum*, *M. avium*, *M. bovis*, *M. bovis-BCG*, *M. chelonae*, *M. fortuitum*, *M. gordonae*, *M. intracellulare*, *M. kansasii*, *M. microti*, *M. scrofulaceum*, *M. paratuberculosis*, *M. leprea*, *M. tuberculosis*, *M. ulcerans* and *M. ranae*.

Whenever used hereinbefore or hereinafter, that the compounds can treat a bacterial infection it is meant that the compounds can treat an infection with one or more bacterial strains. When used however, in relation to the use of DARQ J as an anti-microbial compound, anti-microbial is meant to be a compound that can treat an infection with one or more bacterial strains, provided that said bacterial strains are other than mycobacteria.

Bacterial infections which may be treated by the present compounds include, for example, central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients.

This invention further provides a method for treating a subject afflicted with tuberculosis comprising administering to the subject an agent that interacts with an atpE protein.

Pharmaceutical Compositions

This invention further provides for a pharmaceutical composition comprising an agent that interacts with an atpE protein in a cell, and a pharmaceutically acceptable carrier.

-22-

Such agents may be formulated into compositions comprising an agent together with a pharmaceutically acceptable carrier or diluent. The agent may in the form of a physiologically functional derivative, such as an ester or a salt, such as an acid addition salt or basic metal salt, or an N or S oxide. Compositions may be formulated for any suitable route and means of administration. Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, inhalable, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The choice of carrier or diluent will of course depend on the proposed route of administration, which, may depend on the agent and its therapeutic purpose. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, acetylated triglycerides and the like, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Gennaro et al., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 18th Edition, 1990.

-23-

The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

- 5 The exact dosage and frequency of administration of the present compounds depends on the particular compound used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in
10 the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

- Dosage forms or compositions containing active ingredient in the range of 0.25 to 95%
15 with the balance made up from non-toxic carrier may be prepared. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight of the active ingredients, and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 weight % of a pharmaceutically acceptable carrier, all percentages being based on the total
20 composition.

- For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium
25 crosscarmellose, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 1%-95% active ingredient, more preferably 2-50%, most preferably 5-8%.

- 30 Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water,
35 saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like,

-24-

such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, triethanolamine sodium acetate, etc.

5 The percentage of active compound contained in such parental compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.1% to 10% in solution are employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably, the composition will comprise 0.2-2% of the active agent in solution.

10

Finally, this invention provides for an article of manufacture comprising a packaging and a pharmaceutical agent, wherein (a) the pharmaceutical agent interacts with an atpE protein in a cell, and (b) the packaging comprises a label indicating the use of the agent for treating a bacterial infection in a subject. In particular as an anti-mycobacterial
15 medicine.

Throughout this description the terms "standard methods", "standard protocols" and "standard procedures", when used in the context of molecular biology techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such
20 as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.

25 This invention will be better understood by reference to the Experimental Details that follow, but those skilled in the art will readily appreciate that these are only illustrative of the invention as described more fully in the claims that follow thereafter. Additionally, throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe
30 more fully the state of the art to which this invention pertains.

EXPERIMENTAL

Using *Mycobacterium smegmatis* as a surrogate, we discovered a series of DARQs with
5 potent *in vitro* activity against several mycobacteria (11). To date, 20 molecules of the
DARQ series have a minimal inhibitory concentration (MIC) below 0.5 µg/ml against
Mycobacterium tuberculosis H37Rv, and for three of these the anti-mycobacterial
activity was confirmed in the *in vivo* mouse model.

10 Structurally and mechanistically, DARQs are very different from both fluoroquinolones
(including methoxyquinolones) and other quinoline classes, including mefloquine and
its analogs, 4-methylquinolines and 4-quinolyldhydrazones (12-16). One of the major
structural differences between DARQs and other quinolone or quinoline classes is the
specificity of the functionalized lateral (3') chain borne by the DARQ class. In addition,
15 the lack of mycobacterial cross-resistance with existing chemical classes points to a
different mechanism of action.

The lead compound of the DARQs, hereinafter referred to as J or DARQ J(Fig.1), was
found to have an unique spectrum of potent and selective anti-mycobacterial activity *in*
vitro (Table 1). The median MIC, obtained for the laboratory strain H37Rv and six fully
20 susceptible isolates was 0.060 µg/ml, versus 1.00 µg/ml for rifampin. J demonstrated
similar *in vitro* efficacy against *M. tuberculosis* clinical isolates resistant to the first-line
TB agents rifampin, streptomycin, ethambutol and pyrazinamide; and the second-line
TB agent moxifloxacin. For eight clinical isolates resistant to isoniazid, the median
MIC was 0.010 µg/ml. The lack of cross-resistance with currently used anti-TB agents
25 suggested that J may retain activity against MDR-TB strains. Indeed, using the
BACTEC™ culture system, a clear concentration-dependent inhibition of bacterial
growth was seen when MDR-TB strains were exposed to fixed concentrations of J. Out
of the 30 isolates of MDR-TB, 13 (43%) were found to be susceptible to 0.100 µg/ml of
J and 17 (57%) were susceptible to 0.010 µg/ml of J. A similar high degree of
30 susceptibility (MIC below 0.010 µg/ml) was seen for only one of 10 additional fully
drug-susceptible strains, when tested using the BACTEC™ system, while all strains
were susceptible to 0.100 µg/ml of J.

Potent activity was also demonstrated against other mycobacterial species including
Mycobacterium bovis and *Mycobacterium kansasii*, as well as species naturally
35 resistant to many other anti-TB agents and involved in opportunistic infections, such as
Mycobacterium avium complex (MAC), *Mycobacterium abscessus*, *Mycobacterium*
fortuitum and *Mycobacterium marinum* (Table 1).

-26-

Surprisingly, the activity of J appeared to be specific for mycobacteria. J was barely active against species close to mycobacteria such as *Corynebacterium* (MIC 4.00 µg/ml) and *Nocardia* (MIC > 4.00 µg/ml) and not active against other organisms including Gram positive *Streptococcus pneumoniae*, *Staphylococcus aureus*—including methicillin-resistant strains (MIC > 32 µg/ml)—and *Enterococcus faecalis*, or Gram negative *Escherichia coli*, *Haemophilus influenzae*, and *Helicobacter pylori*.

Exposure of *M. tuberculosis* in log-phase growth to concentrations of J at 100 x MIC resulted in a 10^3 log reduction in bacterial counts after 12 days, indicating that J has bactericidal activity *in vitro*. The effect of J on stationary phase tubercle bacilli has not yet been studied.

Isolation of mutants, cross-resistance and postulated drug target

By investigating mycobacterial resistance, we aimed to identify the molecular drug target and propose a mechanism of action. Resistant mutants of *M. tuberculosis* and *M. smegmatis* were derived by *in vitro* selection at inhibitory concentrations of J, in order to:

- quantify the proportion of resistant mutants in mycobacteria (with rifampin as a control)
- assess the resistance pattern of resistant mutants (including cross-/non-cross-resistance to quinolones)
- investigate the mechanism of action.

From selection experiments, the proportion of mutants with reduced sensitivity to J was 5×10^{-7} and 2×10^{-8} at MIC x 4, and 5×10^{-8} and 1×10^{-8} at MIC x 8 for *M.*

tuberculosis and *M. smegmatis*, respectively (supporting online text). In the case of *M. tuberculosis*, these proportions were comparable to those of mutants resistant to rifampin (10^{-7} to 10^{-8}) and indicates that naturally-occurring resistance to J is rare. In addition, the sensitivity of the *M. tuberculosis* strains resistant to J remained unchanged to the anti-TB agents isoniazid, rifampin, streptomycin, amikacin, ethambutol and moxifloxacin. Further analysis of *M. tuberculosis* and *M. smegmatis* mutants with a reduced susceptibility to J showed that there were no mutations in the DNA gyrase regions *gyrA* and *gyrB*, sequences in which quinolone resistance typically develops. This confirms that the molecular target for J is different from that of the fluoroquinolones.


One approach to determining the molecular target for J and inferring a mechanism of action is to identify and compare resistance-conferring mutations in sensitive and

-27-

resistant strains of *M. tuberculosis* and *M. smegmatis*. The genomes of the resistant *M. tuberculosis* strain BK12 and the two resistant *M. smegmatis* strains R09 and R10, as well as the parental *M. smegmatis*, were sequenced to near completion. We identified resistance-conferring mutations by comparative analysis of the genome sequences of sensitive and resistant strains of *M. tuberculosis* and *M. smegmatis* (Fig. 2). We showed that the only gene affected in all three independent mutants versus corresponding parental wild-type encodes for *atpE*, a part of the F0 subunit of ATP synthase. This suggests that *atpE* is responsible for resistance to J in the mutant strains, indicating that J inhibits a new *M. tuberculosis* target, the proton pump of ATP synthase.

Complementation studies were performed to show that the mutant *atpE* gene is responsible for resistance to J and by direct inference that the *atpE* gene product is the target of J in mycobacteria. Given the fact that it is known that all genes of the ATP synthase operon have to be expressed in a coordinated way, i.e. all genes that encode the F0 part have to be expressed from the same location, we amplified the F0 part of the operon from the resistant *M. smegmatis* strain (D32V) and selected clones that did not acquire additional mutations through the PCR process. Wild-type *M. smegmatis* was transformed with a plasmid containing the thus selected mutant F0 fragment. This rendered the cells resistant to J with a MIC practically identical to that of the resistant strain *M. smegmatis* R09 (D32V). In addition, when the plasmid was re-isolated from these transformants and the *atpE* gene was sequenced, it was shown to have remained the mutant allele (D32V).

The actual effect of DARQ J on ATP production in *M. tuberculosis* was further demonstrated by measuring the effect of J on the total cellular ATP present in the mycobacteria using the ATP Bioluminescence Luciferase Assay Kit HS II of Roche. This assay is based on the ATP driven conversion of D-Luciferin to Oxyluciferin that can be measured at 526 nm.



Briefly, the effect of DARQ J on total ATP was tested in both wild type *M. tuberculosis* and the mutant strain. DCCD which is a well known inhibitor of ATP synthase was used as a positive control and isoniazid which is an inhibitor for biosynthesis of certain

-28-

cell wall components, but has no effect on ATP production, was used as a negative control.

As can be seen in Fig.3, treatment of the wild type *M.tuberculosis* with DARQ J, leads to dose dependent decrease in ATP production in these bacteria. In contrast isoniazid has no effect on ATP production. As already described hereinbefore, exposing these bacteria to high concentration of the DARQ J raised the diarylquinolines resistant mutants of *M.tuberculosis*. When these resistant *M.tuberculosis* were treated with DARQ J these bacteria did not show any decrease in the ATP production even at 100 times the Minimal Inhibitory Concentration (MIC) of this compound. In contrast DCCD was able to block the ATP production in these bacilli suggesting that DARQ J and DCCD have different binding pockets in ATP synthases.

Computer modeling and identification of the DARQ J binding region

To further investigate the different mode of action of DCCD and DARQ J, a computer generated 3D model of the ATP synthase for both the wild type and DARQ J mutant *M.tuberculosis* were generated. The atomic coordinates provided in Tables 4 and 5 were computed by preparing a model of the 3D structure of the published amino acid sequences P63691 and AJ865377. The actual DARQ J binding site was found to be located at the contact area of the A and C subunits, more in particular around Amino Acid 'Arg 210' of the A subunit and 'Glu 61' of the C subunit, as referred to in tables 3, 4 or 5. This fits nicely with the results seen for the screening of resistance-conferring mutations in sensitive and resistant strains of *M. tuberculosis* and *M. smegmatis*, described above.

The model is based on optimization of the relative placement of the A- and C helices of the ATPase structure and the orientation of the amino acids back-bone and side-chain towards minimal computed internal strain. The geometry was obtained by means of a number of molecular dynamics simulation cycles and molecular mechanics relaxations starting from previously published general helix geometry of a different organism [*E-Coli* PDB entry code 1C17 - V.K. Rastogi and M.E. Girvin, *Nature*, 402, 263-268 (1999)]. Molecular dynamics and geometry relaxation were both performed with a forcefield parameterization based on MMFF94s [Halgren, T.A. (1996), *J. Comput. Chem.*, 17, 490-519], but any state of the art molecular dynamics software could be employed [Berendsen, H.J.C., van der Spoel, D. and van Drunen, R., *Comp. Phys. Comm.* 91 (1995), 43-56; Lindahl, E., Hess, B. and van der Spoel, D., *J. Mol. Mod.* 7

-29-

(2001) 306-317.] followed by a suitable geometry optimization [J. W. Ponder and F. M. Richards, J. Comput. Chem., 8, 1016-1024 (1987).].

5 The computed coordinates in the tables 3, 4 and 5 comprise the part (with 30 Angstrom radius volume) of the predicted structure of the region considered relevant for inhibition of the MTB ATPase activity in these enzymes, based on the proposed mode of inhibition and on the occurrence of resistance inducing point mutations in biological assays.

10 Discussion

The DARQ J is a member of a new chemical class of anti-TB agents with an MIC equal to or lower than that of reference compounds. Its spectrum is unique in its specificity to mycobacteria, including atypical species important in humans; MAC, *M. kansasii* and the fast growers *M. fortuitum* and *M. abscessus*. This anti-mycobacterial-specific
15 spectrum differs from that of isoniazid, which has no activity against MAC. The clinical use of J will be highly targeted to the treatment of TB and mycobacterial infections. The inability of J to inhibit non-mycobacteria should translate into less selective pressure and a lower risk of resistance developing in other bacterial species, when compared with antibiotics with broader spectra (9).

20 The target and mechanism of action of J is different from that of other anti-TB agents. A comparison of the sequences of ATP synthases of different bacteria and of eukaryotic ATP synthase, and in particular of the C chain of the F₀ subunit of the ATPase complex, together with the 3D modelling of the ATP synthases of the wild type and mutant *M. tuberculosis*, provides a rationale for the specificity of the antibacterial
25 spectrum and, to a lesser extent, the safety profile.

The dynamics study performed on the constructed Mycobacterium ATPase models show that in these structures a cavity (the binding site according to the atomic coordinates of Table 3) exists on the contact area of the A and C subunits (around
30 Amino Acid 'Arg 210' of the A subunit and 'Glu 61' of the C subunit). The tables 4 and 5 provide the coordinates of two studied variants of the atoms surrounding this site, and their average position. The DARQ J inhibitor is able to interfere with the normal proton transfer step involving these two amino acids by prohibiting these two amino-acids to interact. The stereospecificity of DARQ J can be understood from the asymmetry of the
35 predicted binding site; the active chiral enantiomer accommodates this cavity optimally, other forms of the compound and variants of ATPase are less well matched.

-30-

The binding site we have derived here is on an entirely different part of the ATPase system than DCCD (DARQs are in the membrane part of the enzyme, DCCD binding occurs approximately 90 Angstrom away inside the cell; based on the PDB structure of a Bovine ATPase crystal "1E79" - published in C.Gibbons, M.G.Montgomery, A.G.W. Leslie, J.E.Walker, Nat.Struct.Biol.,7,1055 (2000). Therefore the atoms that could potentially be involved with DCCD type inhibition of MTB ATPase are not in the region listed in the coordinate tables of the binding site (which only just spans the membrane portion of the enzyme) and, reciprocally, this part of the enzyme involved in the DARQ J mode of inhibition is not present in the published "1E79" structure (which only shows the intracellular part). This difference in binding site may explain the different response of *M. tuberculosis* observed in the *in vitro* ATP production assay.

Notwithstanding the above, older studies with DCCD on mitochondrial ATPases suggest another binding site located around an acidic amino-acid in a lipophilic environment of the F₀ region of the enzyme e.g. by Sebald W, Machleidt W, Wachter E., Proc Natl Acad Sci U S A. 1980 Feb;77(2):785-789. This binding position on mitochondrial ATPases can be considered analogous to the one described for the *Mycobacterium* species here.

20

At the same time, targeting a new mechanism ensures that currently circulating TB strains with resistance mutations to available treatments are not cross-resistant to J. It is obvious from our *in vitro* studies that J has at least as high anti-bacterial effect against MDR-TB isolates, even against those with a broad four-drug resistance, as against normal wild type pan-susceptible strains of *M. tuberculosis*. This observation is important since it clearly demonstrates that there is no cross-resistance with existing anti-TB drugs. Given the further identification of the binding pocket in the membrane part of the ATPase, the results of this study will allow further development of new anti-bacterial compounds, in particular anti-mycobacterial compounds targeting ATP synthesis in these organisms.

30

References

1. Global Alliance for TB Drug Development, *Developing a faster TB cure* (2004;
5 <http://www.tballiance.org>).
2. E. L. Corbett *et al.*, *Arch. Intern. Med.* **163**, 1009 (2003).
3. UNAIDS, *AIDS epidemic update 2003* (2003;
www.unaids.org/Unaid/EN/Resources).
4. World Health Organization, *Tuberculosis* (2004;
10 http://www.who.int/health_topics/tuberculosis/en/).
5. R. J. O'Brien, P. P. Nunn, *Am. J. Respir. Crit. Care Med.* **163**, 1055 (2001).
6. World Health Organization, *Tuberculosis Fact Sheet No 104* (2004;
<http://www.who.int/mediacentre/factsheets/fs104/en/>).
7. A. J. Claxton, J. Cramer, C. Pierce, *Clin. Ther.* **23**, 1296 (2001).
- 15 8. N. Lounis *et al.*, *Antimicrob. Agents Chemother.* **45**, 3482 (2001).
9. A. S. Ginsburg, J. H. Grosset, W. R. Bishai, *Lancet Infect. Dis.* **3**, 432 (2003).
10. C. K. Stover *et al.*, *Nature* **405**, 962 (2000).
11. Guillemont J, Emile G, Patent (International Publication Number. WO
2004/011436. International Publication Date 5 February, 2004).
- 20 12. Barbachyn MR, Brickner SJ, Patent (International Publication Number:
WO 93/09103, International Publication Date: 13 May 1993, International
Application Number: PCT/US92/08267, International Filing Date: 1992).
13. R. Jain, B. Vaitilingam, A. Nayyar, P. B. Palde, *Bioorg. Med. Chem.
Lett.* **13**, 1051 (2003).
- 25 14. C. M. Kunin, W. Y. Ellis, *Antimicrob. Agents Chemother.* **44**, 848
(2000).
15. L. Savini, L. Chiasserini, A. Gaeta, C. Pellerano, *Bioorg. Med Chem* **10**,
2193 (2002).
16. S. Vangapandu, M. Jain, R. Jain, S. Kaur, P. P. Singh, *Bioorg. Med.
30 Chem.* **12**, 2501 (2004).
17. K. Andries *et al.*, *Science* **307**, 223 (2005).

Table 1

Mycobacterial species	MIC (µg/ml)
Median values	
<i>M. tuberculosis</i> , H37Rv	0.030
<i>M. tuberculosis</i> , fully susceptible clinical isolates, 6 strains	0.060
<i>M. tuberculosis</i> resistant to isoniazid, 8 strains	0.010
<i>M. tuberculosis</i> resistant to rifampin	0.030
<i>M. tuberculosis</i> resistant to isoniazid and rifampin, 2 strains	0.030
<i>M. tuberculosis</i> resistant to isoniazid and streptomycin	0.010
<i>M. tuberculosis</i> resistant to ethambutol	0.010
<i>M. tuberculosis</i> resistant to pyrazinamide	0.030
<i>M. tuberculosis</i> resistant to moxifloxacin, 2 strains	0.090
<i>M. bovis</i>	0.003
<i>M. avium</i> complex, 7 strains	0.010
<i>M. kansasii</i>	0.003
<i>M. marinum</i>	0.003
<i>M. fortuitum</i> , 3 strains	0.010
<i>M. fortuitum</i> resistant to fluoroquinolone, 2 strains	0.010
<i>M. abscessus</i>	0.250
<i>M. smegmatis</i> , 7 strains	0.007

-33-

Table 2

Sequence P63691 = SEQ ID No.1 = MYCTUB C-subunit, wt

5 Sequence AJ865377 = SEQ ID No.2 = MYCTUB C-subunit, mutant

Sequence P63654 = SEQ ID No. 11 = MYCTUB A-subunit, wt and mutant

Amino acids surrounding the binding site based on the atomic coordinates of Table 3

10 ## C-subunit 1 ## - A chain

Ala²¹, Gly²⁵

C-subunit 2 ## - K chain

Ala²⁴, Gly²⁷, Phe⁵³, Phe⁵⁴, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴, Phe⁶⁵

15

C-subunit 3 ## - L chain

Met¹⁷, Gly¹⁹, Gly²⁰, Ala²¹, Ile²², Gly²³, Ala²⁴, Gly²⁵, Ile²⁶, Gly²⁷, Asp²⁸, Gly²⁹, Ala³¹,
Phe⁵³, Thr⁵⁶, Val⁵⁷, Gly⁵⁸, Leu⁵⁹, Val⁶⁰, Glu⁶¹, Ala⁶², Ala⁶³/Pro⁶³, Tyr⁶⁴, Phe⁶⁵.

20 ## A subunit ## - M chain

Ser¹⁸², Leu¹⁸³, Leu¹⁸⁵, Arg¹⁸⁶ (having the codes Ser 206 – Leu 207 – Leu 209 and Arg
210 in Tables 3)

-34-

Table 3

5	ATOM	1	N	ALA	A	21	6.113	-13.437	-0.893	1.00	0.00	N
	ATOM	2	CA	ALA	A	21	5.269	-13.569	0.293	1.00	0.00	C
	ATOM	3	C	ALA	A	21	3.954	-12.807	0.141	1.00	0.00	C
	ATOM	4	O	ALA	A	21	2.885	-13.379	0.316	1.00	0.00	O
	ATOM	5	CB	ALA	A	21	5.986	-13.138	1.571	1.00	0.00	C
10	ATOM	6	N	GLY	A	25	-0.067	-14.118	-0.399	1.00	0.00	N
	ATOM	7	CA	GLY	A	25	-1.020	-13.780	0.640	1.00	0.00	C
	ATOM	8	C	GLY	A	25	-2.283	-13.168	0.073	1.00	0.00	C
	ATOM	9	O	GLY	A	25	-3.376	-13.689	0.241	1.00	0.00	O
	ATOM	10	N	ALA	K	24	-1.077	-5.399	11.361	1.00	0.00	N
15	ATOM	11	CA	ALA	K	24	-1.976	-5.787	12.444	1.00	0.00	C
	ATOM	12	C	ALA	K	24	-3.305	-5.041	12.351	1.00	0.00	C
	ATOM	13	O	ALA	K	24	-4.356	-5.642	12.491	1.00	0.00	O
	ATOM	14	CB	ALA	K	24	-1.345	-5.577	13.818	1.00	0.00	C
	ATOM	15	N	GLY	K	27	-5.452	-6.238	9.570	1.00	0.00	N
20	ATOM	16	CA	GLY	K	27	-5.851	-7.589	9.928	1.00	0.00	C
	ATOM	17	C	GLY	K	27	-7.090	-7.620	10.800	1.00	0.00	C
	ATOM	18	O	GLY	K	27	-8.059	-8.290	10.473	1.00	0.00	O
	ATOM	19	N	PHE	K	53	-11.017	-14.602	19.149	1.00	0.00	N
	ATOM	20	CA	PHE	K	53	-9.784	-15.282	18.770	1.00	0.00	C
25	ATOM	21	C	PHE	K	53	-9.069	-14.469	17.700	1.00	0.00	C
	ATOM	22	O	PHE	K	53	-7.894	-14.188	17.837	1.00	0.00	O
	ATOM	23	CB	PHE	K	53	-10.007	-16.732	18.330	1.00	0.00	C
	ATOM	24	CG	PHE	K	53	-8.712	-17.498	18.270	1.00	0.00	C
	ATOM	25	CD1	PHE	K	53	-7.970	-17.568	17.070	1.00	0.00	C
30	ATOM	26	CD2	PHE	K	53	-8.215	-18.156	19.416	1.00	0.00	C
	ATOM	27	CE1	PHE	K	53	-6.755	-18.266	17.025	1.00	0.00	C
	ATOM	28	CE2	PHE	K	53	-7.002	-18.858	19.365	1.00	0.00	C
	ATOM	29	CZ	PHE	K	53	-6.270	-18.911	18.171	1.00	0.00	C
	ATOM	30	N	PHE	K	54	-9.831	-14.105	16.597	1.00	0.00	N
35	ATOM	31	CA	PHE	K	54	-9.260	-13.364	15.476	1.00	0.00	C
	ATOM	32	C	PHE	K	54	-8.595	-12.097	15.996	1.00	0.00	C
	ATOM	33	O	PHE	K	54	-7.423	-11.868	15.755	1.00	0.00	O
	ATOM	34	CB	PHE	K	54	-10.281	-12.983	14.388	1.00	0.00	C
	ATOM	35	CG	PHE	K	54	-10.604	-14.066	13.398	1.00	0.00	C
40	ATOM	36	CD1	PHE	K	54	-9.957	-14.298	12.312	1.00	0.00	C
	ATOM	37	CD2	PHE	K	54	-11.580	-14.820	13.486	1.00	0.00	C
	ATOM	38	CE1	PHE	K	54	-10.285	-15.248	11.337	1.00	0.00	C
	ATOM	39	CE2	PHE	K	54	-11.905	-15.767	12.506	1.00	0.00	C
	ATOM	40	CZ	PHE	K	54	-11.260	-15.979	11.430	1.00	0.00	C
45	ATOM	41	N	VAL	K	57	-5.533	-12.244	18.563	1.00	0.00	N
	ATOM	42	CA	VAL	K	57	-4.302	-12.645	17.888	1.00	0.00	C
	ATOM	43	C	VAL	K	57	-3.748	-11.428	17.142	1.00	0.00	C
	ATOM	44	O	VAL	K	57	-2.561	-11.155	17.226	1.00	0.00	O
	ATOM	45	CB	VAL	K	57	-4.472	-13.892	16.988	1.00	0.00	C
50	ATOM	46	CG1	VAL	K	57	-3.247	-14.150	16.128	1.00	0.00	C
	ATOM	47	CG2	VAL	K	57	-4.733	-15.142	17.831	1.00	0.00	C
	ATOM	48	N	GLY	K	58	-4.660	-10.700	16.389	1.00	0.00	N
	ATOM	49	CA	GLY	K	58	-4.292	-9.496	15.662	1.00	0.00	C
	ATOM	50	C	GLY	K	58	-3.574	-8.479	16.534	1.00	0.00	C
55	ATOM	51	O	GLY	K	58	-2.502	-8.003	16.192	1.00	0.00	O
	ATOM	52	N	GLU	K	61	-0.207	-9.648	18.102	1.00	0.00	N
	ATOM	53	CA	GLU	K	61	0.806	-9.654	17.043	1.00	0.00	C
	ATOM	54	C	GLU	K	61	1.665	-8.402	17.132	1.00	0.00	C
	ATOM	55	O	GLU	K	61	2.877	-8.491	17.077	1.00	0.00	O
60	ATOM	56	CB	GLU	K	61	0.193	-9.817	15.646	1.00	0.00	C
	ATOM	57	CG	GLU	K	61	1.204	-9.858	14.524	1.00	0.00	C

-35-

Table 3 - Continued

	ATOM	58	CD	GLU	K	61	0.555	-10.023	13.178	1.00	0.00	C
	ATOM	59	OE1	GLU	K	61	-0.140	-9.444	12.697	1.00	0.00	O
5	ATOM	60	OE2	GLU	K	61	0.829	-10.852	12.555	1.00	0.00	O
	ATOM	61	N	TYR	K	64	4.232	-8.387	19.897	1.00	0.00	N
	ATOM	62	CA	TYR	K	64	5.349	-9.298	19.625	1.00	0.00	C
	ATOM	63	C	TYR	K	64	6.441	-8.615	18.816	1.00	0.00	C
	ATOM	64	O	TYR	K	64	7.607	-8.776	19.118	1.00	0.00	O
10	ATOM	65	CB	TYR	K	64	4.964	-10.610	18.922	1.00	0.00	C
	ATOM	66	CG	TYR	K	64	4.033	-11.512	19.656	1.00	0.00	C
	ATOM	67	CD1	TYR	K	64	4.038	-11.638	21.058	1.00	0.00	C
	ATOM	68	CD2	TYR	K	64	3.155	-12.305	18.914	1.00	0.00	C
	ATOM	69	CE1	TYR	K	64	3.176	-12.505	21.695	1.00	0.00	C
15	ATOM	70	CE2	TYR	K	64	2.306	-13.187	19.542	1.00	0.00	C
	ATOM	71	CZ	TYR	K	64	2.318	-13.274	20.937	1.00	0.00	C
	ATOM	72	OH	TYR	K	64	1.474	-14.099	21.599	1.00	0.00	O
	ATOM	73	N	PHE	K	65	6.031	-7.871	17.720	1.00	0.00	N
	ATOM	74	CA	PHE	K	65	6.997	-7.165	16.873	1.00	0.00	C
20	ATOM	75	C	PHE	K	65	7.762	-6.104	17.631	1.00	0.00	C
	ATOM	76	O	PHE	K	65	8.941	-5.932	17.396	1.00	0.00	O
	ATOM	77	CB	PHE	K	65	6.392	-6.543	15.630	1.00	0.00	C
	ATOM	78	CG	PHE	K	65	5.963	-7.560	14.648	1.00	0.00	C
	ATOM	79	CD1	PHE	K	65	5.824	-7.882	14.293	1.00	0.00	C
25	ATOM	80	CE1	PHE	K	65	5.429	-8.819	13.385	1.00	0.00	C
	ATOM	81	CZ	PHE	K	65	5.167	-9.448	12.818	1.00	0.00	C
	ATOM	82	CE2	PHE	K	65	5.302	-9.137	13.148	1.00	0.00	C
	ATOM	83	CD2	PHE	K	65	5.697	-8.196	14.053	1.00	0.00	C
	ATOM	84	N	MET	L	17	11.107	-10.632	7.686	1.00	0.00	N
30	ATOM	85	CA	MET	L	17	10.139	-10.826	8.764	1.00	0.00	C
	ATOM	86	C	MET	L	17	8.887	-9.997	8.526	1.00	0.00	C
	ATOM	87	O	MET	L	17	7.804	-10.514	8.641	1.00	0.00	O
	ATOM	88	CB	MET	L	17	10.705	-10.543	10.163	1.00	0.00	C
	ATOM	89	CG	MET	L	17	11.688	-11.601	10.657	1.00	0.00	C
35	ATOM	90	SD	MET	L	17	10.846	-13.177	10.983	1.00	0.00	S
	ATOM	91	CE	MET	L	17	11.507	-14.142	9.610	1.00	0.00	C
	ATOM	92	N	GLY	L	19	7.665	-8.503	5.731	1.00	0.00	N
	ATOM	93	CA	GLY	L	19	6.955	-8.955	4.577	1.00	0.00	C
	ATOM	94	C	GLY	L	19	6.222	-10.215	4.817	1.00	0.00	C
40	ATOM	95	O	GLY	L	19	5.027	-10.326	4.589	1.00	0.00	O
	ATOM	96	N	GLY	L	20	7.028	-11.189	5.274	1.00	0.00	N
	ATOM	97	CA	GLY	L	20	6.545	-12.472	5.462	1.00	0.00	C
	ATOM	98	C	GLY	L	20	5.400	-12.516	6.352	1.00	0.00	C
	ATOM	99	O	GLY	L	20	4.328	-12.921	5.962	1.00	0.00	O
45	ATOM	100	N	ALA	L	21	5.696	-12.094	7.607	1.00	0.00	N
	ATOM	101	CA	ALA	L	21	4.773	-12.247	8.668	1.00	0.00	C
	ATOM	102	C	ALA	L	21	3.441	-11.568	8.418	1.00	0.00	C
	ATOM	103	O	ALA	L	21	2.401	-12.101	8.724	1.00	0.00	O
	ATOM	104	CB	ALA	L	21	5.365	-11.795	9.953	1.00	0.00	C
50	ATOM	105	N	ILE	L	22	3.503	-10.313	7.908	1.00	0.00	N
	ATOM	106	CA	ILE	L	22	2.293	-9.551	7.618	1.00	0.00	C
	ATOM	107	C	ILE	L	22	1.551	-10.212	6.464	1.00	0.00	C
	ATOM	108	O	ILE	L	22	0.349	-10.406	6.550	1.00	0.00	O
	ATOM	109	CB	ILE	L	22	2.557	-8.055	7.417	1.00	0.00	C
55	ATOM	110	CG1	ILE	L	22	2.757	-7.350	8.740	1.00	0.00	C
	ATOM	111	CG2	ILE	L	22	1.424	-7.339	6.679	1.00	0.00	C
	ATOM	112	CD1	ILE	L	22	3.979	-7.733	9.410	1.00	0.00	C
	ATOM	113	N	GLY	L	23	2.307	-10.532	5.345	1.00	0.00	N
	ATOM	114	CA	GLY	L	23	1.730	-11.131	4.153	1.00	0.00	C
60	ATOM	115	C	GLY	L	23	0.953	-12.395	4.473	1.00	0.00	C
	ATOM	116	O	GLY	L	23	-0.212	-12.517	4.150	1.00	0.00	O

-36-

Table 3 - Continued

	ATOM	117	N	ALA	L	24	1.683	-13.360	5.127	1.00	0.00	N
	ATOM	118	CA	ALA	L	24	1.102	-14.632	5.548	1.00	0.00	C
5	ATOM	119	C	ALA	L	24	-0.076	-14.444	6.468	1.00	0.00	C
	ATOM	120	O	ALA	L	24	-1.054	-15.158	6.348	1.00	0.00	O
	ATOM	121	CB	ALA	L	24	2.105	-15.541	6.198	1.00	0.00	C
	ATOM	122	N	GLY	L	25	0.067	-13.469	7.438	1.00	0.00	N
	ATOM	123	CA	GLY	L	25	-0.962	-13.170	8.392	1.00	0.00	C
10	ATOM	124	C	GLY	L	25	-2.268	-12.811	7.747	1.00	0.00	C
	ATOM	125	O	GLY	L	25	-3.300	-13.370	8.064	1.00	0.00	O
	ATOM	126	N	ILE	L	26	-2.180	-11.796	6.833	1.00	0.00	N
	ATOM	127	CA	ILE	L	26	-3.331	-11.306	6.108	1.00	0.00	C
	ATOM	128	C	ILE	L	26	-3.969	-12.476	5.367	1.00	0.00	C
15	ATOM	129	O	ILE	L	26	-5.165	-12.691	5.457	1.00	0.00	O
	ATOM	130	CB	ILE	L	26	-2.991	-10.132	5.190	1.00	0.00	C
	ATOM	131	CG1	ILE	L	26	-2.576	-8.894	5.997	1.00	0.00	C
	ATOM	132	CG2	ILE	L	26	-4.165	-9.810	4.293	1.00	0.00	C
	ATOM	133	CD1	ILE	L	26	-1.882	-7.842	5.205	1.00	0.00	C
20	ATOM	134	N	GLY	L	27	-3.109	-13.215	4.602	1.00	0.00	N
	ATOM	135	CA	GLY	L	27	-3.538	-14.338	3.799	1.00	0.00	C
	ATOM	136	C	GLY	L	27	-4.376	-15.318	4.569	1.00	0.00	C
	ATOM	137	O	GLY	L	27	-5.486	-15.649	4.182	1.00	0.00	O
	ATOM	138	N	ASP	L	28	-3.765	-15.784	5.701	1.00	0.00	N
25	ATOM	139	CA	ASP	L	28	-4.384	-16.736	6.597	1.00	0.00	C
	ATOM	140	C	ASP	L	28	-5.751	-16.267	7.012	1.00	0.00	C
	ATOM	141	O	ASP	L	28	-6.700	-17.036	6.990	1.00	0.00	O
	ATOM	142	CB	ASP	L	28	-3.509	-17.005	7.806	1.00	0.00	C
	ATOM	143	CG	ASP	L	28	-4.194	-17.916	8.775	1.00	0.00	C
30	ATOM	144	OD1	ASP	L	28	-4.748	-17.548	9.761	1.00	0.00	O
	ATOM	145	OD2	ASP	L	28	-4.162	-19.199	8.388	1.00	0.00	O
	ATOM	146	N	GLY	L	29	-5.813	-14.962	7.433	1.00	0.00	N
	ATOM	147	CA	GLY	L	29	-7.031	-14.368	7.892	1.00	0.00	C
	ATOM	148	C	GLY	L	29	-8.136	-14.525	6.883	1.00	0.00	C
35	ATOM	149	O	GLY	L	29	-9.135	-15.175	7.140	1.00	0.00	O
	ATOM	150	N	ALA	L	31	-8.315	-16.031	3.866	1.00	0.00	N
	ATOM	151	CA	ALA	L	31	-8.577	-17.400	3.418	1.00	0.00	C
	ATOM	152	C	ALA	L	31	-9.439	-18.145	4.436	1.00	0.00	C
	ATOM	153	O	ALA	L	31	-10.328	-18.897	4.067	1.00	0.00	O
40	ATOM	154	CB	ALA	L	31	-7.301	-18.191	3.147	1.00	0.00	C
	ATOM	155	N	PHE	L	53	-8.637	-24.705	11.956	1.00	0.00	N
	ATOM	156	CA	PHE	L	53	-8.164	-23.333	11.852	1.00	0.00	C
	ATOM	157	C	PHE	L	53	-6.980	-23.146	12.776	1.00	0.00	C
	ATOM	158	O	PHE	L	53	-5.941	-22.715	12.352	1.00	0.00	O
45	ATOM	159	CB	PHE	L	53	-9.246	-22.283	12.113	1.00	0.00	C
	ATOM	160	CG	PHE	L	53	-8.740	-20.882	11.934	1.00	0.00	C
	ATOM	161	CD1	PHE	L	53	-8.446	-20.390	10.644	1.00	0.00	C
	ATOM	162	CD2	PHE	L	53	-8.535	-20.038	13.053	1.00	0.00	C
	ATOM	163	CE1	PHE	L	53	-7.950	-19.094	10.483	1.00	0.00	C
50	ATOM	164	CE2	PHE	L	53	-8.049	-18.738	12.885	1.00	0.00	C
	ATOM	165	CZ	PHE	L	53	-7.751	-18.269	11.601	1.00	0.00	C
	ATOM	166	N	THR	L	56	-3.737	-24.941	11.832	1.00	0.00	N
	ATOM	167	CA	THR	L	56	-3.150	-24.514	10.589	1.00	0.00	C
	ATOM	168	C	THR	L	56	-2.483	-23.143	10.682	1.00	0.00	C
55	ATOM	169	O	THR	L	56	-1.599	-22.885	9.907	1.00	0.00	O
	ATOM	170	CB	THR	L	56	-4.089	-24.659	9.379	1.00	0.00	C
	ATOM	171	OG1	THR	L	56	-3.330	-24.836	8.196	1.00	0.00	O
	ATOM	172	CG2	THR	L	56	-5.044	-23.506	9.164	1.00	0.00	C
	ATOM	173	N	VAL	L	57	-2.942	-22.245	11.635	1.00	0.00	N
60	ATOM	174	CA	VAL	L	57	-2.286	-20.945	11.854	1.00	0.00	C
	ATOM	175	C	VAL	L	57	-0.799	-21.212	12.078	1.00	0.00	C

-37-

Table 3 - Continued

	ATOM	176	O	VAL	L	57	0.047	-20.684	11.375	1.00	0.00	O
	ATOM	177	CB	VAL	L	57	-2.896	-20.104	13.004	1.00	0.00	C
5	ATOM	178	CG1	VAL	L	57	-2.085	-18.841	13.259	1.00	0.00	C
	ATOM	179	CG2	VAL	L	57	-4.335	-19.696	12.714	1.00	0.00	C
	ATOM	180	N	GLY	L	58	-0.521	-22.078	13.113	1.00	0.00	N
	ATOM	181	CA	GLY	L	58	0.822	-22.415	13.487	1.00	0.00	C
	ATOM	182	C	GLY	L	58	1.623	-22.917	12.328	1.00	0.00	C
10	ATOM	183	O	GLY	L	58	2.718	-22.438	12.075	1.00	0.00	O
	ATOM	184	N	LEU	L	59	1.030	-23.955	11.641	1.00	0.00	N
	ATOM	185	CA	LEU	L	59	1.708	-24.654	10.580	1.00	0.00	C
	ATOM	186	C	LEU	L	59	2.185	-23.705	9.498	1.00	0.00	C
	ATOM	187	O	LEU	L	59	3.300	-23.786	9.049	1.00	0.00	O
15	ATOM	188	CB	LEU	L	59	0.855	-25.774	9.958	1.00	0.00	C
	ATOM	189	CG	LEU	L	59	0.528	-26.940	10.883	1.00	0.00	C
	ATOM	190	CD1	LEU	L	59	-0.499	-27.867	10.248	1.00	0.00	C
	ATOM	191	CD2	LEU	L	59	1.757	-27.717	11.236	1.00	0.00	C
	ATOM	192	N	VAL	L	60	1.263	-22.821	9.044	1.00	0.00	N
20	ATOM	193	CA	VAL	L	60	1.554	-21.906	7.967	1.00	0.00	C
	ATOM	194	C	VAL	L	60	2.691	-20.965	8.356	1.00	0.00	C
	ATOM	195	O	VAL	L	60	3.626	-20.759	7.642	1.00	0.00	O
	ATOM	196	CB	VAL	L	60	0.309	-21.177	7.501	1.00	0.00	C
	ATOM	197	CG1	VAL	L	60	0.647	-20.048	6.567	1.00	0.00	C
25	ATOM	198	CG2	VAL	L	60	-0.657	-22.127	6.817	1.00	0.00	C
	ATOM	199	N	GLU	L	61	2.551	-20.346	9.512	1.00	0.00	N
	ATOM	200	CA	GLU	L	61	3.536	-19.393	9.934	1.00	0.00	C
	ATOM	201	C	GLU	L	61	4.879	-19.960	10.193	1.00	0.00	C
	ATOM	202	O	GLU	L	61	5.880	-19.269	10.118	1.00	0.00	O
30	ATOM	203	CB	GLU	L	61	3.063	-18.660	11.104	1.00	0.00	C
	ATOM	204	CG	GLU	L	61	1.925	-17.819	10.799	1.00	0.00	C
	ATOM	205	CD	GLU	L	61	1.586	-17.006	11.921	1.00	0.00	C
	ATOM	206	OE1	GLU	L	61	0.975	-17.516	12.864	1.00	0.00	O
	ATOM	207	OE2	GLU	L	61	1.964	-15.931	11.778	1.00	0.00	O
35	ATOM	208	N	ALA	L	62	4.882	-21.261	10.545	1.00	0.00	N
	ATOM	209	CA	ALA	L	62	6.084	-21.956	10.944	1.00	0.00	C
	ATOM	210	C	ALA	L	62	7.286	-21.785	10.048	1.00	0.00	C
	ATOM	211	O	ALA	L	62	8.377	-21.630	10.538	1.00	0.00	O
	ATOM	212	CB	ALA	L	62	5.859	-23.400	11.174	1.00	0.00	C
40	ATOM	213	N	ALA	L	63	7.092	-21.848	8.706	1.00	0.00	N
	ATOM	214	CA	ALA	L	63	8.178	-21.680	7.793	1.00	0.00	C
	ATOM	215	C	ALA	L	63	8.991	-20.466	8.068	1.00	0.00	C
	ATOM	216	O	ALA	L	63	10.208	-20.527	8.043	1.00	0.00	O
	ATOM	217	CB	ALA	L	63	7.615	-21.644	6.413	1.00	0.00	C
45	ATOM	218	N	TYR	L	64	8.259	-19.325	8.307	1.00	0.00	N
	ATOM	219	CA	TYR	L	64	8.890	-18.068	8.550	1.00	0.00	C
	ATOM	220	C	TYR	L	64	9.659	-18.103	9.830	1.00	0.00	C
	ATOM	221	O	TYR	L	64	10.715	-17.566	9.914	1.00	0.00	O
	ATOM	222	CB	TYR	L	64	7.922	-16.871	8.520	1.00	0.00	C
50	ATOM	223	CG	TYR	L	64	7.295	-16.694	7.184	1.00	0.00	C
	ATOM	224	CD1	TYR	L	64	8.019	-16.167	6.135	1.00	0.00	C
	ATOM	225	CD2	TYR	L	64	5.990	-17.079	6.950	1.00	0.00	C
	ATOM	226	CE1	TYR	L	64	7.462	-16.049	4.875	1.00	0.00	C
	ATOM	227	CE2	TYR	L	64	5.429	-16.966	5.693	1.00	0.00	C
55	ATOM	228	CZ	TYR	L	64	6.164	-16.453	4.661	1.00	0.00	C
	ATOM	229	OH	TYR	L	64	5.574	-16.357	3.438	1.00	0.00	O
	ATOM	230	N	PHE	L	65	9.081	-18.740	10.861	1.00	0.00	N
	ATOM	231	CA	PHE	L	65	9.781	-18.948	12.083	1.00	0.00	C
	ATOM	232	C	PHE	L	65	11.125	-19.657	11.874	1.00	0.00	C
60	ATOM	233	O	PHE	L	65	12.121	-19.278	12.457	1.00	0.00	O
	ATOM	234	CB	PHE	L	65	8.919	-19.603	13.097	1.00	0.00	C

-38-

Table 3 - Continued

	ATOM	235	CG	PHE	L	65	9.632	-20.022	14.089	1.00	0.00	C
	ATOM	236	CD1	PHE	L	65	10.118	-19.245	14.878	1.00	0.00	C
5	ATOM	237	CE1	PHE	L	65	10.820	-19.640	15.762	1.00	0.00	C
	ATOM	238	CZ	PHE	L	65	11.035	-20.813	15.882	1.00	0.00	C
	ATOM	239	CE2	PHE	L	65	10.543	-21.593	15.120	1.00	0.00	C
	ATOM	240	CD2	PHE	L	65	9.847	-21.203	14.227	1.00	0.00	C
	ATOM	241	N	SER	M	206	-1.016	-25.619	19.505	1.00	0.00	N
10	ATOM	242	CA	SER	M	206	-0.838	-24.486	18.597	1.00	0.00	C
	ATOM	243	C	SER	M	206	-0.012	-23.382	19.267	1.00	0.00	C
	ATOM	244	O	SER	M	206	0.971	-22.911	18.713	1.00	0.00	O
	ATOM	245	CB	SER	M	206	-2.188	-23.963	18.088	1.00	0.00	C
	ATOM	246	OG	SER	M	206	-1.997	-22.980	17.074	1.00	0.00	O
15	ATOM	247	N	LEU	M	207	-0.489	-22.952	20.499	1.00	0.00	N
	ATOM	248	CA	LEU	M	207	0.102	-21.823	21.215	1.00	0.00	C
	ATOM	249	C	LEU	M	207	1.546	-22.138	21.608	1.00	0.00	C
	ATOM	250	O	LEU	M	207	2.423	-21.302	21.441	1.00	0.00	O
	ATOM	251	CB	LEU	M	207	-0.714	-21.400	22.455	1.00	0.00	C
20	ATOM	252	CG	LEU	M	207	-1.865	-20.400	22.201	1.00	0.00	C
	ATOM	253	CD1	LEU	M	207	-1.340	-19.000	21.895	1.00	0.00	C
	ATOM	254	CD2	LEU	M	207	-2.853	-20.839	21.125	1.00	0.00	C
	ATOM	255	N	LEU	M	209	3.807	-24.006	20.342	1.00	0.00	N
	ATOM	256	CA	LEU	M	209	4.747	-24.049	19.229	1.00	0.00	C
25	ATOM	257	C	LEU	M	209	5.571	-22.762	19.135	1.00	0.00	C
	ATOM	258	O	LEU	M	209	6.785	-22.821	18.999	1.00	0.00	O
	ATOM	259	CB	LEU	M	209	4.036	-24.368	17.902	1.00	0.00	C
	ATOM	260	CG	LEU	M	209	4.958	-24.569	16.686	1.00	0.00	C
	ATOM	261	CD1	LEU	M	209	5.927	-25.732	16.873	1.00	0.00	C
30	ATOM	262	CD2	LEU	M	209	4.109	-24.811	15.444	1.00	0.00	C
	ATOM	263	N	ARG	M	210	4.854	-21.566	19.167	1.00	0.00	N
	ATOM	264	CA	ARG	M	210	5.530	-20.289	18.933	1.00	0.00	C
	ATOM	265	C	ARG	M	210	6.635	-20.028	19.961	1.00	0.00	C
	ATOM	266	O	ARG	M	210	7.735	-19.631	19.601	1.00	0.00	O
35	ATOM	267	CB	ARG	M	210	4.594	-19.094	18.716	1.00	0.00	C
	ATOM	268	CG	ARG	M	210	4.089	-18.365	19.945	1.00	0.00	C
	ATOM	269	CD	ARG	M	210	2.763	-18.019	20.020	1.00	0.00	C
	ATOM	270	NE	ARG	M	210	2.404	-17.153	21.107	1.00	0.00	N
	ATOM	271	CZ	ARG	M	210	2.203	-17.389	22.361	1.00	0.00	C
40	ATOM	272	NH1	ARG	M	210	2.199	-18.501	22.785	1.00	0.00	N
	ATOM	273	NH2	ARG	M	210	1.994	-16.479	23.278	1.00	0.00	N

-39-

Table 4

5	ATOM	1	N	ALA	A	21	6.345	-14.031	-0.384	1.00	0.00	N
	ATOM	2	CA	ALA	A	21	5.507	-14.175	0.805	1.00	0.00	C
	ATOM	3	C	ALA	A	21	4.183	-13.425	0.676	1.00	0.00	C
	ATOM	4	O	ALA	A	21	3.126	-14.005	0.893	1.00	0.00	O
	ATOM	5	CB	ALA	A	21	6.228	-13.751	2.081	1.00	0.00	C
10	ATOM	6	N	ILE	A	22	4.282	-12.074	0.350	1.00	0.00	N
	ATOM	7	CA	ILE	A	22	3.090	-11.221	0.235	1.00	0.00	C
	ATOM	8	C	ILE	A	22	2.159	-11.728	-0.869	1.00	0.00	C
	ATOM	9	O	ILE	A	22	0.946	-11.670	-0.719	1.00	0.00	O
	ATOM	10	CB	ILE	A	22	3.362	-9.687	0.133	1.00	0.00	C
15	ATOM	11	CG1	ILE	A	22	4.114	-9.223	-1.134	1.00	0.00	C
	ATOM	12	CG2	ILE	A	22	4.108	-9.189	1.374	1.00	0.00	C
	ATOM	13	CD1	ILE	A	22	3.187	-8.776	-2.254	1.00	0.00	C
	ATOM	14	N	GLY	A	23	2.782	-12.213	-2.016	1.00	0.00	N
	ATOM	15	CA	GLY	A	23	2.049	-12.734	-3.156	1.00	0.00	C
20	ATOM	16	C	GLY	A	23	1.095	-13.831	-2.732	1.00	0.00	C
	ATOM	17	O	GLY	A	23	-0.107	-13.720	-2.928	1.00	0.00	O
	ATOM	18	N	ALA	A	24	1.708	-14.925	-2.131	1.00	0.00	N
	ATOM	19	CA	ALA	A	24	0.944	-16.088	-1.682	1.00	0.00	C
	ATOM	20	C	ALA	A	24	-0.144	-15.660	-0.712	1.00	0.00	C
25	ATOM	21	O	ALA	A	24	-1.298	-16.015	-0.897	1.00	0.00	O
	ATOM	22	CB	ALA	A	24	1.797	-17.177	-1.039	1.00	0.00	C
	ATOM	23	N	GLY	A	25	0.280	-14.904	0.373	1.00	0.00	N
	ATOM	24	CA	GLY	A	25	-0.589	-14.587	1.491	1.00	0.00	C
	ATOM	25	C	GLY	A	25	-1.877	-13.947	1.018	1.00	0.00	C
30	ATOM	26	O	GLY	A	25	-2.953	-14.520	1.129	1.00	0.00	O
	ATOM	27	N	ILE	A	26	-1.699	-12.685	0.473	1.00	0.00	N
	ATOM	28	CA	ILE	A	26	-2.827	-11.831	0.104	1.00	0.00	C
	ATOM	29	C	ILE	A	26	-3.654	-12.542	-0.969	1.00	0.00	C
	ATOM	30	O	ILE	A	26	-4.871	-12.600	-0.857	1.00	0.00	O
35	ATOM	31	CB	ILE	A	26	-2.401	-10.397	-0.323	1.00	0.00	C
	ATOM	32	CG1	ILE	A	26	-1.597	-9.649	0.770	1.00	0.00	C
	ATOM	33	CG2	ILE	A	26	-3.603	-9.553	-0.763	1.00	0.00	C
	ATOM	34	CD1	ILE	A	26	-2.318	-9.454	2.099	1.00	0.00	C
	ATOM	35	N	GLY	A	27	-2.942	-13.062	-2.046	1.00	0.00	N
40	ATOM	36	CA	GLY	A	27	-3.584	-13.678	-3.199	1.00	0.00	C
	ATOM	37	C	GLY	A	27	-4.550	-14.779	-2.803	1.00	0.00	C
	ATOM	38	O	GLY	A	27	-5.716	-14.754	-3.175	1.00	0.00	O
	ATOM	39	N	ASP	A	28	-3.985	-15.780	-2.024	1.00	0.00	N
	ATOM	40	CA	ASP	A	28	-4.732	-16.946	-1.539	1.00	0.00	C
45	ATOM	41	C	ASP	A	28	-5.998	-16.489	-0.825	1.00	0.00	C
	ATOM	42	O	ASP	A	28	-7.077	-17.007	-1.083	1.00	0.00	O
	ATOM	43	CB	ASP	A	28	-3.917	-17.846	-0.588	1.00	0.00	C
	ATOM	44	CG	ASP	A	28	-2.860	-18.655	-1.307	1.00	0.00	C
	ATOM	45	OD1	ASP	A	28	-2.422	-18.431	-2.426	1.00	0.00	O
50	ATOM	46	OD2	ASP	A	28	-2.415	-19.668	-0.523	1.00	0.00	O
	ATOM	47	N	GLY	A	29	-5.802	-15.500	0.131	1.00	0.00	N
	ATOM	48	CA	GLY	A	29	-6.869	-14.977	0.960	1.00	0.00	C
	ATOM	49	C	GLY	A	29	-8.039	-14.505	0.122	1.00	0.00	C
	ATOM	50	O	GLY	A	29	-9.123	-15.072	0.181	1.00	0.00	O
55	ATOM	51	N	LEU	A	59	0.538	-20.546	-3.576	1.00	0.00	N
	ATOM	52	CA	LEU	A	59	1.616	-21.013	-2.702	1.00	0.00	C
	ATOM	53	C	LEU	A	59	2.837	-21.443	-3.522	1.00	0.00	C
	ATOM	54	O	LEU	A	59	3.955	-21.055	-3.213	1.00	0.00	O
	ATOM	55	CB	LEU	A	59	1.142	-22.138	-1.760	1.00	0.00	C
60	ATOM	56	CG	LEU	A	59	2.189	-22.609	-0.730	1.00	0.00	C
	ATOM	57	CD1	LEU	A	59	2.569	-21.503	0.256	1.00	0.00	C

-40-

Table 4 - Continued

	ATOM	58	CD2	LEU	A	59	1.650	-23.816	0.035	1.00	0.00	C
	ATOM	59	N	ILE	K	16	10.658	-2.962	11.070	1.00	0.00	N
5	ATOM	60	CA	ILE	K	16	9.857	-4.034	11.671	1.00	0.00	C
	ATOM	61	C	ILE	K	16	8.610	-3.416	12.307	1.00	0.00	C
	ATOM	62	O	ILE	K	16	7.498	-3.841	12.023	1.00	0.00	O
	ATOM	63	CB	ILE	K	16	10.670	-4.907	12.676	1.00	0.00	C
	ATOM	64	CG1	ILE	K	16	11.731	-5.750	11.933	1.00	0.00	C
10	ATOM	65	CG2	ILE	K	16	9.763	-5.838	13.492	1.00	0.00	C
	ATOM	66	CD1	ILE	K	16	12.834	-6.259	12.850	1.00	0.00	C
	ATOM	67	N	GLY	K	19	6.052	-1.275	9.802	1.00	0.00	N
	ATOM	68	CA	GLY	K	19	5.350	-2.226	8.953	1.00	0.00	C
	ATOM	69	C	GLY	K	19	4.316	-2.998	9.750	1.00	0.00	C
15	ATOM	70	O	GLY	K	19	3.177	-3.154	9.331	1.00	0.00	O
	ATOM	71	N	GLY	K	20	4.790	-3.509	10.947	1.00	0.00	N
	ATOM	72	CA	GLY	K	20	3.964	-4.243	11.882	1.00	0.00	C
	ATOM	73	C	GLY	K	20	2.664	-3.538	12.201	1.00	0.00	C
	ATOM	74	O	GLY	K	20	1.605	-4.149	12.169	1.00	0.00	O
20	ATOM	75	N	ALA	K	21	2.805	-2.207	12.561	1.00	0.00	N
	ATOM	76	CA	ALA	K	21	1.688	-1.384	13.006	1.00	0.00	C
	ATOM	77	C	ALA	K	21	0.546	-1.397	12.001	1.00	0.00	C
	ATOM	78	O	ALA	K	21	-0.586	-1.697	12.356	1.00	0.00	O
	ATOM	79	CB	ALA	K	21	2.108	0.053	13.297	1.00	0.00	C
25	ATOM	80	N	ILE	K	22	0.886	-1.005	10.709	1.00	0.00	N
	ATOM	81	CA	ILE	K	22	-0.140	-0.867	9.671	1.00	0.00	C
	ATOM	82	C	ILE	K	22	-0.799	-2.219	9.390	1.00	0.00	C
	ATOM	83	O	ILE	K	22	-2.005	-2.285	9.195	1.00	0.00	O
	ATOM	84	CB	ILE	K	22	0.297	-0.092	8.393	1.00	0.00	C
30	ATOM	85	CG1	ILE	K	22	1.377	-0.768	7.521	1.00	0.00	C
	ATOM	86	CG2	ILE	K	22	0.768	1.314	8.779	1.00	0.00	C
	ATOM	87	CD1	ILE	K	22	0.806	-1.667	6.434	1.00	0.00	C
	ATOM	88	N	GLY	K	23	0.053	-3.318	9.365	1.00	0.00	N
	ATOM	89	CA	GLY	K	23	-0.419	-4.668	9.113	1.00	0.00	C
35	ATOM	90	C	GLY	K	23	-1.487	-5.090	10.101	1.00	0.00	C
	ATOM	91	O	GLY	K	23	-2.565	-5.521	9.715	1.00	0.00	O
	ATOM	92	N	ALA	K	24	-1.109	-4.970	11.431	1.00	0.00	N
	ATOM	93	CA	ALA	K	24	-1.982	-5.345	12.540	1.00	0.00	C
	ATOM	94	C	ALA	K	24	-3.312	-4.596	12.475	1.00	0.00	C
40	ATOM	95	O	ALA	K	24	-4.357	-5.184	12.715	1.00	0.00	O
	ATOM	96	CB	ALA	K	24	-1.317	-5.133	13.898	1.00	0.00	C
	ATOM	97	N	GLY	K	25	-3.230	-3.244	12.158	1.00	0.00	N
	ATOM	98	CA	GLY	K	25	-4.396	-2.382	12.036	1.00	0.00	C
	ATOM	99	C	GLY	K	25	-5.442	-2.961	11.101	1.00	0.00	C
45	ATOM	100	O	GLY	K	25	-6.598	-3.122	11.474	1.00	0.00	O
	ATOM	101	N	ILE	K	26	-4.967	-3.257	9.828	1.00	0.00	N
	ATOM	102	CA	ILE	K	26	-5.823	-3.841	8.789	1.00	0.00	C
	ATOM	103	C	ILE	K	26	-6.427	-5.132	9.343	1.00	0.00	C
	ATOM	104	O	ILE	K	26	-7.637	-5.300	9.305	1.00	0.00	O
50	ATOM	105	CB	ILE	K	26	-5.098	-4.071	7.428	1.00	0.00	C
	ATOM	106	CG1	ILE	K	26	-4.568	-2.767	6.788	1.00	0.00	C
	ATOM	107	CG2	ILE	K	26	-5.980	-4.825	6.426	1.00	0.00	C
	ATOM	108	CD1	ILE	K	26	-5.622	-1.714	6.477	1.00	0.00	C
	ATOM	109	N	GLY	K	27	-5.515	-6.056	9.844	1.00	0.00	N
55	ATOM	110	CA	GLY	K	27	-5.880	-7.396	10.278	1.00	0.00	C
	ATOM	111	C	GLY	K	27	-7.077	-7.409	11.210	1.00	0.00	C
	ATOM	112	O	GLY	K	27	-8.057	-8.096	10.950	1.00	0.00	O
	ATOM	113	N	ASP	K	28	-6.936	-6.610	12.341	1.00	0.00	N
	ATOM	114	CA	ASP	K	28	-7.969	-6.501	13.377	1.00	0.00	C
60	ATOM	115	C	ASP	K	28	-9.319	-6.221	12.728	1.00	0.00	C

-41-

Table 4 - Continued

	ATOM	116	O	ASP	K	28	-10.281	-6.940	12.967	1.00	0.00	O
	ATOM	117	CB	ASP	K	28	-7.684	-5.409	14.428	1.00	0.00	C
5	ATOM	118	CG	ASP	K	28	-6.719	-5.887	15.482	1.00	0.00	C
	ATOM	119	OD1	ASP	K	28	-5.501	-5.869	15.384	1.00	0.00	O
	ATOM	120	OD2	ASP	K	28	-7.384	-6.394	16.550	1.00	0.00	O
	ATOM	121	N	GLY	K	29	-9.348	-5.102	11.901	1.00	0.00	N
	ATOM	122	CA	GLY	K	29	-10.569	-4.615	11.289	1.00	0.00	C
10	ATOM	123	C	GLY	K	29	-11.212	-5.698	10.448	1.00	0.00	C
	ATOM	124	O	GLY	K	29	-12.276	-6.205	10.776	1.00	0.00	O
	ATOM	125	N	VAL	K	30	-10.501	-6.027	9.303	1.00	0.00	N
	ATOM	126	CA	VAL	K	30	-11.107	-6.819	8.230	1.00	0.00	C
	ATOM	127	C	VAL	K	30	-11.579	-8.176	8.753	1.00	0.00	C
15	ATOM	128	O	VAL	K	30	-12.714	-8.565	8.512	1.00	0.00	O
	ATOM	129	CB	VAL	K	30	-10.270	-6.937	6.923	1.00	0.00	C
	ATOM	130	CG1	VAL	K	30	-10.028	-5.560	6.300	1.00	0.00	C
	ATOM	131	CG2	VAL	K	30	-8.940	-7.684	7.063	1.00	0.00	C
	ATOM	132	N	ALA	K	31	-10.636	-8.920	9.451	1.00	0.00	N
20	ATOM	133	CA	ALA	K	31	-10.883	-10.314	9.808	1.00	0.00	C
	ATOM	134	C	ALA	K	31	-11.989	-10.412	10.852	1.00	0.00	C
	ATOM	135	O	ALA	K	31	-12.931	-11.178	10.696	1.00	0.00	O
	ATOM	136	CB	ALA	K	31	-9.624	-11.033	10.283	1.00	0.00	C
	ATOM	137	N	GLY	K	32	-11.816	-9.610	11.974	1.00	0.00	N
25	ATOM	138	CA	GLY	K	32	-12.719	-9.669	13.109	1.00	0.00	C
	ATOM	139	C	GLY	K	32	-14.138	-9.365	12.675	1.00	0.00	C
	ATOM	140	O	GLY	K	32	-15.039	-10.185	12.801	1.00	0.00	O
	ATOM	141	N	PHE	K	53	-10.783	-14.377	18.969	1.00	0.00	N
	ATOM	142	CA	PHE	K	53	-9.482	-14.955	18.629	1.00	0.00	C
30	ATOM	143	C	PHE	K	53	-8.723	-14.019	17.685	1.00	0.00	C
	ATOM	144	O	PHE	K	53	-7.574	-13.689	17.947	1.00	0.00	O
	ATOM	145	CB	PHE	K	53	-9.600	-16.376	18.045	1.00	0.00	C
	ATOM	146	CG	PHE	K	53	-8.257	-17.051	17.883	1.00	0.00	C
	ATOM	147	CD1	PHE	K	53	-7.577	-17.020	16.639	1.00	0.00	C
35	ATOM	148	CD2	PHE	K	53	-7.660	-17.740	18.968	1.00	0.00	C
	ATOM	149	CE1	PHE	K	53	-6.333	-17.661	16.487	1.00	0.00	C
	ATOM	150	CE2	PHE	K	53	-6.416	-18.382	18.810	1.00	0.00	C
	ATOM	151	CZ	PHE	K	53	-5.753	-18.344	17.571	1.00	0.00	C
	ATOM	152	N	PHE	K	54	-9.409	-13.608	16.543	1.00	0.00	N
40	ATOM	153	CA	PHE	K	54	-8.767	-12.782	15.516	1.00	0.00	C
	ATOM	154	C	PHE	K	54	-8.164	-11.541	16.176	1.00	0.00	C
	ATOM	155	O	PHE	K	54	-6.978	-11.270	16.042	1.00	0.00	O
	ATOM	156	CB	PHE	K	54	-9.706	-12.321	14.380	1.00	0.00	C
	ATOM	157	CG	PHE	K	54	-10.176	-13.399	13.433	1.00	0.00	C
45	ATOM	158	CD1	PHE	K	54	-9.257	-14.099	12.611	1.00	0.00	C
	ATOM	159	CD2	PHE	K	54	-11.561	-13.654	13.273	1.00	0.00	C
	ATOM	160	CE1	PHE	K	54	-9.716	-15.014	11.644	1.00	0.00	C
	ATOM	161	CE2	PHE	K	54	-12.014	-14.563	12.300	1.00	0.00	C
	ATOM	162	CZ	PHE	K	54	-11.094	-15.240	11.482	1.00	0.00	C
50	ATOM	163	N	ILE	K	55	-9.075	-10.749	16.863	1.00	0.00	N
	ATOM	164	CA	ILE	K	55	-8.727	-9.405	17.324	1.00	0.00	C
	ATOM	165	C	ILE	K	55	-7.693	-9.410	18.450	1.00	0.00	C
	ATOM	166	O	ILE	K	55	-6.827	-8.544	18.477	1.00	0.00	O
	ATOM	167	CB	ILE	K	55	-9.943	-8.495	17.647	1.00	0.00	C
55	ATOM	168	CG1	ILE	K	55	-10.898	-9.081	18.707	1.00	0.00	C
	ATOM	169	CG2	ILE	K	55	-10.688	-8.166	16.349	1.00	0.00	C
	ATOM	170	CD1	ILE	K	55	-12.005	-8.127	19.121	1.00	0.00	C
	ATOM	171	N	THR	K	56	-7.833	-10.391	19.426	1.00	0.00	N
	ATOM	172	CA	THR	K	56	-6.922	-10.464	20.567	1.00	0.00	C
60	ATOM	173	C	THR	K	56	-5.505	-10.773	20.080	1.00	0.00	C
	ATOM	174	O	THR	K	56	-4.555	-10.147	20.530	1.00	0.00	O
	ATOM	175	CB	THR	K	56	-7.422	-11.383	21.713	1.00	0.00	C

-42-

Table 4 - Continued

5	ATOM	176	OG1	THR	K	56	-6.750	-11.036	22.925	1.00	0.00	O
	ATOM	177	CG2	THR	K	56	-7.216	-12.880	21.504	1.00	0.00	C
	ATOM	178	N	VAL	K	57	-5.382	-11.788	19.134	1.00	0.00	N
	ATOM	179	CA	VAL	K	57	-4.079	-12.161	18.578	1.00	0.00	C
	ATOM	180	C	VAL	K	57	-3.482	-10.952	17.854	1.00	0.00	C
10	ATOM	181	O	VAL	K	57	-2.287	-10.725	17.957	1.00	0.00	O
	ATOM	182	CB	VAL	K	57	-4.122	-13.438	17.699	1.00	0.00	C
	ATOM	183	CG1	VAL	K	57	-2.785	-13.707	17.001	1.00	0.00	C
	ATOM	184	CG2	VAL	K	57	-4.464	-14.666	18.551	1.00	0.00	C
	ATOM	185	N	GLY	K	58	-4.345	-10.176	17.091	1.00	0.00	N
15	ATOM	186	CA	GLY	K	58	-3.919	-8.952	16.422	1.00	0.00	C
	ATOM	187	C	GLY	K	58	-3.232	-7.958	17.352	1.00	0.00	C
	ATOM	188	O	GLY	K	58	-2.167	-7.439	17.046	1.00	0.00	O
	ATOM	189	N	LEU	K	59	-3.928	-7.669	18.517	1.00	0.00	N
	ATOM	190	CA	LEU	K	59	-3.421	-6.732	19.526	1.00	0.00	C
20	ATOM	191	C	LEU	K	59	-2.069	-7.205	20.069	1.00	0.00	C
	ATOM	192	O	LEU	K	59	-1.126	-6.432	20.181	1.00	0.00	O
	ATOM	193	CB	LEU	K	59	-4.441	-6.520	20.664	1.00	0.00	C
	ATOM	194	CG	LEU	K	59	-4.043	-5.453	21.703	1.00	0.00	C
	ATOM	195	CD1	LEU	K	59	-3.930	-4.059	21.088	1.00	0.00	C
25	ATOM	196	CD2	LEU	K	59	-5.062	-5.428	22.840	1.00	0.00	C
	ATOM	197	N	VAL	K	60	-2.028	-8.531	20.469	1.00	0.00	N
	ATOM	198	CA	VAL	K	60	-0.841	-9.149	21.063	1.00	0.00	C
	ATOM	199	C	VAL	K	60	0.332	-9.119	20.061	1.00	0.00	C
	ATOM	200	O	VAL	K	60	1.463	-8.859	20.448	1.00	0.00	O
30	ATOM	201	CB	VAL	K	60	-1.166	-10.563	21.615	1.00	0.00	C
	ATOM	202	CG1	VAL	K	60	0.084	-11.323	22.031	1.00	0.00	C
	ATOM	203	CG2	VAL	K	60	-2.098	-10.481	22.829	1.00	0.00	C
	ATOM	204	N	GLU	K	61	0.026	-9.421	18.739	1.00	0.00	N
	ATOM	205	CA	GLU	K	61	0.996	-9.380	17.639	1.00	0.00	C
35	ATOM	206	C	GLU	K	61	1.731	-8.039	17.634	1.00	0.00	C
	ATOM	207	O	GLU	K	61	2.948	-8.006	17.511	1.00	0.00	O
	ATOM	208	CB	GLU	K	61	0.337	-9.677	16.274	1.00	0.00	C
	ATOM	209	CG	GLU	K	61	1.291	-9.513	15.092	1.00	0.00	C
	ATOM	210	CD	GLU	K	61	0.631	-9.807	13.767	1.00	0.00	C
40	ATOM	211	OE1	GLU	K	61	-0.550	-9.630	13.503	1.00	0.00	O
	ATOM	212	OE2	GLU	K	61	1.553	-10.205	12.854	1.00	0.00	O
	ATOM	213	N	ALA	K	62	0.926	-6.909	17.729	1.00	0.00	N
	ATOM	214	CA	ALA	K	62	1.483	-5.557	17.728	1.00	0.00	C
	ATOM	215	C	ALA	K	62	2.586	-5.411	18.775	1.00	0.00	C
45	ATOM	216	O	ALA	K	62	3.669	-4.923	18.475	1.00	0.00	O
	ATOM	217	CB	ALA	K	62	0.419	-4.487	17.928	1.00	0.00	C
	ATOM	218	N	ALA	K	63	2.251	-5.850	20.051	1.00	0.00	N
	ATOM	219	CA	ALA	K	63	3.203	-5.802	21.159	1.00	0.00	C
	ATOM	220	C	ALA	K	63	4.484	-6.563	20.818	1.00	0.00	C
50	ATOM	221	O	ALA	K	63	5.574	-6.065	21.061	1.00	0.00	O
	ATOM	222	CB	ALA	K	63	2.615	-6.314	22.471	1.00	0.00	C
	ATOM	223	N	TYR	K	64	4.320	-7.827	20.262	1.00	0.00	N
	ATOM	224	CA	TYR	K	64	5.460	-8.695	19.951	1.00	0.00	C
	ATOM	225	C	TYR	K	64	6.472	-8.042	19.015	1.00	0.00	C
55	ATOM	226	O	TYR	K	64	7.665	-8.258	19.180	1.00	0.00	O
	ATOM	227	CB	TYR	K	64	5.069	-10.062	19.359	1.00	0.00	C
	ATOM	228	CG	TYR	K	64	4.322	-11.015	20.266	1.00	0.00	C
	ATOM	229	CD1	TYR	K	64	4.486	-11.028	21.679	1.00	0.00	C
	ATOM	230	CD2	TYR	K	64	3.483	-11.993	19.678	1.00	0.00	C
60	ATOM	231	CE1	TYR	K	64	3.829	-11.984	22.471	1.00	0.00	C
	ATOM	232	CE2	TYR	K	64	2.857	-12.979	20.459	1.00	0.00	C
	ATOM	233	CZ	TYR	K	64	3.033	-12.965	21.859	1.00	0.00	C
	ATOM	234	OH	TYR	K	64	2.416	-13.902	22.671	1.00	0.00	O
	ATOM	235	N	PHE	K	65	5.971	-7.269	17.972	1.00	0.00	N

-43-

Table 4 - Continued

	ATOM	236	CA	PHE	K	65	6.881	-6.566	17.058	1.00	0.00	C
	ATOM	237	C	PHE	K	65	7.823	-5.649	17.839	1.00	0.00	C
5	ATOM	238	O	PHE	K	65	9.014	-5.614	17.560	1.00	0.00	O
	ATOM	239	CB	PHE	K	65	6.180	-5.739	15.966	1.00	0.00	C
	ATOM	240	CG	PHE	K	65	5.527	-6.570	14.890	1.00	0.00	C
	ATOM	241	CD1	PHE	K	65	4.136	-6.471	14.655	1.00	0.00	C
	ATOM	242	CE1	PHE	K	65	3.536	-7.174	13.596	1.00	0.00	C
10	ATOM	243	CZ	PHE	K	65	4.312	-8.000	12.767	1.00	0.00	C
	ATOM	244	CE2	PHE	K	65	5.693	-8.121	12.994	1.00	0.00	C
	ATOM	245	CD2	PHE	K	65	6.298	-7.409	14.046	1.00	0.00	C
	ATOM	246	N	ASN	K	67	8.600	-5.837	21.135	1.00	0.00	N
	ATOM	247	CA	ASN	K	67	9.499	-6.640	21.975	1.00	0.00	C
15	ATOM	248	C	ASN	K	67	10.712	-7.094	21.170	1.00	0.00	C
	ATOM	249	O	ASN	K	67	11.841	-6.910	21.603	1.00	0.00	O
	ATOM	250	CB	ASN	K	67	8.840	-7.875	22.619	1.00	0.00	C
	ATOM	251	CG	ASN	K	67	7.877	-7.498	23.726	1.00	0.00	C
	ATOM	252	OD1	ASN	K	67	6.675	-7.388	23.534	1.00	0.00	O
20	ATOM	253	ND2	ASN	K	67	8.480	-7.263	24.941	1.00	0.00	N
	ATOM	254	N	LEU	K	68	10.429	-7.744	19.975	1.00	0.00	N
	ATOM	255	CA	LEU	K	68	11.456	-8.357	19.131	1.00	0.00	C
	ATOM	256	C	LEU	K	68	12.495	-7.303	18.752	1.00	0.00	C
	ATOM	257	O	LEU	K	68	13.684	-7.496	18.968	1.00	0.00	O
25	ATOM	258	CB	LEU	K	68	10.830	-9.066	17.909	1.00	0.00	C
	ATOM	259	CG	LEU	K	68	11.796	-9.975	17.120	1.00	0.00	C
	ATOM	260	CD1	LEU	K	68	11.014	-11.105	16.449	1.00	0.00	C
	ATOM	261	CD2	LEU	K	68	12.577	-9.208	16.051	1.00	0.00	C
	ATOM	262	N	GLY	L	14	14.989	-7.715	8.662	1.00	0.00	N
30	ATOM	263	CA	GLY	L	14	13.793	-6.924	8.905	1.00	0.00	C
	ATOM	264	C	GLY	L	14	12.803	-7.025	7.757	1.00	0.00	C
	ATOM	265	O	GLY	L	14	11.628	-7.291	7.964	1.00	0.00	O
	ATOM	266	N	ILE	L	16	12.496	-9.152	5.091	1.00	0.00	N
	ATOM	267	CA	ILE	L	16	11.861	-10.451	4.837	1.00	0.00	C
35	ATOM	268	C	ILE	L	16	10.744	-10.700	5.848	1.00	0.00	C
	ATOM	269	O	ILE	L	16	9.660	-11.122	5.468	1.00	0.00	O
	ATOM	270	CB	ILE	L	16	12.856	-11.634	4.660	1.00	0.00	C
	ATOM	271	CG1	ILE	L	16	12.208	-12.880	4.017	1.00	0.00	C
	ATOM	272	CG2	ILE	L	16	13.681	-11.997	5.896	1.00	0.00	C
40	ATOM	273	CD1	ILE	L	16	11.497	-13.860	4.942	1.00	0.00	C
	ATOM	274	N	MET	L	17	11.051	-10.447	7.180	1.00	0.00	N
	ATOM	275	CA	MET	L	17	10.081	-10.700	8.246	1.00	0.00	C
	ATOM	276	C	MET	L	17	8.818	-9.866	8.100	1.00	0.00	C
	ATOM	277	O	MET	L	17	7.742	-10.352	8.419	1.00	0.00	O
45	ATOM	278	CB	MET	L	17	10.651	-10.523	9.664	1.00	0.00	C
	ATOM	279	CG	MET	L	17	11.609	-11.637	10.084	1.00	0.00	C
	ATOM	280	SD	MET	L	17	10.743	-13.242	10.212	1.00	0.00	S
	ATOM	281	CE	MET	L	17	11.465	-14.067	8.772	1.00	0.00	C
	ATOM	282	N	ALA	L	18	8.969	-8.564	7.642	1.00	0.00	N
50	ATOM	283	CA	ALA	L	18	7.807	-7.726	7.352	1.00	0.00	C
	ATOM	284	C	ALA	L	18	6.915	-8.420	6.322	1.00	0.00	C
	ATOM	285	O	ALA	L	18	5.715	-8.548	6.522	1.00	0.00	O
	ATOM	286	CB	ALA	L	18	8.183	-6.319	6.895	1.00	0.00	C
	ATOM	287	N	GLY	L	19	7.564	-8.879	5.182	1.00	0.00	N
55	ATOM	288	CA	GLY	L	19	6.870	-9.586	4.117	1.00	0.00	C
	ATOM	289	C	GLY	L	19	6.019	-10.723	4.654	1.00	0.00	C
	ATOM	290	O	GLY	L	19	4.826	-10.794	4.389	1.00	0.00	O
	ATOM	291	N	GLY	L	20	6.714	-11.641	5.428	1.00	0.00	N
	ATOM	292	CA	GLY	L	20	6.091	-12.813	6.017	1.00	0.00	C
60	ATOM	293	C	GLY	L	20	4.924	-12.424	6.902	1.00	0.00	C
	ATOM	294	O	GLY	L	20	3.775	-12.706	6.596	1.00	0.00	O
	ATOM	295	N	ALA	L	21	5.288	-11.749	8.053	1.00	0.00	N

-44-

Table 4 - Continued

	ATOM	296	CA	ALA	L	21	4.370	-11.537	9.169	1.00	0.00	C
	ATOM	297	C	ALA	L	21	3.087	-10.818	8.764	1.00	0.00	C
5	ATOM	298	O	ALA	L	21	2.008	-11.206	9.192	1.00	0.00	O
	ATOM	299	CB	ALA	L	21	5.030	-10.783	10.317	1.00	0.00	C
	ATOM	300	N	ILE	L	22	3.250	-9.680	7.980	1.00	0.00	N
	ATOM	301	CA	ILE	L	22	2.109	-8.859	7.573	1.00	0.00	C
	ATOM	302	C	ILE	L	22	1.336	-9.638	6.508	1.00	0.00	C
10	ATOM	303	O	ILE	L	22	0.144	-9.865	6.661	1.00	0.00	O
	ATOM	304	CB	ILE	L	22	2.489	-7.415	7.124	1.00	0.00	C
	ATOM	305	CG1	ILE	L	22	2.941	-6.542	8.320	1.00	0.00	C
	ATOM	306	CG2	ILE	L	22	1.297	-6.718	6.455	1.00	0.00	C
	ATOM	307	CD1	ILE	L	22	4.411	-6.675	8.676	1.00	0.00	C
15	ATOM	308	N	GLY	L	23	2.058	-10.000	5.378	1.00	0.00	N
	ATOM	309	CA	GLY	L	23	1.420	-10.535	4.184	1.00	0.00	C
	ATOM	310	C	GLY	L	23	0.632	-11.791	4.483	1.00	0.00	C
	ATOM	311	O	GLY	L	23	-0.575	-11.846	4.285	1.00	0.00	O
	ATOM	312	N	ALA	L	24	1.408	-12.831	4.972	1.00	0.00	N
20	ATOM	313	CA	ALA	L	24	0.840	-14.126	5.333	1.00	0.00	C
	ATOM	314	C	ALA	L	24	-0.200	-13.997	6.437	1.00	0.00	C
	ATOM	315	O	ALA	L	24	-1.182	-14.722	6.421	1.00	0.00	O
	ATOM	316	CB	ALA	L	24	1.894	-15.147	5.746	1.00	0.00	C
	ATOM	317	N	GLY	L	25	0.065	-13.074	7.441	1.00	0.00	N
25	ATOM	318	CA	GLY	L	25	-0.835	-12.872	8.565	1.00	0.00	C
	ATOM	319	C	GLY	L	25	-2.244	-12.510	8.132	1.00	0.00	C
	ATOM	320	O	GLY	L	25	-3.203	-13.173	8.505	1.00	0.00	O
	ATOM	321	N	ILE	L	26	-2.329	-11.374	7.337	1.00	0.00	N
	ATOM	322	CA	ILE	L	26	-3.608	-10.852	6.834	1.00	0.00	C
30	ATOM	323	C	ILE	L	26	-4.264	-11.948	5.991	1.00	0.00	C
	ATOM	324	O	ILE	L	26	-5.440	-12.236	6.166	1.00	0.00	O
	ATOM	325	CB	ILE	L	26	-3.469	-9.511	6.056	1.00	0.00	C
	ATOM	326	CG1	ILE	L	26	-3.005	-8.379	7.001	1.00	0.00	C
	ATOM	327	CG2	ILE	L	26	-4.794	-9.115	5.386	1.00	0.00	C
35	ATOM	328	CD1	ILE	L	26	-2.547	-7.131	6.263	1.00	0.00	C
	ATOM	329	N	GLY	L	27	-3.444	-12.534	5.034	1.00	0.00	N
	ATOM	330	CA	GLY	L	27	-3.895	-13.566	4.116	1.00	0.00	C
	ATOM	331	C	GLY	L	27	-4.612	-14.699	4.822	1.00	0.00	C
	ATOM	332	O	GLY	L	27	-5.743	-15.030	4.495	1.00	0.00	O
40	ATOM	333	N	ASP	L	28	-3.866	-15.300	5.825	1.00	0.00	N
	ATOM	334	CA	ASP	L	28	-4.342	-16.404	6.656	1.00	0.00	C
	ATOM	335	C	ASP	L	28	-5.678	-16.044	7.295	1.00	0.00	C
	ATOM	336	O	ASP	L	28	-6.607	-16.838	7.255	1.00	0.00	O
	ATOM	337	CB	ASP	L	28	-3.304	-16.805	7.718	1.00	0.00	C
45	ATOM	338	CG	ASP	L	28	-3.834	-17.837	8.680	1.00	0.00	C
	ATOM	339	OD1	ASP	L	28	-4.192	-17.594	9.822	1.00	0.00	O
	ATOM	340	OD2	ASP	L	28	-3.898	-19.067	8.109	1.00	0.00	O
	ATOM	341	N	GLY	L	29	-5.735	-14.805	7.918	1.00	0.00	N
	ATOM	342	CA	GLY	L	29	-6.922	-14.317	8.598	1.00	0.00	C
50	ATOM	343	C	GLY	L	29	-8.156	-14.418	7.720	1.00	0.00	C
	ATOM	344	O	GLY	L	29	-9.113	-15.099	8.061	1.00	0.00	O
	ATOM	345	N	VAL	L	30	-8.091	-13.675	6.548	1.00	0.00	N
	ATOM	346	CA	VAL	L	30	-9.233	-13.575	5.632	1.00	0.00	C
	ATOM	347	C	VAL	L	30	-9.587	-14.913	4.961	1.00	0.00	C
55	ATOM	348	O	VAL	L	30	-10.748	-15.158	4.661	1.00	0.00	O
	ATOM	349	CB	VAL	L	30	-9.143	-12.412	4.611	1.00	0.00	C
	ATOM	350	CG1	VAL	L	30	-9.013	-11.058	5.310	1.00	0.00	C
	ATOM	351	CG2	VAL	L	30	-8.035	-12.576	3.573	1.00	0.00	C
	ATOM	352	N	ALA	L	31	-8.539	-15.791	4.710	1.00	0.00	N
60	ATOM	353	CA	ALA	L	31	-8.767	-17.161	4.238	1.00	0.00	C
	ATOM	354	C	ALA	L	31	-9.633	-17.938	5.230	1.00	0.00	C
	ATOM	355	O	ALA	L	31	-10.516	-18.686	4.834	1.00	0.00	O

-45-

Table 4 - Continued

	ATOM	356	CB	ALA	L	31	-7.472	-17.928	3.981	1.00	0.00	C
	ATOM	357	N	GLY	L	32	-9.321	-17.746	6.570	1.00	0.00	N
5	ATOM	358	CA	GLY	L	32	-10.106	-18.295	7.661	1.00	0.00	C
	ATOM	359	C	GLY	L	32	-11.567	-17.924	7.538	1.00	0.00	C
	ATOM	360	O	GLY	L	32	-12.428	-18.788	7.620	1.00	0.00	O
	ATOM	361	N	THR	L	51	-11.764	-26.332	14.771	1.00	0.00	N
	ATOM	362	CA	THR	L	51	-10.467	-26.987	14.935	1.00	0.00	C
10	ATOM	363	C	THR	L	51	-9.452	-26.599	13.848	1.00	0.00	C
	ATOM	364	O	THR	L	51	-8.351	-26.190	14.199	1.00	0.00	O
	ATOM	365	CB	THR	L	51	-10.589	-28.519	15.109	1.00	0.00	C
	ATOM	366	OG1	THR	L	51	-11.578	-28.792	16.105	1.00	0.00	O
	ATOM	367	CG2	THR	L	51	-9.288	-29.157	15.580	1.00	0.00	C
15	ATOM	368	N	PRO	L	52	-9.797	-26.799	12.499	1.00	0.00	N
	ATOM	369	CA	PRO	L	52	-8.818	-26.678	11.427	1.00	0.00	C
	ATOM	370	C	PRO	L	52	-8.028	-25.377	11.428	1.00	0.00	C
	ATOM	371	O	PRO	L	52	-6.825	-25.388	11.203	1.00	0.00	O
	ATOM	372	CB	PRO	L	52	-9.592	-26.833	10.125	1.00	0.00	C
20	ATOM	373	CG	PRO	L	52	-10.863	-27.542	10.527	1.00	0.00	C
	ATOM	374	CD	PRO	L	52	-11.104	-27.123	11.962	1.00	0.00	C
	ATOM	375	N	PHE	L	53	-8.777	-24.222	11.638	1.00	0.00	N
	ATOM	376	CA	PHE	L	53	-8.158	-22.904	11.575	1.00	0.00	C
	ATOM	377	C	PHE	L	53	-7.070	-22.835	12.640	1.00	0.00	C
25	ATOM	378	O	PHE	L	53	-5.919	-22.563	12.328	1.00	0.00	O
	ATOM	379	CB	PHE	L	53	-9.165	-21.749	11.710	1.00	0.00	C
	ATOM	380	CG	PHE	L	53	-8.486	-20.406	11.576	1.00	0.00	C
	ATOM	381	CD1	PHE	L	53	-8.068	-19.938	10.308	1.00	0.00	C
	ATOM	382	CD2	PHE	L	53	-8.232	-19.601	12.715	1.00	0.00	C
30	ATOM	383	CE1	PHE	L	53	-7.415	-18.699	10.186	1.00	0.00	C
	ATOM	384	CE2	PHE	L	53	-7.598	-18.352	12.585	1.00	0.00	C
	ATOM	385	CZ	PHE	L	53	-7.185	-17.903	11.320	1.00	0.00	C
	ATOM	386	N	PHE	L	54	-7.493	-23.069	13.942	1.00	0.00	N
	ATOM	387	CA	PHE	L	54	-6.624	-22.780	15.082	1.00	0.00	C
35	ATOM	388	C	PHE	L	54	-5.283	-23.500	14.934	1.00	0.00	C
	ATOM	389	O	PHE	L	54	-4.238	-22.899	15.149	1.00	0.00	O
	ATOM	390	CB	PHE	L	54	-7.258	-23.112	16.446	1.00	0.00	C
	ATOM	391	CG	PHE	L	54	-8.520	-22.346	16.780	1.00	0.00	C
	ATOM	392	CD1	PHE	L	54	-8.627	-20.946	16.577	1.00	0.00	C
40	ATOM	393	CD2	PHE	L	54	-9.626	-23.027	17.347	1.00	0.00	C
	ATOM	394	CE1	PHE	L	54	-9.810	-20.260	16.905	1.00	0.00	C
	ATOM	395	CE2	PHE	L	54	-10.796	-22.330	17.701	1.00	0.00	C
	ATOM	396	CZ	PHE	L	54	-10.892	-20.948	17.473	1.00	0.00	C
	ATOM	397	N	ILE	L	55	-5.352	-24.850	14.595	1.00	0.00	N
45	ATOM	398	CA	ILE	L	55	-4.139	-25.666	14.492	1.00	0.00	C
	ATOM	399	C	ILE	L	55	-3.201	-25.129	13.402	1.00	0.00	C
	ATOM	400	O	ILE	L	55	-2.003	-25.002	13.627	1.00	0.00	O
	ATOM	401	CB	ILE	L	55	-4.402	-27.198	14.419	1.00	0.00	C
	ATOM	402	CG1	ILE	L	55	-3.088	-27.977	14.635	1.00	0.00	C
50	ATOM	403	CG2	ILE	L	55	-5.106	-27.651	13.136	1.00	0.00	C
	ATOM	404	CD1	ILE	L	55	-3.303	-29.446	14.966	1.00	0.00	C
	ATOM	405	N	THR	L	56	-3.789	-24.860	12.169	1.00	0.00	N
	ATOM	406	CA	THR	L	56	-2.977	-24.541	10.996	1.00	0.00	C
	ATOM	407	C	THR	L	56	-2.190	-23.229	11.131	1.00	0.00	C
55	ATOM	408	O	THR	L	56	-1.166	-23.089	10.475	1.00	0.00	O
	ATOM	409	CB	THR	L	56	-3.767	-24.642	9.664	1.00	0.00	C
	ATOM	410	OG1	THR	L	56	-2.866	-24.908	8.586	1.00	0.00	O
	ATOM	411	CG2	THR	L	56	-4.606	-23.421	9.294	1.00	0.00	C
	ATOM	412	N	VAL	L	57	-2.720	-22.244	11.970	1.00	0.00	N
60	ATOM	413	CA	VAL	L	57	-2.067	-20.936	12.149	1.00	0.00	C
	ATOM	414	C	VAL	L	57	-0.599	-21.186	12.511	1.00	0.00	C
	ATOM	415	O	VAL	L	57	0.303	-20.738	11.815	1.00	0.00	O

-46-

Table 4 - Continued

	ATOM	416	CB	VAL	L	57	-2.746	-20.000	13.195	1.00	0.00	C
	ATOM	417	CG1	VAL	L	57	-1.993	-18.675	13.324	1.00	0.00	C
5	ATOM	418	CG2	VAL	L	57	-4.196	-19.681	12.839	1.00	0.00	C
	ATOM	419	N	GLY	L	58	-0.405	-21.929	13.671	1.00	0.00	N
	ATOM	420	CA	GLY	L	58	0.911	-22.161	14.239	1.00	0.00	C
	ATOM	421	C	GLY	L	58	1.842	-22.808	13.236	1.00	0.00	C
	ATOM	422	O	GLY	L	58	2.952	-22.341	13.023	1.00	0.00	O
10	ATOM	423	N	LEU	L	59	1.332	-23.958	12.645	1.00	0.00	N
	ATOM	424	CA	LEU	L	59	2.136	-24.819	11.776	1.00	0.00	C
	ATOM	425	C	LEU	L	59	2.757	-24.020	10.627	1.00	0.00	C
	ATOM	426	O	LEU	L	59	3.950	-24.127	10.374	1.00	0.00	O
	ATOM	427	CB	LEU	L	59	1.344	-26.017	11.210	1.00	0.00	C
15	ATOM	428	CG	LEU	L	59	0.863	-27.034	12.268	1.00	0.00	C
	ATOM	429	CD1	LEU	L	59	-0.081	-28.045	11.621	1.00	0.00	C
	ATOM	430	CD2	LEU	L	59	2.027	-27.772	12.932	1.00	0.00	C
	ATOM	431	N	VAL	L	60	1.872	-23.244	9.886	1.00	0.00	N
	ATOM	432	CA	VAL	L	60	2.291	-22.521	8.680	1.00	0.00	C
20	ATOM	433	C	VAL	L	60	3.333	-21.474	9.071	1.00	0.00	C
	ATOM	434	O	VAL	L	60	4.419	-21.440	8.507	1.00	0.00	O
	ATOM	435	CB	VAL	L	60	1.098	-21.909	7.895	1.00	0.00	C
	ATOM	436	CG1	VAL	L	60	1.551	-20.964	6.776	1.00	0.00	C
	ATOM	437	CG2	VAL	L	60	0.246	-23.017	7.273	1.00	0.00	C
25	ATOM	438	N	GLU	L	61	2.931	-20.563	10.039	1.00	0.00	N
	ATOM	439	CA	GLU	L	61	3.735	-19.381	10.357	1.00	0.00	C
	ATOM	440	C	GLU	L	61	5.107	-19.722	10.949	1.00	0.00	C
	ATOM	441	O	GLU	L	61	6.043	-18.942	10.816	1.00	0.00	O
	ATOM	442	CB	GLU	L	61	2.988	-18.378	11.246	1.00	0.00	C
30	ATOM	443	CG	GLU	L	61	1.789	-17.773	10.507	1.00	0.00	C
	ATOM	444	CD	GLU	L	61	1.165	-16.637	11.308	1.00	0.00	C
	ATOM	445	OE1	GLU	L	61	0.658	-16.959	12.417	1.00	0.00	O
	ATOM	446	OE2	GLU	L	61	1.212	-15.497	10.769	1.00	0.00	O
	ATOM	447	N	ALA	L	62	5.207	-20.935	11.625	1.00	0.00	N
35	ATOM	448	CA	ALA	L	62	6.476	-21.443	12.148	1.00	0.00	C
	ATOM	449	C	ALA	L	62	7.593	-21.430	11.110	1.00	0.00	C
	ATOM	450	O	ALA	L	62	8.733	-21.152	11.454	1.00	0.00	O
	ATOM	451	CB	ALA	L	62	6.351	-22.844	12.734	1.00	0.00	C
	ATOM	452	N	ALA	L	63	7.235	-21.777	9.810	1.00	0.00	N
40	ATOM	453	CA	ALA	L	63	8.205	-21.820	8.714	1.00	0.00	C
	ATOM	454	C	ALA	L	63	9.043	-20.543	8.636	1.00	0.00	C
	ATOM	455	O	ALA	L	63	10.257	-20.607	8.499	1.00	0.00	O
	ATOM	456	CB	ALA	L	63	7.547	-22.083	7.362	1.00	0.00	C
	ATOM	457	N	TYR	L	64	8.333	-19.349	8.701	1.00	0.00	N
45	ATOM	458	CA	TYR	L	64	9.006	-18.049	8.621	1.00	0.00	C
	ATOM	459	C	TYR	L	64	10.000	-17.881	9.768	1.00	0.00	C
	ATOM	460	O	TYR	L	64	11.097	-17.379	9.562	1.00	0.00	O
	ATOM	461	CB	TYR	L	64	8.042	-16.849	8.590	1.00	0.00	C
	ATOM	462	CG	TYR	L	64	7.194	-16.820	7.341	1.00	0.00	C
50	ATOM	463	CD1	TYR	L	64	7.770	-16.499	6.085	1.00	0.00	C
	ATOM	464	CD2	TYR	L	64	5.811	-17.118	7.404	1.00	0.00	C
	ATOM	465	CE1	TYR	L	64	6.990	-16.502	4.914	1.00	0.00	C
	ATOM	466	CE2	TYR	L	64	5.024	-17.125	6.238	1.00	0.00	C
	ATOM	467	CZ	TYR	L	64	5.615	-16.821	4.997	1.00	0.00	C
55	ATOM	468	OH	TYR	L	64	4.807	-16.847	3.870	1.00	0.00	O
	ATOM	469	N	PHE	L	65	9.571	-18.285	11.026	1.00	0.00	N
	ATOM	470	CA	PHE	L	65	10.456	-18.198	12.188	1.00	0.00	C
	ATOM	471	C	PHE	L	65	11.751	-19.001	11.982	1.00	0.00	C
	ATOM	472	O	PHE	L	65	12.807	-18.572	12.428	1.00	0.00	O
60	ATOM	473	CB	PHE	L	65	9.751	-18.584	13.503	1.00	0.00	C
	ATOM	474	CG	PHE	L	65	10.605	-18.264	14.707	1.00	0.00	C
	ATOM	475	CD1	PHE	L	65	10.790	-16.921	15.123	1.00	0.00	C

-47-

Table 4 - Continued

	ATOM	476	CE1	PHE	L	65	11.649	-16.616	16.194	1.00	0.00	C
	ATOM	477	CZ	PHE	L	65	12.328	-17.647	16.867	1.00	0.00	C
5	ATOM	478	CE2	PHE	L	65	12.135	-18.985	16.481	1.00	0.00	C
	ATOM	479	CD2	PHE	L	65	11.277	-19.295	15.410	1.00	0.00	C
	ATOM	480	N	ILE	L	66	11.648	-20.219	11.314	1.00	0.00	N
	ATOM	481	CA	ILE	L	66	12.834	-21.039	11.020	1.00	0.00	C
	ATOM	482	C	ILE	L	66	13.831	-20.203	10.207	1.00	0.00	C
10	ATOM	483	O	ILE	L	66	15.012	-20.185	10.527	1.00	0.00	O
	ATOM	484	CB	ILE	L	66	12.536	-22.402	10.326	1.00	0.00	C
	ATOM	485	CG1	ILE	L	66	11.537	-23.293	11.099	1.00	0.00	C
	ATOM	486	CG2	ILE	L	66	13.824	-23.190	10.054	1.00	0.00	C
	ATOM	487	CD1	ILE	L	66	11.915	-23.605	12.541	1.00	0.00	C
15	ATOM	488	N	ASN	L	67	13.319	-19.523	9.103	1.00	0.00	N
	ATOM	489	CA	ASN	L	67	14.170	-18.671	8.257	1.00	0.00	C
	ATOM	490	C	ASN	L	67	14.893	-17.621	9.100	1.00	0.00	C
	ATOM	491	O	ASN	L	67	16.086	-17.414	8.918	1.00	0.00	O
	ATOM	492	CB	ASN	L	67	13.433	-17.956	7.109	1.00	0.00	C
20	ATOM	493	CG	ASN	L	67	12.966	-18.928	6.045	1.00	0.00	C
	ATOM	494	OD1	ASN	L	67	11.854	-19.433	6.070	1.00	0.00	O
	ATOM	495	ND2	ASN	L	67	13.914	-19.210	5.086	1.00	0.00	N
	ATOM	496	N	LEU	L	68	14.100	-16.932	10.018	1.00	0.00	N
	ATOM	497	CA	LEU	L	68	14.623	-15.890	10.911	1.00	0.00	C
25	ATOM	498	C	LEU	L	68	15.848	-16.461	11.624	1.00	0.00	C
	ATOM	499	O	LEU	L	68	16.945	-15.935	11.495	1.00	0.00	O
	ATOM	500	CB	LEU	L	68	13.567	-15.371	11.923	1.00	0.00	C
	ATOM	501	CG	LEU	L	68	13.797	-13.942	12.458	1.00	0.00	C
	ATOM	502	CD1	LEU	L	68	12.687	-13.579	13.446	1.00	0.00	C
30	ATOM	503	CD2	LEU	L	68	15.146	-13.745	13.146	1.00	0.00	C
	ATOM	504	N	ALA	L	69	15.599	-17.586	12.403	1.00	0.00	N
	ATOM	505	CA	ALA	L	69	16.590	-18.175	13.295	1.00	0.00	C
	ATOM	506	C	ALA	L	69	17.875	-18.501	12.545	1.00	0.00	C
	ATOM	507	O	ALA	L	69	18.956	-18.146	12.993	1.00	0.00	O
35	ATOM	508	CB	ALA	L	69	16.062	-19.423	13.999	1.00	0.00	C
	ATOM	509	N	SER	M	199	-10.235	-24.828	20.448	1.00	0.00	N
	ATOM	510	CA	SER	M	199	-10.460	-26.277	20.457	1.00	0.00	C
	ATOM	511	C	SER	M	199	-9.383	-26.909	21.342	1.00	0.00	C
	ATOM	512	O	SER	M	199	-8.255	-26.439	21.436	1.00	0.00	O
40	ATOM	513	CB	SER	M	199	-10.426	-26.831	19.028	1.00	0.00	C
	ATOM	514	OG	SER	M	199	-10.782	-28.211	19.040	1.00	0.00	O
	ATOM	515	N	ALA	M	202	-6.359	-28.395	19.399	1.00	0.00	N
	ATOM	516	CA	ALA	M	202	-5.624	-27.448	18.568	1.00	0.00	C
	ATOM	517	C	ALA	M	202	-4.672	-26.589	19.389	1.00	0.00	C
45	ATOM	518	O	ALA	M	202	-3.496	-26.490	19.067	1.00	0.00	O
	ATOM	519	CB	ALA	M	202	-6.548	-26.552	17.752	1.00	0.00	C
	ATOM	520	N	LYS	M	203	-5.259	-25.887	20.436	1.00	0.00	N
	ATOM	521	CA	LYS	M	203	-4.565	-24.776	21.085	1.00	0.00	C
	ATOM	522	C	LYS	M	203	-3.211	-25.173	21.673	1.00	0.00	C
50	ATOM	523	O	LYS	M	203	-2.244	-24.472	21.408	1.00	0.00	O
	ATOM	524	CB	LYS	M	203	-5.421	-24.006	22.104	1.00	0.00	C
	ATOM	525	CG	LYS	M	203	-6.351	-23.021	21.397	1.00	0.00	C
	ATOM	526	CD	LYS	M	203	-7.207	-22.239	22.391	1.00	0.00	C
	ATOM	527	CE	LYS	M	203	-7.942	-21.073	21.731	1.00	0.00	C
55	ATOM	528	NZ	LYS	M	203	-8.880	-21.518	20.704	1.00	0.00	N
	ATOM	529	N	PRO	M	204	-3.121	-26.287	22.520	1.00	0.00	N
	ATOM	530	CA	PRO	M	204	-1.857	-26.688	23.113	1.00	0.00	C
	ATOM	531	C	PRO	M	204	-0.698	-26.719	22.124	1.00	0.00	C
	ATOM	532	O	PRO	M	204	0.311	-26.064	22.348	1.00	0.00	O
60	ATOM	533	CB	PRO	M	204	-2.120	-28.029	23.781	1.00	0.00	C
	ATOM	534	CG	PRO	M	204	-3.599	-27.984	24.098	1.00	0.00	C
	ATOM	535	CD	PRO	M	204	-4.203	-27.116	23.010	1.00	0.00	C

-48-

Table 4 - Continued

	ATOM	536	N	ILE	M	205	-0.871	-27.523	21.001	1.00	0.00	N
	ATOM	537	CA	ILE	M	205	0.201	-27.693	20.012	1.00	0.00	C
5	ATOM	538	C	ILE	M	205	0.518	-26.340	19.365	1.00	0.00	C
	ATOM	539	O	ILE	M	205	1.669	-25.924	19.342	1.00	0.00	O
	ATOM	540	CB	ILE	M	205	-0.021	-28.884	19.030	1.00	0.00	C
	ATOM	541	CG1	ILE	M	205	1.238	-29.236	18.204	1.00	0.00	C
	ATOM	542	CG2	ILE	M	205	-1.273	-28.799	18.151	1.00	0.00	C
10	ATOM	543	CD1	ILE	M	205	1.490	-28.405	16.949	1.00	0.00	C
	ATOM	544	N	SER	M	206	-0.566	-25.670	18.816	1.00	0.00	N
	ATOM	545	CA	SER	M	206	-0.425	-24.504	17.945	1.00	0.00	C
	ATOM	546	C	SER	M	206	0.370	-23.401	18.645	1.00	0.00	C
	ATOM	547	O	SER	M	206	1.352	-22.898	18.114	1.00	0.00	O
15	ATOM	548	CB	SER	M	206	-1.797	-24.005	17.472	1.00	0.00	C
	ATOM	549	OG	SER	M	206	-1.651	-23.006	16.468	1.00	0.00	O
	ATOM	550	N	LEU	M	207	-0.143	-23.008	19.874	1.00	0.00	N
	ATOM	551	CA	LEU	M	207	0.392	-21.871	20.615	1.00	0.00	C
	ATOM	552	C	LEU	M	207	1.815	-22.188	21.070	1.00	0.00	C
20	ATOM	553	O	LEU	M	207	2.709	-21.379	20.864	1.00	0.00	O
	ATOM	554	CB	LEU	M	207	-0.487	-21.463	21.816	1.00	0.00	C
	ATOM	555	CG	LEU	M	207	-1.681	-20.526	21.513	1.00	0.00	C
	ATOM	556	CD1	LEU	M	207	-1.223	-19.102	21.205	1.00	0.00	C
	ATOM	557	CD2	LEU	M	207	-2.610	-21.034	20.412	1.00	0.00	C
25	ATOM	558	N	SER	M	208	1.997	-23.392	21.748	1.00	0.00	N
	ATOM	559	CA	SER	M	208	3.280	-23.736	22.372	1.00	0.00	C
	ATOM	560	C	SER	M	208	4.455	-23.617	21.403	1.00	0.00	C
	ATOM	561	O	SER	M	208	5.522	-23.154	21.783	1.00	0.00	O
	ATOM	562	CB	SER	M	208	3.290	-25.118	23.033	1.00	0.00	C
30	ATOM	563	OG	SER	M	208	3.107	-26.159	22.078	1.00	0.00	O
	ATOM	564	N	LEU	M	209	4.216	-24.105	20.122	1.00	0.00	N
	ATOM	565	CA	LEU	M	209	5.240	-24.173	19.081	1.00	0.00	C
	ATOM	566	C	LEU	M	209	6.054	-22.878	19.001	1.00	0.00	C
	ATOM	567	O	LEU	M	209	7.275	-22.927	18.919	1.00	0.00	O
35	ATOM	568	CB	LEU	M	209	4.615	-24.547	17.722	1.00	0.00	C
	ATOM	569	CG	LEU	M	209	5.609	-24.789	16.570	1.00	0.00	C
	ATOM	570	CD1	LEU	M	209	6.590	-25.923	16.871	1.00	0.00	C
	ATOM	571	CD2	LEU	M	209	4.831	-25.116	15.295	1.00	0.00	C
	ATOM	572	N	ARG	M	210	5.314	-21.695	19.000	1.00	0.00	N
40	ATOM	573	CA	ARG	M	210	5.938	-20.386	18.796	1.00	0.00	C
	ATOM	574	C	ARG	M	210	7.094	-20.160	19.780	1.00	0.00	C
	ATOM	575	O	ARG	M	210	8.194	-19.788	19.390	1.00	0.00	O
	ATOM	576	CB	ARG	M	210	4.919	-19.217	18.766	1.00	0.00	C
	ATOM	577	CG	ARG	M	210	4.539	-18.617	20.123	1.00	0.00	C
45	ATOM	578	CD	ARG	M	210	3.368	-17.645	20.037	1.00	0.00	C
	ATOM	579	NE	ARG	M	210	3.204	-16.963	21.336	1.00	0.00	N
	ATOM	580	CZ	ARG	M	210	2.675	-17.521	22.478	1.00	0.00	C
	ATOM	581	NH1	ARG	M	210	2.108	-18.771	22.534	1.00	0.00	N
	ATOM	582	NH2	ARG	M	210	2.702	-16.823	23.658	1.00	0.00	N
50	ATOM	583	N	LEU	M	211	6.766	-20.348	21.118	1.00	0.00	N
	ATOM	584	CA	LEU	M	211	7.668	-19.970	22.201	1.00	0.00	C
	ATOM	585	C	LEU	M	211	8.744	-21.017	22.457	1.00	0.00	C
	ATOM	586	O	LEU	M	211	9.830	-20.675	22.903	1.00	0.00	O
	ATOM	587	CB	LEU	M	211	6.921	-19.556	23.477	1.00	0.00	C
55	ATOM	588	CG	LEU	M	211	6.253	-20.691	24.283	1.00	0.00	C
	ATOM	589	CD1	LEU	M	211	7.071	-21.031	25.529	1.00	0.00	C
	ATOM	590	CD2	LEU	M	211	4.828	-20.304	24.668	1.00	0.00	C
	ATOM	591	N	PHE	M	212	8.395	-22.335	22.194	1.00	0.00	N
	ATOM	592	CA	PHE	M	212	9.343	-23.437	22.323	1.00	0.00	C
60	ATOM	593	C	PHE	M	212	10.537	-23.177	21.400	1.00	0.00	C
	ATOM	594	O	PHE	M	212	11.684	-23.308	21.810	1.00	0.00	O
	ATOM	595	CB	PHE	M	212	8.657	-24.790	22.053	1.00	0.00	C

-49-

Table 4 - Continued

	ATOM	596	CG	PHE	M	212	9.531	-26.001	22.266	1.00	0.00	C
	ATOM	597	CD1	PHE	M	212	9.585	-27.015	21.279	1.00	0.00	C
5	ATOM	598	CD2	PHE	M	212	10.273	-26.176	23.463	1.00	0.00	C
	ATOM	599	CE1	PHE	M	212	10.360	-28.171	21.483	1.00	0.00	C
	ATOM	600	CE2	PHE	M	212	11.054	-27.328	23.659	1.00	0.00	C
	ATOM	601	CZ	PHE	M	212	11.095	-28.324	22.671	1.00	0.00	C
	ATOM	602	N	GLY	M	213	10.213	-22.782	20.106	1.00	0.00	N
10	ATOM	603	CA	GLY	M	213	11.222	-22.358	19.149	1.00	0.00	C
	ATOM	604	C	GLY	M	213	12.077	-21.244	19.726	1.00	0.00	C
	ATOM	605	O	GLY	M	213	13.296	-21.353	19.773	1.00	0.00	O
	ATOM	606	N	ASN	M	214	11.360	-20.130	20.149	1.00	0.00	N
	ATOM	607	CA	ASN	M	214	12.007	-18.898	20.604	1.00	0.00	C
15	ATOM	608	C	ASN	M	214	13.063	-19.144	21.674	1.00	0.00	C
	ATOM	609	O	ASN	M	214	14.176	-18.654	21.546	1.00	0.00	O
	ATOM	610	CB	ASN	M	214	11.001	-17.841	21.083	1.00	0.00	C
	ATOM	611	CG	ASN	M	214	11.704	-16.606	21.615	1.00	0.00	C
	ATOM	612	OD1	ASN	M	214	11.859	-16.419	22.813	1.00	0.00	O
20	ATOM	613	ND2	ASN	M	214	12.177	-15.754	20.643	1.00	0.00	N
	ATOM	614	N	GLN	M	252	6.092	-15.258	27.574	1.00	0.00	N
	ATOM	615	CA	GLN	M	252	5.399	-15.988	26.508	1.00	0.00	C
	ATOM	616	C	GLN	M	252	4.487	-17.062	27.109	1.00	0.00	C
	ATOM	617	O	GLN	M	252	3.343	-17.209	26.701	1.00	0.00	O
25	ATOM	618	CB	GLN	M	252	6.348	-16.641	25.488	1.00	0.00	C
	ATOM	619	CG	GLN	M	252	7.165	-15.662	24.639	1.00	0.00	C
	ATOM	620	CD	GLN	M	252	6.294	-14.812	23.745	1.00	0.00	C
	ATOM	621	OE1	GLN	M	252	5.949	-13.685	24.069	1.00	0.00	O
	ATOM	622	NE2	GLN	M	252	5.911	-15.431	22.578	1.00	0.00	N
30	ATOM	623	N	ILE	M	255	1.315	-15.654	28.673	1.00	0.00	N
	ATOM	624	CA	ILE	M	255	0.314	-15.323	27.648	1.00	0.00	C
	ATOM	625	C	ILE	M	255	-0.456	-16.594	27.270	1.00	0.00	C
	ATOM	626	O	ILE	M	255	-1.677	-16.562	27.206	1.00	0.00	O
	ATOM	627	CB	ILE	M	255	0.899	-14.600	26.397	1.00	0.00	C
35	ATOM	628	CG1	ILE	M	255	1.511	-13.217	26.721	1.00	0.00	C
	ATOM	629	CG2	ILE	M	255	-0.132	-14.462	25.269	1.00	0.00	C
	ATOM	630	CD1	ILE	M	255	0.539	-12.178	27.265	1.00	0.00	C
	ATOM	631	N	PHE	M	256	0.309	-17.724	26.987	1.00	0.00	N
	ATOM	632	CA	PHE	M	256	-0.300	-19.014	26.640	1.00	0.00	C
40	ATOM	633	C	PHE	M	256	-1.370	-19.377	27.673	1.00	0.00	C
	ATOM	634	O	PHE	M	256	-2.501	-19.676	27.309	1.00	0.00	O
	ATOM	635	CB	PHE	M	256	0.741	-20.143	26.468	1.00	0.00	C
	ATOM	636	CG	PHE	M	256	0.139	-21.530	26.434	1.00	0.00	C
	ATOM	637	CD1	PHE	M	256	0.410	-22.456	27.472	1.00	0.00	C
45	ATOM	638	CD2	PHE	M	256	-0.735	-21.920	25.391	1.00	0.00	C
	ATOM	639	CE1	PHE	M	256	-0.169	-23.740	27.459	1.00	0.00	C
	ATOM	640	CE2	PHE	M	256	-1.314	-23.203	25.379	1.00	0.00	C
	ATOM	641	CZ	PHE	M	256	-1.029	-24.114	26.412	1.00	0.00	C
	ATOM	642	N	LEU	M	259	-4.533	-17.251	27.581	1.00	0.00	N
50	ATOM	643	CA	LEU	M	259	-5.286	-17.370	26.332	1.00	0.00	C
	ATOM	644	C	LEU	M	259	-6.190	-18.597	26.384	1.00	0.00	C
	ATOM	645	O	LEU	M	259	-7.382	-18.501	26.120	1.00	0.00	O
	ATOM	646	CB	LEU	M	259	-4.356	-17.357	25.099	1.00	0.00	C
	ATOM	647	CG	LEU	M	259	-5.088	-17.225	23.745	1.00	0.00	C
55	ATOM	648	CD1	LEU	M	259	-4.218	-16.458	22.749	1.00	0.00	C
	ATOM	649	CD2	LEU	M	259	-5.448	-18.586	23.146	1.00	0.00	C

-50-

Table 5

5	ATOM	1	N	ALA	A	21	5.881	-12.842	-1.403	1.00	0.00	N
	ATOM	2	CA	ALA	A	21	5.032	-12.962	-0.219	1.00	0.00	C
	ATOM	3	C	ALA	A	21	3.724	-12.190	-0.393	1.00	0.00	C
	ATOM	4	O	ALA	A	21	2.644	-12.753	-0.261	1.00	0.00	O
10	ATOM	5	CB	ALA	A	21	5.743	-12.524	1.061	1.00	0.00	C
	ATOM	6	N	ILE	A	22	3.865	-10.830	-0.654	1.00	0.00	N
	ATOM	7	CA	ILE	A	22	2.696	-9.942	-0.707	1.00	0.00	C
	ATOM	8	C	ILE	A	22	1.780	-10.304	-1.877	1.00	0.00	C
15	ATOM	9	O	ILE	A	22	0.564	-10.249	-1.742	1.00	0.00	O
	ATOM	10	CB	ILE	A	22	3.012	-8.420	-0.634	1.00	0.00	C
	ATOM	11	CG1	ILE	A	22	3.808	-7.845	-1.829	1.00	0.00	C
	ATOM	12	CG2	ILE	A	22	3.732	-8.094	0.679	1.00	0.00	C
20	ATOM	13	CD1	ILE	A	22	2.917	-7.216	-2.890	1.00	0.00	C
	ATOM	14	N	ALA	A	24	1.317	-13.263	-3.458	1.00	0.00	N
	ATOM	15	CA	ALA	A	24	0.563	-14.470	-3.134	1.00	0.00	C
	ATOM	16	C	ALA	A	24	-0.656	-14.135	-2.280	1.00	0.00	C
25	ATOM	17	O	ALA	A	24	-1.754	-14.581	-2.580	1.00	0.00	O
	ATOM	18	CB	ALA	A	24	1.423	-15.525	-2.443	1.00	0.00	C
	ATOM	19	N	GLY	A	25	-0.414	-13.331	-1.171	1.00	0.00	N
	ATOM	20	CA	GLY	A	25	-1.450	-12.972	-0.212	1.00	0.00	C
30	ATOM	21	C	GLY	A	25	-2.689	-12.390	-0.872	1.00	0.00	C
	ATOM	22	O	GLY	A	25	-3.799	-12.857	-0.647	1.00	0.00	O
	ATOM	23	N	LEU	A	59	-1.069	-19.335	-3.710	1.00	0.00	N
	ATOM	24	CA	LEU	A	59	-0.138	-19.537	-2.599	1.00	0.00	C
35	ATOM	25	C	LEU	A	59	1.257	-19.890	-3.118	1.00	0.00	C
	ATOM	26	O	LEU	A	59	2.236	-19.287	-2.700	1.00	0.00	O
	ATOM	27	CB	LEU	A	59	-0.654	-20.593	-1.599	1.00	0.00	C
	ATOM	28	CG	LEU	A	59	0.253	-20.834	-0.375	1.00	0.00	C
40	ATOM	29	CD1	LEU	A	59	0.412	-19.583	0.489	1.00	0.00	C
	ATOM	30	CD2	LEU	A	59	-0.317	-21.972	0.469	1.00	0.00	C
	ATOM	31	N	ILE	K	16	10.647	-2.985	11.484	1.00	0.00	N
	ATOM	32	CA	ILE	K	16	9.949	-4.131	12.078	1.00	0.00	C
45	ATOM	33	C	ILE	K	16	8.633	-3.639	12.688	1.00	0.00	C
	ATOM	34	O	ILE	K	16	7.578	-4.192	12.405	1.00	0.00	O
	ATOM	35	CB	ILE	K	16	10.839	-4.911	13.092	1.00	0.00	C
	ATOM	36	CG1	ILE	K	16	11.982	-5.650	12.360	1.00	0.00	C
50	ATOM	37	CG2	ILE	K	16	10.028	-5.918	13.915	1.00	0.00	C
	ATOM	38	CD1	ILE	K	16	13.158	-5.961	13.274	1.00	0.00	C
	ATOM	39	N	GLY	K	19	5.970	-2.022	10.048	1.00	0.00	N
	ATOM	40	CA	GLY	K	19	5.412	-3.072	9.210	1.00	0.00	C
55	ATOM	41	C	GLY	K	19	4.400	-3.910	9.967	1.00	0.00	C
	ATOM	42	O	GLY	K	19	3.291	-4.135	9.498	1.00	0.00	O
	ATOM	43	N	GLY	K	20	4.855	-4.394	11.185	1.00	0.00	N
	ATOM	44	CA	GLY	K	20	4.029	-5.189	12.076	1.00	0.00	C
60	ATOM	45	C	GLY	K	20	2.705	-4.513	12.381	1.00	0.00	C
	ATOM	46	O	GLY	K	20	1.655	-5.133	12.286	1.00	0.00	O
	ATOM	47	N	ALA	K	21	2.813	-3.195	12.802	1.00	0.00	N
	ATOM	48	CA	ALA	K	21	1.674	-2.403	13.259	1.00	0.00	C
55	ATOM	49	C	ALA	K	21	0.573	-2.358	12.210	1.00	0.00	C
	ATOM	50	O	ALA	K	21	-0.571	-2.687	12.496	1.00	0.00	O
	ATOM	51	CB	ALA	K	21	2.069	-0.980	13.646	1.00	0.00	C
	ATOM	52	N	ILE	K	22	0.959	-1.866	10.968	1.00	0.00	N
60	ATOM	53	CA	ILE	K	22	-0.022	-1.644	9.902	1.00	0.00	C
	ATOM	54	C	ILE	K	22	-0.648	-2.967	9.462	1.00	0.00	C
	ATOM	55	O	ILE	K	22	-1.839	-3.017	9.187	1.00	0.00	O
	ATOM	56	CB	ILE	K	22	0.471	-0.759	8.721	1.00	0.00	C
60	ATOM	57	CG1	ILE	K	22	1.645	-1.331	7.895	1.00	0.00	C

-51-

Table 5 - Continued

	ATOM	58	CG2	ILE	K	22	0.838	0.636	9.238	1.00	0.00	C
	ATOM	59	CD1	ILE	K	22	1.196	-2.128	6.680	1.00	0.00	C
5	ATOM	60	N	GLY	K	23	0.209	-4.060	9.392	1.00	0.00	N
	ATOM	61	CA	GLY	K	23	-0.252	-5.389	9.028	1.00	0.00	C
	ATOM	62	C	GLY	K	23	-1.370	-5.851	9.940	1.00	0.00	C
	ATOM	63	O	GLY	K	23	-2.445	-6.210	9.480	1.00	0.00	O
	ATOM	64	N	ALA	K	24	-1.045	-5.828	11.290	1.00	0.00	N
10	ATOM	65	CA	ALA	K	24	-1.970	-6.229	12.347	1.00	0.00	C
	ATOM	66	C	ALA	K	24	-3.298	-5.486	12.227	1.00	0.00	C
	ATOM	67	O	ALA	K	24	-4.355	-6.101	12.268	1.00	0.00	O
	ATOM	68	CB	ALA	K	24	-1.374	-6.022	13.737	1.00	0.00	C
	ATOM	69	N	GLY	K	25	-3.201	-4.105	12.103	1.00	0.00	N
15	ATOM	70	CA	GLY	K	25	-4.358	-3.224	12.066	1.00	0.00	C
	ATOM	71	C	GLY	K	25	-5.345	-3.604	10.977	1.00	0.00	C
	ATOM	72	O	GLY	K	25	-6.530	-3.776	11.233	1.00	0.00	O
	ATOM	73	N	GLY	K	27	-5.390	-6.420	9.296	1.00	0.00	N
	ATOM	74	CA	GLY	K	27	-5.822	-7.781	9.578	1.00	0.00	C
20	ATOM	75	C	GLY	K	27	-7.102	-7.831	10.391	1.00	0.00	C
	ATOM	76	O	GLY	K	27	-8.060	-8.484	9.997	1.00	0.00	O
	ATOM	77	N	ASP	K	28	-7.068	-7.107	11.579	1.00	0.00	N
	ATOM	78	CA	ASP	K	28	-8.213	-7.027	12.494	1.00	0.00	C
	ATOM	79	C	ASP	K	28	-9.473	-6.650	11.728	1.00	0.00	C
25	ATOM	80	O	ASP	K	28	-10.504	-7.289	11.892	1.00	0.00	O
	ATOM	81	CB	ASP	K	28	-8.029	-6.024	13.647	1.00	0.00	C
	ATOM	82	CG	ASP	K	28	-7.176	-6.602	14.743	1.00	0.00	C
	ATOM	83	OD1	ASP	K	28	-5.961	-6.498	14.817	1.00	0.00	O
	ATOM	84	OD2	ASP	K	28	-7.934	-7.314	15.613	1.00	0.00	O
30	ATOM	85	N	ALA	K	31	-10.360	-9.341	8.254	1.00	0.00	N
	ATOM	86	CA	ALA	K	31	-10.695	-10.710	8.645	1.00	0.00	C
	ATOM	87	C	ALA	K	31	-11.886	-10.733	9.598	1.00	0.00	C
	ATOM	88	O	ALA	K	31	-12.791	-11.543	9.438	1.00	0.00	O
	ATOM	89	CB	ALA	K	31	-9.513	-11.450	9.262	1.00	0.00	C
35	ATOM	90	N	PHE	K	53	-11.251	-14.828	19.330	1.00	0.00	N
	ATOM	91	CA	PHE	K	53	-10.086	-15.610	18.910	1.00	0.00	C
	ATOM	92	C	PHE	K	53	-9.416	-14.919	17.715	1.00	0.00	C
	ATOM	93	O	PHE	K	53	-8.214	-14.687	17.727	1.00	0.00	O
	ATOM	94	CB	PHE	K	53	-10.413	-17.088	18.615	1.00	0.00	C
40	ATOM	95	CG	PHE	K	53	-9.168	-17.944	18.656	1.00	0.00	C
	ATOM	96	CD1	PHE	K	53	-8.363	-18.116	17.502	1.00	0.00	C
	ATOM	97	CD2	PHE	K	53	-8.769	-18.572	19.864	1.00	0.00	C
	ATOM	98	CE1	PHE	K	53	-7.177	-18.871	17.564	1.00	0.00	C
	ATOM	99	CE2	PHE	K	53	-7.587	-19.335	19.920	1.00	0.00	C
45	ATOM	100	CZ	PHE	K	53	-6.787	-19.478	18.772	1.00	0.00	C
	ATOM	101	N	PHE	K	54	-10.253	-14.602	16.650	1.00	0.00	N
	ATOM	102	CA	PHE	K	54	-9.754	-13.946	15.437	1.00	0.00	C
	ATOM	103	C	PHE	K	54	-9.027	-12.653	15.816	1.00	0.00	C
	ATOM	104	O	PHE	K	54	-7.868	-12.465	15.469	1.00	0.00	O
50	ATOM	105	CB	PHE	K	54	-10.857	-13.644	14.396	1.00	0.00	C
	ATOM	106	CG	PHE	K	54	-11.031	-14.732	13.363	1.00	0.00	C
	ATOM	107	CD1	PHE	K	54	-10.657	-14.497	12.014	1.00	0.00	C
	ATOM	108	CD2	PHE	K	54	-11.600	-15.986	13.699	1.00	0.00	C
	ATOM	109	CE1	PHE	K	54	-10.855	-15.483	11.030	1.00	0.00	C
55	ATOM	110	CE2	PHE	K	54	-11.796	-16.971	12.711	1.00	0.00	C
	ATOM	111	CZ	PHE	K	54	-11.427	-16.719	11.377	1.00	0.00	C
	ATOM	112	N	ILE	K	55	-9.789	-11.720	16.511	1.00	0.00	N
	ATOM	113	CA	ILE	K	55	-9.296	-10.359	16.735	1.00	0.00	C
	ATOM	114	C	ILE	K	55	-8.075	-10.305	17.655	1.00	0.00	C
60	ATOM	115	O	ILE	K	55	-7.239	-9.431	17.475	1.00	0.00	O

-52-

Table 5 - Continued

	ATOM	116	CB	ILE	K	55	-10.374	-9.314	17.141	1.00	0.00	C
	ATOM	117	CG1	ILE	K	55	-11.066	-9.614	18.484	1.00	0.00	C
5	ATOM	118	CG2	ILE	K	55	-11.397	-9.148	16.011	1.00	0.00	C
	ATOM	119	CD1	ILE	K	55	-11.876	-8.446	19.024	1.00	0.00	C
	ATOM	120	N	THR	K	56	-8.005	-11.228	18.695	1.00	0.00	N
	ATOM	121	CA	THR	K	56	-6.877	-11.241	19.628	1.00	0.00	C
	ATOM	122	C	THR	K	56	-5.591	-11.653	18.909	1.00	0.00	C
10	ATOM	123	O	THR	K	56	-4.545	-11.076	19.169	1.00	0.00	O
	ATOM	124	CB	THR	K	56	-7.142	-12.025	20.940	1.00	0.00	C
	ATOM	125	OG1	THR	K	56	-6.232	-11.582	21.949	1.00	0.00	O
	ATOM	126	CG2	THR	K	56	-6.997	-13.539	20.848	1.00	0.00	C
	ATOM	127	N	VAL	K	57	-5.684	-12.700	17.993	1.00	0.00	N
15	ATOM	128	CA	VAL	K	57	-4.525	-13.128	17.197	1.00	0.00	C
	ATOM	129	C	VAL	K	57	-4.015	-11.905	16.430	1.00	0.00	C
	ATOM	130	O	VAL	K	57	-2.835	-11.585	16.495	1.00	0.00	O
	ATOM	131	CB	VAL	K	57	-4.821	-14.346	16.278	1.00	0.00	C
	ATOM	132	CG1	VAL	K	57	-3.708	-14.594	15.256	1.00	0.00	C
20	ATOM	133	CG2	VAL	K	57	-5.001	-15.618	17.111	1.00	0.00	C
	ATOM	134	N	GLY	K	58	-4.974	-11.224	15.688	1.00	0.00	N
	ATOM	135	CA	GLY	K	58	-4.665	-10.040	14.902	1.00	0.00	C
	ATOM	136	C	GLY	K	58	-3.915	-8.999	15.716	1.00	0.00	C
	ATOM	137	O	GLY	K	58	-2.837	-8.566	15.338	1.00	0.00	O
25	ATOM	138	N	LEU	K	59	-4.569	-8.588	16.866	1.00	0.00	N
	ATOM	139	CA	LEU	K	59	-4.102	-7.488	17.709	1.00	0.00	C
	ATOM	140	C	LEU	K	59	-2.696	-7.785	18.219	1.00	0.00	C
	ATOM	141	O	LEU	K	59	-1.786	-6.994	18.011	1.00	0.00	O
	ATOM	142	CB	LEU	K	59	-5.084	-7.200	18.866	1.00	0.00	C
30	ATOM	143	CG	LEU	K	59	-4.667	-6.055	19.810	1.00	0.00	C
	ATOM	144	CD1	LEU	K	59	-4.617	-4.705	19.094	1.00	0.00	C
	ATOM	145	CD2	LEU	K	59	-5.640	-5.983	20.985	1.00	0.00	C
	ATOM	146	N	VAL	K	60	-2.575	-8.958	18.956	1.00	0.00	N
	ATOM	147	CA	VAL	K	60	-1.376	-9.313	19.723	1.00	0.00	C
35	ATOM	148	C	VAL	K	60	-0.172	-9.621	18.808	1.00	0.00	C
	ATOM	149	O	VAL	K	60	0.965	-9.587	19.262	1.00	0.00	O
	ATOM	150	CB	VAL	K	60	-1.666	-10.425	20.774	1.00	0.00	C
	ATOM	151	CG1	VAL	K	60	-0.436	-10.797	21.603	1.00	0.00	C
	ATOM	152	CG2	VAL	K	60	-2.756	-9.980	21.761	1.00	0.00	C
40	ATOM	153	N	GLU	K	61	-0.439	-9.875	17.464	1.00	0.00	N
	ATOM	154	CA	GLU	K	61	0.617	-9.928	16.448	1.00	0.00	C
	ATOM	155	C	GLU	K	61	1.600	-8.765	16.629	1.00	0.00	C
	ATOM	156	O	GLU	K	61	2.806	-8.976	16.643	1.00	0.00	O
	ATOM	157	CB	GLU	K	61	0.048	-9.957	15.018	1.00	0.00	C
45	ATOM	158	CG	GLU	K	61	1.116	-10.204	13.955	1.00	0.00	C
	ATOM	159	CD	GLU	K	61	0.480	-10.239	12.589	1.00	0.00	C
	ATOM	160	OE1	GLU	K	61	0.270	-9.258	11.891	1.00	0.00	O
	ATOM	161	OE2	GLU	K	61	0.106	-11.500	12.255	1.00	0.00	O
	ATOM	162	N	ALA	K	62	1.026	-7.499	16.735	1.00	0.00	N
50	ATOM	163	CA	ALA	K	62	1.838	-6.288	16.832	1.00	0.00	C
	ATOM	164	C	ALA	K	62	2.817	-6.381	18.011	1.00	0.00	C
	ATOM	165	O	ALA	K	62	4.014	-6.325	17.766	1.00	0.00	O
	ATOM	166	CB	ALA	K	62	1.026	-4.994	16.802	1.00	0.00	C
	ATOM	167	N	TYR	K	64	4.143	-8.947	19.533	1.00	0.00	N
55	ATOM	168	CA	TYR	K	64	5.238	-9.901	19.299	1.00	0.00	C
	ATOM	169	C	TYR	K	64	6.411	-9.187	18.617	1.00	0.00	C
	ATOM	170	O	TYR	K	64	7.549	-9.293	19.057	1.00	0.00	O
	ATOM	171	CB	TYR	K	64	4.859	-11.158	18.485	1.00	0.00	C
	ATOM	172	CG	TYR	K	64	3.743	-12.009	19.045	1.00	0.00	C
60	ATOM	173	CD1	TYR	K	64	3.591	-12.248	20.436	1.00	0.00	C
	ATOM	174	CD2	TYR	K	64	2.826	-12.617	18.151	1.00	0.00	C
	ATOM	175	CE1	TYR	K	64	2.524	-13.026	20.919	1.00	0.00	C

-53-

Table 5 - Continued

	ATOM	176	CE2	TYR	K	64	1.754	-13.394	18.625	1.00	0.00	C
	ATOM	177	CZ	TYR	K	64	1.603	-13.582	20.014	1.00	0.00	C
5	ATOM	178	OH	TYR	K	64	0.533	-14.296	20.528	1.00	0.00	O
	ATOM	179	N	PHE	K	65	6.092	-8.473	17.468	1.00	0.00	N
	ATOM	180	CA	PHE	K	65	7.112	-7.764	16.688	1.00	0.00	C
	ATOM	181	C	PHE	K	65	7.701	-6.560	17.423	1.00	0.00	C
	ATOM	182	O	PHE	K	65	8.869	-6.250	17.232	1.00	0.00	O
10	ATOM	183	CB	PHE	K	65	6.605	-7.346	15.295	1.00	0.00	C
	ATOM	184	CG	PHE	K	65	6.399	-8.550	14.405	1.00	0.00	C
	ATOM	185	CD1	PHE	K	65	7.512	-9.293	13.931	1.00	0.00	C
	ATOM	186	CE1	PHE	K	65	7.321	-10.463	13.174	1.00	0.00	C
	ATOM	187	CZ	PHE	K	65	6.021	-10.897	12.868	1.00	0.00	C
15	ATOM	188	CE2	PHE	K	65	4.911	-10.153	13.301	1.00	0.00	C
	ATOM	189	CD2	PHE	K	65	5.096	-8.983	14.061	1.00	0.00	C
	ATOM	190	N	ILE	K	66	6.849	-5.852	18.262	1.00	0.00	N
	ATOM	191	CA	ILE	K	66	7.323	-4.737	19.093	1.00	0.00	C
	ATOM	192	C	ILE	K	66	8.436	-5.275	19.995	1.00	0.00	C
20	ATOM	193	O	ILE	K	66	9.510	-4.692	20.045	1.00	0.00	O
	ATOM	194	CB	ILE	K	66	6.205	-4.010	19.896	1.00	0.00	C
	ATOM	195	CG1	ILE	K	66	5.194	-3.331	18.944	1.00	0.00	C
	ATOM	196	CG2	ILE	K	66	6.795	-2.959	20.847	1.00	0.00	C
	ATOM	197	CD1	ILE	K	66	3.915	-2.888	19.641	1.00	0.00	C
25	ATOM	198	N	ASN	K	67	8.135	-6.412	20.737	1.00	0.00	N
	ATOM	199	CA	ASN	K	67	9.101	-7.043	21.643	1.00	0.00	C
	ATOM	200	C	ASN	K	67	10.396	-7.398	20.922	1.00	0.00	C
	ATOM	201	O	ASN	K	67	11.470	-7.186	21.466	1.00	0.00	O
	ATOM	202	CB	ASN	K	67	8.561	-8.295	22.359	1.00	0.00	C
30	ATOM	203	CG	ASN	K	67	7.789	-7.913	23.607	1.00	0.00	C
	ATOM	204	OD1	ASN	K	67	6.585	-7.703	23.596	1.00	0.00	O
	ATOM	205	ND2	ASN	K	67	8.574	-7.784	24.731	1.00	0.00	N
	ATOM	206	N	LEU	K	68	10.265	-8.000	19.676	1.00	0.00	N
	ATOM	207	CA	LEU	K	68	11.425	-8.412	18.874	1.00	0.00	C
35	ATOM	208	C	LEU	K	68	12.356	-7.211	18.673	1.00	0.00	C
	ATOM	209	O	LEU	K	68	13.544	-7.283	18.962	1.00	0.00	O
	ATOM	210	CB	LEU	K	68	11.000	-9.085	17.550	1.00	0.00	C
	ATOM	211	CG	LEU	K	68	12.106	-9.924	16.872	1.00	0.00	C
	ATOM	212	CD1	LEU	K	68	11.478	-11.029	16.022	1.00	0.00	C
40	ATOM	213	CD2	LEU	K	68	13.020	-9.082	15.983	1.00	0.00	C
	ATOM	214	N	GLY	L	14	15.198	-8.074	9.311	1.00	0.00	N
	ATOM	215	CA	GLY	L	14	14.066	-7.197	9.559	1.00	0.00	C
	ATOM	216	C	GLY	L	14	12.995	-7.318	8.489	1.00	0.00	C
	ATOM	217	O	GLY	L	14	11.827	-7.504	8.800	1.00	0.00	O
45	ATOM	218	N	ILE	L	16	12.564	-9.668	6.039	1.00	0.00	N
	ATOM	219	CA	ILE	L	16	11.972	-10.997	5.849	1.00	0.00	C
	ATOM	220	C	ILE	L	16	10.872	-11.230	6.896	1.00	0.00	C
	ATOM	221	O	ILE	L	16	9.821	-11.769	6.579	1.00	0.00	O
	ATOM	222	CB	ILE	L	16	13.034	-12.140	5.737	1.00	0.00	C
50	ATOM	223	CG1	ILE	L	16	12.723	-13.142	4.605	1.00	0.00	C
	ATOM	224	CG2	ILE	L	16	13.344	-12.873	7.046	1.00	0.00	C
	ATOM	225	CD1	ILE	L	16	11.458	-13.971	4.775	1.00	0.00	C
	ATOM	226	N	MET	L	17	11.163	-10.818	8.193	1.00	0.00	N
	ATOM	227	CA	MET	L	17	10.196	-10.952	9.281	1.00	0.00	C
55	ATOM	228	C	MET	L	17	8.956	-10.129	8.951	1.00	0.00	C
	ATOM	229	O	MET	L	17	7.865	-10.675	8.862	1.00	0.00	O
	ATOM	230	CB	MET	L	17	10.759	-10.564	10.663	1.00	0.00	C
	ATOM	231	CG	MET	L	17	11.766	-11.566	11.230	1.00	0.00	C
	ATOM	232	SD	MET	L	17	10.949	-13.111	11.753	1.00	0.00	S
60	ATOM	233	CE	MET	L	17	11.549	-14.216	10.448	1.00	0.00	C
	ATOM	234	N	ALA	L	18	9.158	-8.765	8.795	1.00	0.00	N
	ATOM	235	CA	ALA	L	18	8.046	-7.822	8.702	1.00	0.00	C

-54-

Table 5 - Continued

5	ATOM	236	C	ALA	L	18	7.152	-8.180	7.521	1.00	0.00	C
	ATOM	237	O	ALA	L	18	5.979	-8.477	7.692	1.00	0.00	O
	ATOM	238	CB	ALA	L	18	8.510	-6.370	8.625	1.00	0.00	C
	ATOM	239	N	GLY	L	19	7.766	-8.127	6.279	1.00	0.00	N
	ATOM	240	CA	GLY	L	19	7.039	-8.324	5.037	1.00	0.00	C
10	ATOM	241	C	GLY	L	19	6.426	-9.707	4.980	1.00	0.00	C
	ATOM	242	O	GLY	L	19	5.227	-9.857	4.788	1.00	0.00	O
	ATOM	243	N	GLY	L	20	7.342	-10.737	5.121	1.00	0.00	N
	ATOM	244	CA	GLY	L	20	7.000	-12.131	4.906	1.00	0.00	C
	ATOM	245	C	GLY	L	20	5.877	-12.608	5.802	1.00	0.00	C
15	ATOM	246	O	GLY	L	20	4.881	-13.136	5.327	1.00	0.00	O
	ATOM	247	N	ALA	L	21	6.105	-12.439	7.161	1.00	0.00	N
	ATOM	248	CA	ALA	L	21	5.177	-12.957	8.167	1.00	0.00	C
	ATOM	249	C	ALA	L	21	3.795	-12.317	8.072	1.00	0.00	C
	ATOM	250	O	ALA	L	21	2.795	-12.996	8.255	1.00	0.00	O
20	ATOM	251	CB	ALA	L	21	5.700	-12.806	9.589	1.00	0.00	C
	ATOM	252	N	ILE	L	22	3.756	-10.947	7.836	1.00	0.00	N
	ATOM	253	CA	ILE	L	22	2.476	-10.243	7.663	1.00	0.00	C
	ATOM	254	C	ILE	L	22	1.766	-10.786	6.419	1.00	0.00	C
	ATOM	255	O	ILE	L	22	0.554	-10.946	6.440	1.00	0.00	O
25	ATOM	256	CB	ILE	L	22	2.626	-8.694	7.709	1.00	0.00	C
	ATOM	257	CG1	ILE	L	22	2.574	-8.158	9.161	1.00	0.00	C
	ATOM	258	CG2	ILE	L	22	1.550	-7.959	6.902	1.00	0.00	C
	ATOM	259	CD1	ILE	L	22	3.547	-8.791	10.144	1.00	0.00	C
	ATOM	260	N	GLY	L	23	2.556	-11.065	5.313	1.00	0.00	N
30	ATOM	261	CA	GLY	L	23	2.039	-11.727	4.122	1.00	0.00	C
	ATOM	262	C	GLY	L	23	1.274	-12.998	4.463	1.00	0.00	C
	ATOM	263	O	GLY	L	23	0.151	-13.189	4.016	1.00	0.00	O
	ATOM	264	N	ALA	L	24	1.957	-13.889	5.281	1.00	0.00	N
	ATOM	265	CA	ALA	L	24	1.364	-15.139	5.762	1.00	0.00	C
35	ATOM	266	C	ALA	L	24	0.049	-14.890	6.499	1.00	0.00	C
	ATOM	267	O	ALA	L	24	-0.925	-15.594	6.275	1.00	0.00	O
	ATOM	268	CB	ALA	L	24	2.317	-15.935	6.650	1.00	0.00	C
	ATOM	269	N	GLY	L	25	0.070	-13.864	7.434	1.00	0.00	N
	ATOM	270	CA	GLY	L	25	-1.089	-13.467	8.219	1.00	0.00	C
40	ATOM	271	C	GLY	L	25	-2.292	-13.111	7.362	1.00	0.00	C
	ATOM	272	O	GLY	L	25	-3.397	-13.566	7.623	1.00	0.00	O
	ATOM	273	N	ILE	L	26	-2.031	-12.218	6.329	1.00	0.00	N
	ATOM	274	CA	ILE	L	26	-3.054	-11.761	5.381	1.00	0.00	C
	ATOM	275	C	ILE	L	26	-3.674	-13.003	4.743	1.00	0.00	C
45	ATOM	276	O	ILE	L	26	-4.889	-13.145	4.749	1.00	0.00	O
	ATOM	277	CB	ILE	L	26	-2.514	-10.752	4.324	1.00	0.00	C
	ATOM	278	CG1	ILE	L	26	-2.147	-9.409	4.994	1.00	0.00	C
	ATOM	279	CG2	ILE	L	26	-3.535	-10.506	3.201	1.00	0.00	C
	ATOM	280	CD1	ILE	L	26	-1.217	-8.554	4.146	1.00	0.00	C
50	ATOM	281	N	GLY	L	27	-2.774	-13.896	4.170	1.00	0.00	N
	ATOM	282	CA	GLY	L	27	-3.181	-15.110	3.481	1.00	0.00	C
	ATOM	283	C	GLY	L	27	-4.140	-15.936	4.316	1.00	0.00	C
	ATOM	284	O	GLY	L	27	-5.230	-16.267	3.870	1.00	0.00	O
	ATOM	285	N	ASP	L	28	-3.663	-16.268	5.578	1.00	0.00	N
55	ATOM	286	CA	ASP	L	28	-4.426	-17.067	6.539	1.00	0.00	C
	ATOM	287	C	ASP	L	28	-5.824	-16.490	6.730	1.00	0.00	C
	ATOM	288	O	ASP	L	28	-6.793	-17.235	6.725	1.00	0.00	O
	ATOM	289	CB	ASP	L	28	-3.714	-17.205	7.894	1.00	0.00	C
	ATOM	290	CG	ASP	L	28	-4.554	-17.995	8.870	1.00	0.00	C
60	ATOM	291	OD1	ASP	L	28	-5.304	-17.502	9.701	1.00	0.00	O
	ATOM	292	OD2	ASP	L	28	-4.426	-19.331	8.666	1.00	0.00	O
	ATOM	293	N	GLY	L	29	-5.891	-15.120	6.948	1.00	0.00	N
	ATOM	294	CA	GLY	L	29	-7.140	-14.419	7.187	1.00	0.00	C
	ATOM	295	C	GLY	L	29	-8.116	-14.632	6.046	1.00	0.00	C

-55-

Table 5 - Continued

5	ATOM	296	O	GLY	L	29	-9.157	-15.251	6.219	1.00	0.00	O
	ATOM	297	N	VAL	L	30	-7.724	-14.059	4.844	1.00	0.00	N
	ATOM	298	CA	VAL	L	30	-8.629	-13.949	3.692	1.00	0.00	C
	ATOM	299	C	VAL	L	30	-9.094	-15.327	3.208	1.00	0.00	C
	ATOM	300	O	VAL	L	30	-10.279	-15.543	2.987	1.00	0.00	O
10	ATOM	301	CB	VAL	L	30	-8.106	-13.054	2.531	1.00	0.00	C
	ATOM	302	CG1	VAL	L	30	-7.924	-11.606	2.995	1.00	0.00	C
	ATOM	303	CG2	VAL	L	30	-6.817	-13.548	1.866	1.00	0.00	C
	ATOM	304	N	ALA	L	31	-8.091	-16.272	3.023	1.00	0.00	N
	ATOM	305	CA	ALA	L	31	-8.388	-17.640	2.597	1.00	0.00	C
15	ATOM	306	C	ALA	L	31	-9.244	-18.351	3.642	1.00	0.00	C
	ATOM	307	O	ALA	L	31	-10.141	-19.108	3.299	1.00	0.00	O
	ATOM	308	CB	ALA	L	31	-7.130	-18.455	2.312	1.00	0.00	C
	ATOM	309	N	GLY	L	32	-8.904	-18.097	4.963	1.00	0.00	N
	ATOM	310	CA	GLY	L	32	-9.633	-18.628	6.099	1.00	0.00	C
20	ATOM	311	C	GLY	L	32	-11.116	-18.323	6.071	1.00	0.00	C
	ATOM	312	O	GLY	L	32	-11.909	-19.166	6.460	1.00	0.00	O
	ATOM	313	N	PHE	L	53	-8.496	-25.187	12.274	1.00	0.00	N
	ATOM	314	CA	PHE	L	53	-8.171	-23.763	12.130	1.00	0.00	C
	ATOM	315	C	PHE	L	53	-6.890	-23.457	12.911	1.00	0.00	C
25	ATOM	316	O	PHE	L	53	-5.962	-22.867	12.377	1.00	0.00	O
	ATOM	317	CB	PHE	L	53	-9.326	-22.816	12.515	1.00	0.00	C
	ATOM	318	CG	PHE	L	53	-8.993	-21.357	12.292	1.00	0.00	C
	ATOM	319	CD1	PHE	L	53	-8.825	-20.842	10.980	1.00	0.00	C
	ATOM	320	CD2	PHE	L	53	-8.839	-20.476	13.391	1.00	0.00	C
30	ATOM	321	CE1	PHE	L	53	-8.485	-19.490	10.779	1.00	0.00	C
	ATOM	322	CE2	PHE	L	53	-8.500	-19.125	13.186	1.00	0.00	C
	ATOM	323	CZ	PHE	L	53	-8.317	-18.634	11.882	1.00	0.00	C
	ATOM	324	N	PHE	L	54	-6.879	-23.863	14.237	1.00	0.00	N
	ATOM	325	CA	PHE	L	54	-5.791	-23.484	15.142	1.00	0.00	C
35	ATOM	326	C	PHE	L	54	-4.446	-24.003	14.630	1.00	0.00	C
	ATOM	327	O	PHE	L	54	-3.462	-23.274	14.628	1.00	0.00	O
	ATOM	328	CB	PHE	L	54	-6.001	-23.941	16.598	1.00	0.00	C
	ATOM	329	CG	PHE	L	54	-7.288	-23.500	17.265	1.00	0.00	C
	ATOM	330	CD1	PHE	L	54	-7.981	-22.312	16.907	1.00	0.00	C
40	ATOM	331	CD2	PHE	L	54	-7.828	-24.299	18.301	1.00	0.00	C
	ATOM	332	CE1	PHE	L	54	-9.188	-21.961	17.539	1.00	0.00	C
	ATOM	333	CE2	PHE	L	54	-9.027	-23.943	18.937	1.00	0.00	C
	ATOM	334	CZ	PHE	L	54	-9.708	-22.777	18.557	1.00	0.00	C
	ATOM	335	N	ILE	L	55	-4.415	-25.339	14.241	1.00	0.00	N
45	ATOM	336	CA	ILE	L	55	-3.169	-25.944	13.764	1.00	0.00	C
	ATOM	337	C	ILE	L	55	-2.708	-25.302	12.450	1.00	0.00	C
	ATOM	338	O	ILE	L	55	-1.515	-25.103	12.267	1.00	0.00	O
	ATOM	339	CB	ILE	L	55	-3.180	-27.498	13.738	1.00	0.00	C
	ATOM	340	CG1	ILE	L	55	-1.738	-28.049	13.695	1.00	0.00	C
50	ATOM	341	CG2	ILE	L	55	-4.026	-28.078	12.602	1.00	0.00	C
	ATOM	342	CD1	ILE	L	55	-1.648	-29.541	13.981	1.00	0.00	C
	ATOM	343	N	THR	L	56	-3.685	-25.022	11.495	1.00	0.00	N
	ATOM	344	CA	THR	L	56	-3.324	-24.487	10.182	1.00	0.00	C
	ATOM	345	C	THR	L	56	-2.776	-23.057	10.234	1.00	0.00	C
55	ATOM	346	O	THR	L	56	-2.032	-22.682	9.339	1.00	0.00	O
	ATOM	347	CB	THR	L	56	-4.411	-24.676	9.094	1.00	0.00	C
	ATOM	348	OG1	THR	L	56	-3.794	-24.763	7.805	1.00	0.00	O
	ATOM	349	CG2	THR	L	56	-5.482	-23.591	9.035	1.00	0.00	C
	ATOM	350	N	VAL	L	57	-3.164	-22.246	11.299	1.00	0.00	N
60	ATOM	351	CA	VAL	L	57	-2.504	-20.955	11.560	1.00	0.00	C
	ATOM	352	C	VAL	L	57	-0.999	-21.238	11.646	1.00	0.00	C
	ATOM	353	O	VAL	L	57	-0.210	-20.630	10.934	1.00	0.00	O
	ATOM	354	CB	VAL	L	57	-3.046	-20.209	12.813	1.00	0.00	C
	ATOM	355	CG1	VAL	L	57	-2.177	-19.007	13.193	1.00	0.00	C

-56-

Table 5 - Continued

5	ATOM	356	CG2	VAL	L	57	-4.475	-19.712	12.588	1.00	0.00	C
	ATOM	357	N	GLY	L	58	-0.638	-22.227	12.555	1.00	0.00	N
	ATOM	358	CA	GLY	L	58	0.734	-22.669	12.735	1.00	0.00	C
	ATOM	359	C	GLY	L	58	1.405	-23.027	11.420	1.00	0.00	C
	ATOM	360	O	GLY	L	58	2.484	-22.536	11.126	1.00	0.00	O
10	ATOM	361	N	LEU	L	59	0.728	-23.952	10.636	1.00	0.00	N
	ATOM	362	CA	LEU	L	59	1.280	-24.490	9.384	1.00	0.00	C
	ATOM	363	C	LEU	L	59	1.613	-23.390	8.370	1.00	0.00	C
	ATOM	364	O	LEU	L	59	2.651	-23.446	7.725	1.00	0.00	O
	ATOM	365	CB	LEU	L	59	0.366	-25.532	8.706	1.00	0.00	C
15	ATOM	366	CG	LEU	L	59	0.194	-26.846	9.498	1.00	0.00	C
	ATOM	367	CD1	LEU	L	59	-0.918	-27.689	8.875	1.00	0.00	C
	ATOM	368	CD2	LEU	L	59	1.486	-27.663	9.541	1.00	0.00	C
	ATOM	369	N	VAL	L	60	0.655	-22.399	8.202	1.00	0.00	N
	ATOM	370	CA	VAL	L	60	0.818	-21.290	7.253	1.00	0.00	C
20	ATOM	371	C	VAL	L	60	2.049	-20.455	7.640	1.00	0.00	C
	ATOM	372	O	VAL	L	60	2.832	-20.078	6.778	1.00	0.00	O
	ATOM	373	CB	VAL	L	60	-0.480	-20.445	7.107	1.00	0.00	C
	ATOM	374	CG1	VAL	L	60	-0.256	-19.131	6.358	1.00	0.00	C
	ATOM	375	CG2	VAL	L	60	-1.560	-21.237	6.361	1.00	0.00	C
25	ATOM	376	N	GLU	L	61	2.172	-20.129	8.986	1.00	0.00	N
	ATOM	377	CA	GLU	L	61	3.337	-19.405	9.510	1.00	0.00	C
	ATOM	378	C	GLU	L	61	4.651	-20.199	9.436	1.00	0.00	C
	ATOM	379	O	GLU	L	61	5.716	-19.596	9.419	1.00	0.00	O
	ATOM	380	CB	GLU	L	61	3.138	-18.941	10.962	1.00	0.00	C
30	ATOM	381	CG	GLU	L	61	2.061	-17.864	11.090	1.00	0.00	C
	ATOM	382	CD	GLU	L	61	2.006	-17.374	12.535	1.00	0.00	C
	ATOM	383	OE1	GLU	L	61	1.291	-18.073	13.310	1.00	0.00	O
	ATOM	384	OE2	GLU	L	61	2.715	-16.364	12.786	1.00	0.00	O
	ATOM	385	N	ALA	L	62	4.558	-21.588	9.464	1.00	0.00	N
35	ATOM	386	CA	ALA	L	62	5.692	-22.469	9.740	1.00	0.00	C
	ATOM	387	C	ALA	L	62	6.978	-22.140	8.986	1.00	0.00	C
	ATOM	388	O	ALA	L	62	8.021	-22.108	9.623	1.00	0.00	O
	ATOM	389	CB	ALA	L	62	5.366	-23.956	9.613	1.00	0.00	C
	ATOM	390	N	TYR	L	64	8.184	-19.301	7.912	1.00	0.00	N
40	ATOM	391	CA	TYR	L	64	8.775	-18.086	8.479	1.00	0.00	C
	ATOM	392	C	TYR	L	64	9.317	-18.325	9.892	1.00	0.00	C
	ATOM	393	O	TYR	L	64	10.332	-17.753	10.266	1.00	0.00	O
	ATOM	394	CB	TYR	L	64	7.803	-16.892	8.449	1.00	0.00	C
	ATOM	395	CG	TYR	L	64	7.396	-16.567	7.028	1.00	0.00	C
45	ATOM	396	CD1	TYR	L	64	8.268	-15.834	6.184	1.00	0.00	C
	ATOM	397	CD2	TYR	L	64	6.169	-17.040	6.496	1.00	0.00	C
	ATOM	398	CE1	TYR	L	64	7.935	-15.597	4.837	1.00	0.00	C
	ATOM	399	CE2	TYR	L	64	5.833	-16.808	5.148	1.00	0.00	C
	ATOM	400	CZ	TYR	L	64	6.713	-16.085	4.325	1.00	0.00	C
50	ATOM	401	OH	TYR	L	64	6.340	-15.867	3.006	1.00	0.00	O
	ATOM	402	N	PHE	L	65	8.591	-19.196	10.695	1.00	0.00	N
	ATOM	403	CA	PHE	L	65	9.106	-19.699	11.977	1.00	0.00	C
	ATOM	404	C	PHE	L	65	10.500	-20.313	11.766	1.00	0.00	C
	ATOM	405	O	PHE	L	65	11.435	-19.983	12.486	1.00	0.00	O
55	ATOM	406	CB	PHE	L	65	8.086	-20.622	12.690	1.00	0.00	C
	ATOM	407	CG	PHE	L	65	8.660	-21.781	13.471	1.00	0.00	C
	ATOM	408	CD1	PHE	L	65	9.445	-21.570	14.632	1.00	0.00	C
	ATOM	409	CE1	PHE	L	65	9.992	-22.664	15.330	1.00	0.00	C
	ATOM	410	CZ	PHE	L	65	9.742	-23.979	14.897	1.00	0.00	C
60	ATOM	411	CE2	PHE	L	65	8.951	-24.200	13.758	1.00	0.00	C
	ATOM	412	CD2	PHE	L	65	8.417	-23.111	13.045	1.00	0.00	C
	ATOM	413	N	ILE	L	66	10.602	-21.255	10.746	1.00	0.00	N
	ATOM	414	CA	ILE	L	66	11.863	-21.934	10.436	1.00	0.00	C
	ATOM	415	C	ILE	L	66	12.921	-20.880	10.109	1.00	0.00	C

-57-

Table 5 - Continued

	ATOM	416	O	ILE	L	66	14.024	-20.969	10.629	1.00	0.00	O
	ATOM	417	CB	ILE	L	66	11.743	-23.027	9.333	1.00	0.00	C
5	ATOM	418	CG1	ILE	L	66	10.834	-24.206	9.754	1.00	0.00	C
	ATOM	419	CG2	ILE	L	66	13.112	-23.552	8.880	1.00	0.00	C
	ATOM	420	CD1	ILE	L	66	11.332	-25.031	10.935	1.00	0.00	C
	ATOM	421	N	ASN	L	67	12.568	-19.878	9.205	1.00	0.00	N
	ATOM	422	CA	ASN	L	67	13.514	-18.826	8.807	1.00	0.00	C
10	ATOM	423	C	ASN	L	67	14.165	-18.202	10.035	1.00	0.00	C
	ATOM	424	O	ASN	L	67	15.379	-18.068	10.066	1.00	0.00	O
	ATOM	425	CB	ASN	L	67	12.928	-17.686	7.946	1.00	0.00	C
	ATOM	426	CG	ASN	L	67	12.679	-18.089	6.508	1.00	0.00	C
	ATOM	427	OD1	ASN	L	67	11.560	-18.310	6.072	1.00	0.00	O
15	ATOM	428	ND2	ASN	L	67	13.821	-18.186	5.747	1.00	0.00	N
	ATOM	429	N	LEU	L	68	13.303	-17.783	11.044	1.00	0.00	N
	ATOM	430	CA	LEU	L	68	13.771	-17.078	12.243	1.00	0.00	C
	ATOM	431	C	LEU	L	68	14.883	-17.907	12.894	1.00	0.00	C
	ATOM	432	O	LEU	L	68	16.014	-17.453	13.016	1.00	0.00	O
20	ATOM	433	CB	LEU	L	68	12.610	-16.759	13.216	1.00	0.00	C
	ATOM	434	CG	LEU	L	68	12.886	-15.638	14.239	1.00	0.00	C
	ATOM	435	CD1	LEU	L	68	11.590	-15.292	14.973	1.00	0.00	C
	ATOM	436	CD2	LEU	L	68	13.950	-16.005	15.272	1.00	0.00	C
	ATOM	437	N	ALA	L	69	14.497	-19.171	13.327	1.00	0.00	N
25	ATOM	438	CA	ALA	L	69	15.382	-20.029	14.117	1.00	0.00	C
	ATOM	439	C	ALA	L	69	16.671	-20.348	13.360	1.00	0.00	C
	ATOM	440	O	ALA	L	69	17.761	-20.262	13.911	1.00	0.00	O
	ATOM	441	CB	ALA	L	69	14.694	-21.321	14.552	1.00	0.00	C
	ATOM	442	N	PRO	K	63	2.328	-6.569	19.314	1.00	0.00	N
30	ATOM	443	CA	PRO	K	63	3.195	-6.836	20.450	1.00	0.00	C
	ATOM	444	C	PRO	K	63	4.365	-7.788	20.267	1.00	0.00	C
	ATOM	445	O	PRO	K	63	5.439	-7.509	20.781	1.00	0.00	O
	ATOM	446	CB	PRO	K	63	2.260	-7.282	21.557	1.00	0.00	C
	ATOM	447	CG	PRO	K	63	0.996	-6.494	21.282	1.00	0.00	C
35	ATOM	448	CD	PRO	K	63	0.991	-6.259	19.780	1.00	0.00	C
	ATOM	449	N	PRO	L	63	6.948	-21.920	7.602	1.00	0.00	N
	ATOM	450	CA	PRO	L	63	8.151	-21.540	6.873	1.00	0.00	C
	ATOM	451	C	PRO	L	63	8.940	-20.389	7.501	1.00	0.00	C
	ATOM	452	O	PRO	L	63	10.158	-20.447	7.588	1.00	0.00	O
40	ATOM	453	CB	PRO	L	63	7.683	-21.204	5.464	1.00	0.00	C
	ATOM	454	CG	PRO	L	63	6.402	-21.994	5.304	1.00	0.00	C
	ATOM	455	CD	PRO	L	63	5.820	-22.071	6.701	1.00	0.00	C
	ATOM	456	N	SER	M	206	-1.465	-25.569	20.193	1.00	0.00	N
	ATOM	457	CA	SER	M	206	-1.251	-24.467	19.250	1.00	0.00	C
45	ATOM	458	C	SER	M	206	-0.394	-23.364	19.890	1.00	0.00	C
	ATOM	459	O	SER	M	206	0.590	-22.924	19.311	1.00	0.00	O
	ATOM	460	CB	SER	M	206	-2.578	-23.921	18.704	1.00	0.00	C
	ATOM	461	OG	SER	M	206	-2.343	-22.955	17.679	1.00	0.00	O
	ATOM	462	N	LEU	M	207	-0.835	-22.896	21.123	1.00	0.00	N
50	ATOM	463	CA	LEU	M	207	-0.188	-21.775	21.816	1.00	0.00	C
	ATOM	464	C	LEU	M	207	1.276	-22.088	22.145	1.00	0.00	C
	ATOM	465	O	LEU	M	207	2.137	-21.226	22.019	1.00	0.00	O
	ATOM	466	CB	LEU	M	207	-0.942	-21.337	23.093	1.00	0.00	C
	ATOM	467	CG	LEU	M	207	-2.049	-20.274	22.888	1.00	0.00	C
55	ATOM	468	CD1	LEU	M	207	-1.457	-18.899	22.585	1.00	0.00	C
	ATOM	469	CD2	LEU	M	207	-3.097	-20.644	21.838	1.00	0.00	C
	ATOM	470	N	LEU	M	209	3.398	-23.907	20.563	1.00	0.00	N
	ATOM	471	CA	LEU	M	209	4.255	-23.926	19.376	1.00	0.00	C
	ATOM	472	C	LEU	M	209	5.088	-22.645	19.269	1.00	0.00	C
60	ATOM	473	O	LEU	M	209	6.295	-22.716	19.078	1.00	0.00	O
	ATOM	474	CB	LEU	M	209	3.458	-24.190	18.082	1.00	0.00	C
	ATOM	475	CG	LEU	M	209	4.307	-24.350	16.802	1.00	0.00	C

-58-

Table 5 - Continued

	ATOM	476	CD1	LEU	M	209	5.264	-25.541	16.875	1.00	0.00	C
	ATOM	477	CD2	LEU	M	209	3.386	-24.506	15.593	1.00	0.00	C
5	ATOM	478	N	ARG	M	210	4.395	-21.436	19.334	1.00	0.00	N
	ATOM	479	CA	ARG	M	210	5.121	-20.192	19.071	1.00	0.00	C
	ATOM	480	C	ARG	M	210	6.175	-19.896	20.142	1.00	0.00	C
	ATOM	481	O	ARG	M	210	7.276	-19.473	19.811	1.00	0.00	O
	ATOM	482	CB	ARG	M	210	4.268	-18.971	18.667	1.00	0.00	C
10	ATOM	483	CG	ARG	M	210	3.638	-18.112	19.768	1.00	0.00	C
	ATOM	484	CD	ARG	M	210	2.158	-18.393	20.003	1.00	0.00	C
	ATOM	485	NE	ARG	M	210	1.604	-17.342	20.877	1.00	0.00	N
	ATOM	486	CZ	ARG	M	210	1.731	-17.257	22.245	1.00	0.00	C
	ATOM	487	NH1	ARG	M	210	2.289	-18.232	23.037	1.00	0.00	N
15	ATOM	488	NH2	ARG	M	210	1.286	-16.136	22.899	1.00	0.00	N
	ATOM	489	N	LEU	M	211	5.795	-20.083	21.471	1.00	0.00	N
	ATOM	490	CA	LEU	M	211	6.734	-19.803	22.567	1.00	0.00	C
	ATOM	491	C	LEU	M	211	7.939	-20.746	22.556	1.00	0.00	C
	ATOM	492	O	LEU	M	211	9.039	-20.338	22.899	1.00	0.00	O
20	ATOM	493	CB	LEU	M	211	6.067	-19.645	23.947	1.00	0.00	C
	ATOM	494	CG	LEU	M	211	5.526	-20.909	24.642	1.00	0.00	C
	ATOM	495	CD1	LEU	M	211	6.600	-21.602	25.484	1.00	0.00	C
	ATOM	496	CD2	LEU	M	211	4.341	-20.550	25.539	1.00	0.00	C
	ATOM	497	N	PHE	M	212	7.680	-22.052	22.157	1.00	0.00	N
25	ATOM	498	CA	PHE	M	212	8.707	-23.084	21.988	1.00	0.00	C
	ATOM	499	C	PHE	M	212	9.819	-22.550	21.076	1.00	0.00	C
	ATOM	500	O	PHE	M	212	10.996	-22.649	21.401	1.00	0.00	O
	ATOM	501	CB	PHE	M	212	8.068	-24.391	21.469	1.00	0.00	C
	ATOM	502	CG	PHE	M	212	9.004	-25.542	21.220	1.00	0.00	C
30	ATOM	503	CD1	PHE	M	212	9.208	-26.025	19.902	1.00	0.00	C
	ATOM	504	CD2	PHE	M	212	9.628	-26.211	22.299	1.00	0.00	C
	ATOM	505	CE1	PHE	M	212	10.009	-27.158	19.672	1.00	0.00	C
	ATOM	506	CE2	PHE	M	212	10.431	-27.339	22.062	1.00	0.00	C
	ATOM	507	CZ	PHE	M	212	10.625	-27.813	20.752	1.00	0.00	C
35	ATOM	508	N	GLY	M	213	9.388	-21.965	19.891	1.00	0.00	N
	ATOM	509	CA	GLY	M	213	10.301	-21.336	18.951	1.00	0.00	C
	ATOM	510	C	GLY	M	213	11.123	-20.232	19.597	1.00	0.00	C
	ATOM	511	O	GLY	M	213	12.347	-20.250	19.546	1.00	0.00	O
	ATOM	512	N	ASN	M	214	10.364	-19.229	20.191	1.00	0.00	N
40	ATOM	513	CA	ASN	M	214	10.951	-17.998	20.736	1.00	0.00	C
	ATOM	514	C	ASN	M	214	12.113	-18.295	21.676	1.00	0.00	C
	ATOM	515	O	ASN	M	214	13.171	-17.697	21.543	1.00	0.00	O
	ATOM	516	CB	ASN	M	214	9.942	-17.090	21.468	1.00	0.00	C
	ATOM	517	CG	ASN	M	214	9.292	-16.100	20.522	1.00	0.00	C
45	ATOM	518	OD1	ASN	M	214	9.826	-15.042	20.224	1.00	0.00	O
	ATOM	519	ND2	ASN	M	214	8.080	-16.508	20.015	1.00	0.00	N
	ATOM	520	N	GLN	M	252	5.809	-14.680	27.293	1.00	0.00	N
	ATOM	521	CA	GLN	M	252	4.947	-15.475	26.417	1.00	0.00	C
	ATOM	522	C	GLN	M	252	3.965	-16.318	27.234	1.00	0.00	C
50	ATOM	523	O	GLN	M	252	2.796	-16.423	26.885	1.00	0.00	O
	ATOM	524	CB	GLN	M	252	5.729	-16.384	25.460	1.00	0.00	C
	ATOM	525	CG	GLN	M	252	6.493	-15.632	24.365	1.00	0.00	C
	ATOM	526	CD	GLN	M	252	5.558	-14.976	23.366	1.00	0.00	C
	ATOM	527	OE1	GLN	M	252	5.266	-13.790	23.431	1.00	0.00	O
55	ATOM	528	NE2	GLN	M	252	5.051	-15.838	22.419	1.00	0.00	N
	ATOM	529	N	ILE	M	255	0.964	-14.328	28.520	1.00	0.00	N
	ATOM	530	CA	ILE	M	255	-0.102	-14.190	27.516	1.00	0.00	C
	ATOM	531	C	ILE	M	255	-0.955	-15.467	27.497	1.00	0.00	C
	ATOM	532	O	ILE	M	255	-2.176	-15.390	27.471	1.00	0.00	O
60	ATOM	533	CB	ILE	M	255	0.417	-13.804	26.101	1.00	0.00	C
	ATOM	534	CG1	ILE	M	255	1.209	-12.476	26.083	1.00	0.00	C
	ATOM	535	CG2	ILE	M	255	-0.717	-13.748	25.070	1.00	0.00	C

-59-

Table 5 - Continued

	ATOM	536	CD1	ILE	M	255	0.452	-11.258	26.598	1.00	0.00	C
	ATOM	537	N	PHE	M	256	-0.261	-16.672	27.484	1.00	0.00	N
5	ATOM	538	CA	PHE	M	256	-0.946	-17.970	27.541	1.00	0.00	C
	ATOM	539	C	PHE	M	256	-1.898	-18.032	28.747	1.00	0.00	C
	ATOM	540	O	PHE	M	256	-3.034	-18.468	28.616	1.00	0.00	O
	ATOM	541	CB	PHE	M	256	0.059	-19.141	27.510	1.00	0.00	C
	ATOM	542	CG	PHE	M	256	-0.534	-20.518	27.696	1.00	0.00	C
10	ATOM	543	CD1	PHE	M	256	-0.013	-21.386	28.689	1.00	0.00	C
	ATOM	544	CD2	PHE	M	256	-1.597	-20.985	26.882	1.00	0.00	C
	ATOM	545	CE1	PHE	M	256	-0.539	-22.680	28.863	1.00	0.00	C
	ATOM	546	CE2	PHE	M	256	-2.128	-22.276	27.065	1.00	0.00	C
	ATOM	547	CZ	PHE	M	256	-1.597	-23.125	28.052	1.00	0.00	C
15	ATOM	548	N	LEU	M	259	-5.058	-16.050	28.251	1.00	0.00	N
	ATOM	549	CA	LEU	M	259	-5.940	-16.735	27.308	1.00	0.00	C
	ATOM	550	C	LEU	M	259	-6.805	-17.754	28.046	1.00	0.00	C
	ATOM	551	O	LEU	M	259	-8.018	-17.761	27.887	1.00	0.00	O
	ATOM	552	CB	LEU	M	259	-5.159	-17.348	26.128	1.00	0.00	C
20	ATOM	553	CG	LEU	M	259	-6.050	-17.856	24.974	1.00	0.00	C
	ATOM	554	CD1	LEU	M	259	-5.327	-17.681	23.640	1.00	0.00	C
	ATOM	555	CD2	LEU	M	259	-6.433	-19.328	25.144	1.00	0.00	C
	ATOM	556	N	ILE	M	205	-1.811	-26.903	22.691	1.00	0.00	N
	ATOM	557	CA	ILE	M	205	-0.778	-27.375	21.760	1.00	0.00	C
25	ATOM	558	C	ILE	M	205	-0.407	-26.242	20.791	1.00	0.00	C
	ATOM	559	O	ILE	M	205	0.770	-25.964	20.598	1.00	0.00	O
	ATOM	560	CB	ILE	M	205	-1.070	-28.769	21.130	1.00	0.00	C
	ATOM	561	CG1	ILE	M	205	0.183	-29.444	20.526	1.00	0.00	C
	ATOM	562	CG2	ILE	M	205	-2.263	-28.819	20.179	1.00	0.00	C
30	ATOM	563	CD1	ILE	M	205	0.576	-29.023	19.115	1.00	0.00	C
	ATOM	564	N	SER	M	208	1.542	-23.361	22.633	1.00	0.00	N
	ATOM	565	CA	SER	M	208	2.900	-23.765	22.998	1.00	0.00	C
	ATOM	566	C	SER	M	208	3.883	-23.597	21.833	1.00	0.00	C
	ATOM	567	O	SER	M	208	5.032	-23.247	22.054	1.00	0.00	O
35	ATOM	568	CB	SER	M	208	2.985	-25.173	23.602	1.00	0.00	C
	ATOM	569	OG	SER	M	208	2.785	-26.197	22.634	1.00	0.00	O

-60-

Table 6

5	ATOM	1	N	ILE	K	5	27.058	-0.783	12.427	1.00	0.00	N
	ATOM	2	CA	ILE	K	5	26.005	-1.691	12.91	1.00	0.00	C
	ATOM	3	C	ILE	K	5	24.924	-0.881	13.636	1.00	0.00	C
	ATOM	4	O	ILE	K	5	23.769	-1.281	13.67	1.00	0.00	O
	ATOM	5	CB	ILE	K	5	26.579	-2.844	13.786	1.00	0.00	C
10	ATOM	6	CG1	ILE	K	5	25.508	-3.932	14.021	1.00	0.00	C
	ATOM	7	CG2	ILE	K	5	27.182	-2.353	15.11	1.00	0.00	C
	ATOM	8	CD1	ILE	K	5	26.069	-5.224	14.594	1.00	0.00	C
	ATOM	21	N	ALA	K	6	25.369	0.283	14.253	1.00	0.00	N
	ATOM	22	CA	ALA	K	6	24.511	1.128	15.082	1.00	0.00	C
15	ATOM	23	C	ALA	K	6	23.265	1.544	14.305	1.00	0.00	C
	ATOM	24	O	ALA	K	6	22.147	1.344	14.761	1.00	0.00	O
	ATOM	25	CB	ALA	K	6	25.244	2.356	15.619	1.00	0.00	C
	ATOM	31	N	ALA	K	7	23.517	2.156	13.081	1.00	0.00	N
	ATOM	32	CA	ALA	K	7	22.441	2.61	12.201	1.00	0.00	C
20	ATOM	33	C	ALA	K	7	21.495	1.458	11.876	1.00	0.00	C
	ATOM	34	O	ALA	K	7	20.285	1.619	11.95	1.00	0.00	O
	ATOM	35	CB	ALA	K	7	22.963	3.241	10.913	1.00	0.00	C
	ATOM	41	N	GLY	K	8	22.114	0.275	11.484	1.00	0.00	N
	ATOM	42	CA	GLY	K	8	21.387	-0.928	11.111	1.00	0.00	C
25	ATOM	43	C	GLY	K	8	20.361	-1.344	12.15	1.00	0.00	C
	ATOM	44	O	GLY	K	8	19.223	-1.636	11.812	1.00	0.00	O
	ATOM	48	N	ALA	K	9	20.834	-1.403	13.453	1.00	0.00	N
	ATOM	49	CA	ALA	K	9	19.997	-1.824	14.574	1.00	0.00	C
	ATOM	50	C	ALA	K	9	18.758	-0.942	14.691	1.00	0.00	C
30	ATOM	51	O	ALA	K	9	17.646	-1.449	14.766	1.00	0.00	O
	ATOM	52	CB	ALA	K	9	20.76	-1.855	15.898	1.00	0.00	C
	ATOM	58	N	LEU	K	10	18.999	0.426	14.75	1.00	0.00	N
	ATOM	59	CA	LEU	K	10	17.924	1.389	15	1.00	0.00	C
	ATOM	60	C	LEU	K	10	16.887	1.33	13.879	1.00	0.00	C
35	ATOM	61	O	LEU	K	10	15.7	1.191	14.146	1.00	0.00	O
	ATOM	62	CB	LEU	K	10	18.423	2.836	15.198	1.00	0.00	C
	ATOM	63	CG	LEU	K	10	18.696	3.198	16.672	1.00	0.00	C
	ATOM	64	CD1	LEU	K	10	19.859	2.414	17.278	1.00	0.00	C
	ATOM	65	CD2	LEU	K	10	18.969	4.695	16.798	1.00	0.00	C
40	ATOM	77	N	ILE	K	11	17.378	1.5	12.587	1.00	0.00	N
	ATOM	78	CA	ILE	K	11	16.48	1.562	11.429	1.00	0.00	C
	ATOM	79	C	ILE	K	11	15.7	0.252	11.263	1.00	0.00	C
	ATOM	80	O	ILE	K	11	14.534	0.274	10.896	1.00	0.00	O
	ATOM	81	CB	ILE	K	11	17.176	2.041	10.122	1.00	0.00	C
45	ATOM	82	CG1	ILE	K	11	16.131	2.575	9.12	1.00	0.00	C
	ATOM	83	CG2	ILE	K	11	18.055	0.966	9.473	1.00	0.00	C
	ATOM	84	CD1	ILE	K	11	16.741	3.382	7.984	1.00	0.00	C
	ATOM	96	N	GLY	K	12	16.41	-0.914	11.531	1.00	0.00	N
	ATOM	97	CA	GLY	K	12	15.813	-2.237	11.499	1.00	0.00	C
50	ATOM	98	C	GLY	K	12	14.611	-2.303	12.416	1.00	0.00	C
	ATOM	99	O	GLY	K	12	13.536	-2.709	12	1.00	0.00	O
	ATOM	103	N	GLY	K	13	14.846	-1.88	13.717	1.00	0.00	N
	ATOM	104	CA	GLY	K	13	13.807	-1.823	14.732	1.00	0.00	C
	ATOM	105	C	GLY	K	13	12.578	-1.072	14.253	1.00	0.00	C
55	ATOM	106	O	GLY	K	13	11.46	-1.551	14.387	1.00	0.00	O
	ATOM	110	N	GLY	K	14	12.838	0.172	13.697	1.00	0.00	N
	ATOM	111	CA	GLY	K	14	11.798	1.03	13.153	1.00	0.00	C
	ATOM	112	C	GLY	K	14	10.931	0.316	12.128	1.00	0.00	C
	ATOM	113	O	GLY	K	14	9.712	0.341	12.22	1.00	0.00	O
60	ATOM	117	N	LEU	K	15	11.635	-0.303	11.102	1.00	0.00	N
	ATOM	118	CA	LEU	K	15	10.993	-1.025	9.999	1.00	0.00	C
	ATOM	119	C	LEU	K	15	10.067	-2.105	10.557	1.00	0.00	C

-61-

Table 6 - Continued

	ATOM	120	O	LEU	K	15	8.915	-2.197	10.152	1.00	0.00	O
	ATOM	121	CB	LEU	K	15	12.035	-1.587	9.004	1.00	0.00	C
5	ATOM	122	CG	LEU	K	15	11.445	-2.194	7.711	1.00	0.00	C
	ATOM	123	CD1	LEU	K	15	12.428	-2.021	6.554	1.00	0.00	C
	ATOM	124	CD2	LEU	K	15	11.123	-3.683	7.861	1.00	0.00	C
	ATOM	136	N	ILE	K	16	10.642	-2.954	11.496	1.00	0.00	N
	ATOM	137	CA	ILE	K	16	9.942	-4.097	12.092	1.00	0.00	C
10	ATOM	138	C	ILE	K	16	8.626	-3.603	12.7	1.00	0.00	C
	ATOM	139	O	ILE	K	16	7.571	-4.156	12.418	1.00	0.00	O
	ATOM	140	CB	ILE	K	16	10.83	-4.875	13.109	1.00	0.00	C
	ATOM	141	CG1	ILE	K	16	11.973	-5.618	12.381	1.00	0.00	C
	ATOM	142	CG2	ILE	K	16	10.018	-5.879	13.935	1.00	0.00	C
15	ATOM	143	CD1	ILE	K	16	13.148	-5.927	13.297	1.00	0.00	C
	ATOM	155	N	MET	K	17	8.739	-2.545	13.594	1.00	0.00	N
	ATOM	156	CA	MET	K	17	7.591	-2.019	14.334	1.00	0.00	C
	ATOM	157	C	MET	K	17	6.504	-1.535	13.381	1.00	0.00	C
	ATOM	158	O	MET	K	17	5.348	-1.902	13.537	1.00	0.00	O
20	ATOM	159	CB	MET	K	17	7.962	-0.901	15.322	1.00	0.00	C
	ATOM	160	CG	MET	K	17	8.601	-1.47	16.585	1.00	0.00	C
	ATOM	161	SD	MET	K	17	8.93	-0.146	17.788	1.00	0.00	S
	ATOM	162	CE	MET	K	17	10.614	0.288	17.282	1.00	0.00	C
	ATOM	172	N	ALA	K	18	6.911	-0.636	12.403	1.00	0.00	N
25	ATOM	173	CA	ALA	K	18	5.964	0.011	11.493	1.00	0.00	C
	ATOM	174	C	ALA	K	18	5.188	-1.023	10.677	1.00	0.00	C
	ATOM	175	O	ALA	K	18	3.97	-0.95	10.578	1.00	0.00	O
	ATOM	176	CB	ALA	K	18	6.641	1.021	10.569	1.00	0.00	C
	ATOM	182	N	GLY	K	19	5.967	-1.991	10.054	1.00	0.00	N
30	ATOM	183	CA	GLY	K	19	5.408	-3.043	9.218	1.00	0.00	C
	ATOM	184	C	GLY	K	19	4.394	-3.878	9.977	1.00	0.00	C
	ATOM	185	O	GLY	K	19	3.286	-4.103	9.508	1.00	0.00	O
	ATOM	189	N	GLY	K	20	4.848	-4.359	11.197	1.00	0.00	N
	ATOM	190	CA	GLY	K	20	4.021	-5.15	12.09	1.00	0.00	C
35	ATOM	191	C	GLY	K	20	2.697	-4.472	12.392	1.00	0.00	C
	ATOM	192	O	GLY	K	20	1.647	-5.091	12.298	1.00	0.00	O
	ATOM	196	N	ALA	K	21	2.806	-3.152	12.809	1.00	0.00	N
	ATOM	197	CA	ALA	K	21	1.667	-2.358	13.263	1.00	0.00	C
	ATOM	198	C	ALA	K	21	0.567	-2.315	12.213	1.00	0.00	C
40	ATOM	199	O	ALA	K	21	-0.577	-2.642	12.5	1.00	0.00	O
	ATOM	200	CB	ALA	K	21	2.064	-0.934	13.646	1.00	0.00	C
	ATOM	206	N	ILE	K	22	0.955	-1.827	10.97	1.00	0.00	N
	ATOM	207	CA	ILE	K	22	-0.025	-1.608	9.903	1.00	0.00	C
	ATOM	208	C	ILE	K	22	-0.652	-2.932	9.466	1.00	0.00	C
45	ATOM	209	O	ILE	K	22	-1.843	-2.981	9.19	1.00	0.00	O
	ATOM	210	CB	ILE	K	22	0.469	-0.726	8.719	1.00	0.00	C
	ATOM	211	CG1	ILE	K	22	1.644	-1.303	7.896	1.00	0.00	C
	ATOM	212	CG2	ILE	K	22	0.837	0.67	9.233	1.00	0.00	C
	ATOM	213	CD1	ILE	K	22	1.194	-2.103	6.683	1.00	0.00	C
50	ATOM	225	N	GLY	K	23	0.203	-4.026	9.4	1.00	0.00	N
	ATOM	226	CA	GLY	K	23	-0.258	-5.356	9.039	1.00	0.00	C
	ATOM	227	C	GLY	K	23	-1.377	-5.813	9.952	1.00	0.00	C
	ATOM	228	O	GLY	K	23	-2.452	-6.173	9.493	1.00	0.00	O
	ATOM	232	N	ALA	K	24	-1.053	-5.787	11.302	1.00	0.00	N
55	ATOM	233	CA	ALA	K	24	-1.98	-6.184	12.36	1.00	0.00	C
	ATOM	234	C	ALA	K	24	-3.307	-5.44	12.237	1.00	0.00	C
	ATOM	235	O	ALA	K	24	-4.364	-6.054	12.279	1.00	0.00	O
	ATOM	236	CB	ALA	K	24	-1.384	-5.973	13.75	1.00	0.00	C
	ATOM	242	N	GLY	K	25	-3.208	-4.059	12.109	1.00	0.00	N
60	ATOM	243	CA	GLY	K	25	-4.364	-3.177	12.068	1.00	0.00	C

-62-

Table 6 - Continued

	ATOM	244	C	GLY	K	25	-5.351	-3.56	10.98	1.00	0.00	C
	ATOM	245	O	GLY	K	25	-6.536	-3.73	11.236	1.00	0.00	O
5	ATOM	249	N	ILE	K	26	-4.796	-3.657	9.709	1.00	0.00	N
	ATOM	250	CA	ILE	K	26	-5.591	-4.032	8.536	1.00	0.00	C
	ATOM	251	C	ILE	K	26	-6.235	-5.396	8.795	1.00	0.00	C
	ATOM	252	O	ILE	K	26	-7.416	-5.566	8.528	1.00	0.00	O
	ATOM	253	CB	ILE	K	26	-4.783	-4	7.206	1.00	0.00	C
10	ATOM	254	CG1	ILE	K	26	-4.292	-2.579	6.838	1.00	0.00	C
	ATOM	255	CG2	ILE	K	26	-5.561	-4.608	6.032	1.00	0.00	C
	ATOM	256	CD1	ILE	K	26	-5.385	-1.554	6.559	1.00	0.00	C
	ATOM	268	N	GLY	K	27	-5.397	-6.38	9.307	1.00	0.00	N
	ATOM	269	CA	GLY	K	27	-5.83	-7.74	9.594	1.00	0.00	C
15	ATOM	270	C	GLY	K	27	-7.112	-7.787	10.405	1.00	0.00	C
	ATOM	271	O	GLY	K	27	-8.07	-8.439	10.013	1.00	0.00	O
	ATOM	275	N	ASP	K	28	-7.077	-7.058	11.591	1.00	0.00	N
	ATOM	276	CA	ASP	K	28	-8.223	-6.975	12.505	1.00	0.00	C
	ATOM	277	C	ASP	K	28	-9.482	-6.599	11.738	1.00	0.00	C
20	ATOM	278	O	ASP	K	28	-10.514	-7.236	11.903	1.00	0.00	O
	ATOM	279	CB	ASP	K	28	-8.039	-5.969	13.656	1.00	0.00	C
	ATOM	280	CG	ASP	K	28	-7.187	-6.544	14.754	1.00	0.00	C
	ATOM	281	OD1	ASP	K	28	-5.972	-6.441	14.829	1.00	0.00	O
	ATOM	282	OD2	ASP	K	28	-7.946	-7.253	15.625	1.00	0.00	O
25	ATOM	288	N	GLY	K	29	-9.359	-5.492	10.907	1.00	0.00	N
	ATOM	289	CA	GLY	K	29	-10.461	-4.983	10.114	1.00	0.00	C
	ATOM	290	C	GLY	K	29	-11.002	-6.071	9.208	1.00	0.00	C
	ATOM	291	O	GLY	K	29	-12.083	-6.597	9.429	1.00	0.00	O
	ATOM	295	N	VAL	K	30	-10.178	-6.399	8.143	1.00	0.00	N
30	ATOM	296	CA	VAL	K	30	-10.67	-7.186	7.009	1.00	0.00	C
	ATOM	297	C	VAL	K	30	-11.213	-8.543	7.465	1.00	0.00	C
	ATOM	298	O	VAL	K	30	-12.315	-8.919	7.092	1.00	0.00	O
	ATOM	299	CB	VAL	K	30	-9.698	-7.303	5.8	1.00	0.00	C
	ATOM	300	CG1	VAL	K	30	-9.406	-5.926	5.198	1.00	0.00	C
35	ATOM	301	CG2	VAL	K	30	-8.382	-8.03	6.091	1.00	0.00	C
	ATOM	311	N	ALA	K	31	-10.37	-9.299	8.271	1.00	0.00	N
	ATOM	312	CA	ALA	K	31	-10.706	-10.667	8.665	1.00	0.00	C
	ATOM	313	C	ALA	K	31	-11.898	-10.686	9.618	1.00	0.00	C
	ATOM	314	O	ALA	K	31	-12.803	-11.495	9.46	1.00	0.00	O
40	ATOM	315	CB	ALA	K	31	-9.525	-11.407	9.286	1.00	0.00	C
	ATOM	321	N	GLY	K	32	-11.834	-9.779	10.669	1.00	0.00	N
	ATOM	322	CA	GLY	K	32	-12.843	-9.719	11.713	1.00	0.00	C
	ATOM	323	C	GLY	K	32	-14.212	-9.398	11.15	1.00	0.00	C
	ATOM	324	O	GLY	K	32	-15.182	-10.089	11.427	1.00	0.00	O
45	ATOM	328	N	ASN	K	33	-14.267	-8.257	10.363	1.00	0.00	N
	ATOM	329	CA	ASN	K	33	-15.523	-7.785	9.783	1.00	0.00	C
	ATOM	330	C	ASN	K	33	-16.1	-8.775	8.775	1.00	0.00	C
	ATOM	331	O	ASN	K	33	-17.312	-8.902	8.669	1.00	0.00	O
	ATOM	332	CB	ASN	K	33	-15.438	-6.39	9.141	1.00	0.00	C
50	ATOM	333	CG	ASN	K	33	-15.197	-5.297	10.168	1.00	0.00	C
	ATOM	334	OD1	ASN	K	33	-14.133	-4.701	10.251	1.00	0.00	O
	ATOM	335	ND2	ASN	K	33	-16.269	-5.042	10.995	1.00	0.00	N
	ATOM	342	N	ALA	K	34	-15.199	-9.465	7.974	1.00	0.00	N
	ATOM	343	CA	ALA	K	34	-15.658	-10.508	7.052	1.00	0.00	C
55	ATOM	344	C	ALA	K	34	-16.41	-11.608	7.806	1.00	0.00	C
	ATOM	345	O	ALA	K	34	-17.483	-12.02	7.386	1.00	0.00	O
	ATOM	346	CB	ALA	K	34	-14.527	-11.101	6.219	1.00	0.00	C
	ATOM	352	N	LEU	K	35	-15.783	-12.094	8.95	1.00	0.00	N
	ATOM	353	CA	LEU	K	35	-16.377	-13.139	9.789	1.00	0.00	C
60	ATOM	354	C	LEU	K	35	-17.768	-12.695	10.244	1.00	0.00	C
	ATOM	355	O	LEU	K	35	-18.742	-13.411	10.043	1.00	0.00	O
	ATOM	356	CB	LEU	K	35	-15.479	-13.513	10.99	1.00	0.00	C

-63-

Table 6 - Continued

	ATOM	357	CG	LEU	K	35	-16.052	-14.618	11.902	1.00	0.00	C
	ATOM	358	CD1	LEU	K	35	-16.009	-15.99	11.23	1.00	0.00	C
5	ATOM	359	CD2	LEU	K	35	-15.276	-14.658	13.216	1.00	0.00	C
	ATOM	371	N	ILE	K	36	-17.815	-11.478	10.924	1.00	0.00	N
	ATOM	372	CA	ILE	K	36	-19.036	-11.013	11.585	1.00	0.00	C
	ATOM	373	C	ILE	K	36	-20.189	-10.855	10.589	1.00	0.00	C
	ATOM	374	O	ILE	K	36	-21.332	-11.098	10.941	1.00	0.00	O
10	ATOM	375	CB	ILE	K	36	-18.824	-9.757	12.487	1.00	0.00	C
	ATOM	376	CG1	ILE	K	36	-19.806	-9.719	13.676	1.00	0.00	C
	ATOM	377	CG2	ILE	K	36	-18.929	-8.435	11.725	1.00	0.00	C
	ATOM	378	CD1	ILE	K	36	-19.42	-10.675	14.794	1.00	0.00	C
	ATOM	390	N	SER	K	37	-19.865	-10.405	9.312	1.00	0.00	N
15	ATOM	391	CA	SER	K	37	-20.884	-10.186	8.284	1.00	0.00	C
	ATOM	392	C	SER	K	37	-21.815	-11.397	8.16	1.00	0.00	C
	ATOM	393	O	SER	K	37	-23.023	-11.239	8.041	1.00	0.00	O
	ATOM	394	CB	SER	K	37	-20.287	-9.841	6.914	1.00	0.00	C
	ATOM	395	OG	SER	K	37	-19.614	-8.584	6.969	1.00	0.00	O
20	ATOM	401	N	GLY	K	38	-21.186	-12.637	8.153	1.00	0.00	N
	ATOM	402	CA	GLY	K	38	-21.939	-13.876	8.213	1.00	0.00	C
	ATOM	403	C	GLY	K	38	-22.605	-14.037	9.569	1.00	0.00	C
	ATOM	404	O	GLY	K	38	-23.824	-14.017	9.682	1.00	0.00	O
	ATOM	408	N	VAL	K	39	-21.718	-14.263	10.616	1.00	0.00	N
25	ATOM	409	CA	VAL	K	39	-22.168	-14.679	11.946	1.00	0.00	C
	ATOM	410	C	VAL	K	39	-22.563	-13.39	12.682	1.00	0.00	C
	ATOM	411	O	VAL	K	39	-21.756	-12.748	13.341	1.00	0.00	O
	ATOM	412	CB	VAL	K	39	-21.084	-15.481	12.719	1.00	0.00	C
	ATOM	413	CG1	VAL	K	39	-21.656	-16.043	14.02	1.00	0.00	C
30	ATOM	414	CG2	VAL	K	39	-20.526	-16.646	11.894	1.00	0.00	C
	ATOM	424	N	ALA	K	40	-23.894	-13.035	12.506	1.00	0.00	N
	ATOM	425	CA	ALA	K	40	-24.463	-11.774	13.006	1.00	0.00	C
	ATOM	426	C	ALA	K	40	-25.936	-11.94	13.362	1.00	0.00	C
	ATOM	427	O	ALA	K	40	-26.358	-11.554	14.443	1.00	0.00	O
35	ATOM	428	CB	ALA	K	40	-24.298	-10.61	12.033	1.00	0.00	C
	ATOM	434	N	ARG	K	41	-26.737	-12.496	12.37	1.00	0.00	N
	ATOM	435	CA	ARG	K	41	-28.114	-12.909	12.642	1.00	0.00	C
	ATOM	436	C	ARG	K	41	-28.115	-14.033	13.684	1.00	0.00	C
	ATOM	437	O	ARG	K	41	-28.983	-14.075	14.545	1.00	0.00	O
40	ATOM	438	CB	ARG	K	41	-28.899	-13.343	11.39	1.00	0.00	C
	ATOM	439	CG	ARG	K	41	-29.26	-12.176	10.458	1.00	0.00	C
	ATOM	440	CD	ARG	K	41	-28.242	-11.958	9.338	1.00	0.00	C
	ATOM	441	NE	ARG	K	41	-28.568	-10.728	8.596	1.00	0.00	N
	ATOM	442	CZ	ARG	K	41	-28.108	-9.468	8.913	1.00	0.00	C
45	ATOM	443	NH1	ARG	K	41	-27.365	-9.179	10.037	1.00	0.00	N
	ATOM	444	NH2	ARG	K	41	-28.387	-8.41	8.087	1.00	0.00	N
	ATOM	457	N	GLN	K	42	-27.106	-14.986	13.554	1.00	0.00	N
	ATOM	458	CA	GLN	K	42	-26.838	-15.971	14.603	1.00	0.00	C
	ATOM	459	C	GLN	K	42	-26.427	-15.168	15.845	1.00	0.00	C
50	ATOM	460	O	GLN	K	42	-25.66	-14.219	15.736	1.00	0.00	O
	ATOM	461	CB	GLN	K	42	-25.692	-16.926	14.241	1.00	0.00	C
	ATOM	462	CG	GLN	K	42	-26.038	-17.841	13.067	1.00	0.00	C
	ATOM	463	CD	GLN	K	42	-24.858	-18.734	12.753	1.00	0.00	C
	ATOM	464	OE1	GLN	K	42	-23.974	-18.394	11.98	1.00	0.00	O
55	ATOM	465	NE2	GLN	K	42	-24.852	-19.924	13.446	1.00	0.00	N
	ATOM	474	N	PRO	K	43	-26.929	-15.616	17.076	1.00	0.00	N
	ATOM	475	CA	PRO	K	43	-26.718	-14.888	18.317	1.00	0.00	C
	ATOM	476	C	PRO	K	43	-25.257	-14.537	18.565	1.00	0.00	C
	ATOM	477	O	PRO	K	43	-24.341	-15.313	18.304	1.00	0.00	O
60	ATOM	478	CB	PRO	K	43	-27.219	-15.818	19.412	1.00	0.00	C
	ATOM	479	CG	PRO	K	43	-28.251	-16.685	18.727	1.00	0.00	C
	ATOM	480	CD	PRO	K	43	-27.812	-16.751	17.277	1.00	0.00	C

-64-

Table 6 - Continued

	ATOM	488	N	GLU	K	44	-25.104	-13.304	19.191	1.00	0.00	N
	ATOM	489	CA	GLU	K	44	-23.821	-12.843	19.719	1.00	0.00	C
5	ATOM	490	C	GLU	K	44	-23.618	-13.555	21.061	1.00	0.00	C
	ATOM	491	O	GLU	K	44	-23.904	-13.05	22.137	1.00	0.00	O
	ATOM	492	CB	GLU	K	44	-23.689	-11.309	19.801	1.00	0.00	C
	ATOM	493	CG	GLU	K	44	-24.829	-10.561	20.501	1.00	0.00	C
	ATOM	494	CD	GLU	K	44	-24.464	-9.106	20.633	1.00	0.00	C
10	ATOM	495	OE1	GLU	K	44	-24.639	-8.26	19.768	1.00	0.00	O
	ATOM	496	OE2	GLU	K	44	-23.844	-8.861	21.816	1.00	0.00	O
	ATOM	504	N	ALA	K	45	-23.108	-14.832	20.905	1.00	0.00	N
	ATOM	505	CA	ALA	K	45	-22.829	-15.746	22.006	1.00	0.00	C
	ATOM	506	C	ALA	K	45	-21.818	-16.757	21.467	1.00	0.00	C
15	ATOM	507	O	ALA	K	45	-20.672	-16.776	21.891	1.00	0.00	O
	ATOM	508	CB	ALA	K	45	-24.083	-16.4	22.583	1.00	0.00	C
	ATOM	514	N	GLN	K	46	-22.284	-17.575	20.441	1.00	0.00	N
	ATOM	515	CA	GLN	K	46	-21.387	-18.407	19.636	1.00	0.00	C
	ATOM	516	C	GLN	K	46	-20.471	-17.482	18.834	1.00	0.00	C
20	ATOM	517	O	GLN	K	46	-19.257	-17.639	18.851	1.00	0.00	O
	ATOM	518	CB	GLN	K	46	-22.133	-19.373	18.697	1.00	0.00	C
	ATOM	519	CG	GLN	K	46	-22.759	-20.568	19.422	1.00	0.00	C
	ATOM	520	CD	GLN	K	46	-23.88	-20.164	20.364	1.00	0.00	C
	ATOM	521	OE1	GLN	K	46	-24.797	-19.434	20.015	1.00	0.00	O
25	ATOM	522	NE2	GLN	K	46	-23.776	-20.701	21.628	1.00	0.00	N
	ATOM	531	N	GLY	K	47	-21.113	-16.481	18.113	1.00	0.00	N
	ATOM	532	CA	GLY	K	47	-20.379	-15.473	17.363	1.00	0.00	C
	ATOM	533	C	GLY	K	47	-19.364	-14.732	18.212	1.00	0.00	C
	ATOM	534	O	GLY	K	47	-18.227	-14.543	17.801	1.00	0.00	O
30	ATOM	538	N	ARG	K	48	-19.851	-14.254	19.419	1.00	0.00	N
	ATOM	539	CA	ARG	K	48	-19.045	-13.46	20.342	1.00	0.00	C
	ATOM	540	C	ARG	K	48	-17.993	-14.261	21.128	1.00	0.00	C
	ATOM	541	O	ARG	K	48	-17.214	-13.663	21.854	1.00	0.00	O
	ATOM	542	CB	ARG	K	48	-19.954	-12.677	21.313	1.00	0.00	C
35	ATOM	543	CG	ARG	K	48	-19.359	-11.324	21.726	1.00	0.00	C
	ATOM	544	CD	ARG	K	48	-20.308	-10.519	22.607	1.00	0.00	C
	ATOM	545	NE	ARG	K	48	-20.356	-11.117	23.953	1.00	0.00	N
	ATOM	546	CZ	ARG	K	48	-21.46	-11.2	24.769	1.00	0.00	C
	ATOM	547	NH1	ARG	K	48	-22.727	-10.788	24.417	1.00	0.00	N
40	ATOM	548	NH2	ARG	K	48	-21.325	-11.724	26.032	1.00	0.00	N
	ATOM	561	N	LEU	K	49	-17.971	-15.646	20.987	1.00	0.00	N
	ATOM	562	CA	LEU	K	49	-16.83	-16.458	21.424	1.00	0.00	C
	ATOM	563	C	LEU	K	49	-15.744	-16.45	20.342	1.00	0.00	C
	ATOM	564	O	LEU	K	49	-14.582	-16.192	20.63	1.00	0.00	O
45	ATOM	565	CB	LEU	K	49	-17.252	-17.894	21.798	1.00	0.00	C
	ATOM	566	CG	LEU	K	49	-16.109	-18.79	22.321	1.00	0.00	C
	ATOM	567	CD1	LEU	K	49	-15.498	-18.26	23.619	1.00	0.00	C
	ATOM	568	CD2	LEU	K	49	-16.627	-20.209	22.542	1.00	0.00	C
	ATOM	580	N	PHE	K	50	-16.16	-16.818	19.064	1.00	0.00	N
50	ATOM	581	CA	PHE	K	50	-15.203	-17.015	17.967	1.00	0.00	C
	ATOM	582	C	PHE	K	50	-14.483	-15.701	17.636	1.00	0.00	C
	ATOM	583	O	PHE	K	50	-13.28	-15.693	17.411	1.00	0.00	O
	ATOM	584	CB	PHE	K	50	-15.847	-17.62	16.692	1.00	0.00	C
	ATOM	585	CG	PHE	K	50	-15.074	-18.773	16.077	1.00	0.00	C
55	ATOM	586	CD1	PHE	K	50	-13.675	-18.707	15.835	1.00	0.00	C
	ATOM	587	CE1	PHE	K	50	-12.985	-19.792	15.262	1.00	0.00	C
	ATOM	588	CZ	PHE	K	50	-13.679	-20.958	14.898	1.00	0.00	C
	ATOM	589	CE2	PHE	K	50	-15.066	-21.038	15.111	1.00	0.00	C
	ATOM	590	CD2	PHE	K	50	-15.757	-19.958	15.696	1.00	0.00	C
60	ATOM	600	N	THR	K	51	-15.291	-14.571	17.559	1.00	0.00	N
	ATOM	601	CA	THR	K	51	-14.79	-13.258	17.147	1.00	0.00	C
	ATOM	602	C	THR	K	51	-13.543	-12.867	17.958	1.00	0.00	C

-65-

Table 6 - Continued

	ATOM	603	O	THR	K	51	-12.534	-12.554	17.343	1.00	0.00	O
	ATOM	604	CB	THR	K	51	-15.891	-12.173	17.107	1.00	0.00	C
5	ATOM	605	OG1	THR	K	51	-16.873	-12.559	16.143	1.00	0.00	O
	ATOM	606	CG2	THR	K	51	-15.364	-10.808	16.678	1.00	0.00	C
	ATOM	614	N	PRO	K	52	-13.59	-12.897	19.362	1.00	0.00	N
	ATOM	615	CA	PRO	K	52	-12.407	-12.708	20.183	1.00	0.00	C
	ATOM	616	C	PRO	K	52	-11.143	-13.421	19.738	1.00	0.00	C
10	ATOM	617	O	PRO	K	52	-10.081	-12.818	19.762	1.00	0.00	O
	ATOM	618	CB	PRO	K	52	-12.818	-13.12	21.581	1.00	0.00	C
	ATOM	619	CG	PRO	K	52	-14.286	-12.768	21.63	1.00	0.00	C
	ATOM	620	CD	PRO	K	52	-14.776	-12.857	20.191	1.00	0.00	C
	ATOM	628	N	PHE	K	53	-11.273	-14.753	19.362	1.00	0.00	N
15	ATOM	629	CA	PHE	K	53	-10.108	-15.537	18.945	1.00	0.00	C
	ATOM	630	C	PHE	K	53	-9.437	-14.85	17.749	1.00	0.00	C
	ATOM	631	O	PHE	K	53	-8.235	-14.619	17.761	1.00	0.00	O
	ATOM	632	CB	PHE	K	53	-10.436	-17.016	18.655	1.00	0.00	C
	ATOM	633	CG	PHE	K	53	-9.193	-17.873	18.699	1.00	0.00	C
20	ATOM	634	CD1	PHE	K	53	-8.387	-18.048	17.547	1.00	0.00	C
	ATOM	635	CD2	PHE	K	53	-8.795	-18.497	19.91	1.00	0.00	C
	ATOM	636	CE1	PHE	K	53	-7.202	-18.805	17.612	1.00	0.00	C
	ATOM	637	CE2	PHE	K	53	-7.613	-19.261	19.968	1.00	0.00	C
	ATOM	638	CZ	PHE	K	53	-6.813	-19.409	18.822	1.00	0.00	C
25	ATOM	648	N	PHE	K	54	-10.273	-14.535	16.683	1.00	0.00	N
	ATOM	649	CA	PHE	K	54	-9.772	-13.883	15.468	1.00	0.00	C
	ATOM	650	C	PHE	K	54	-9.045	-12.59	15.844	1.00	0.00	C
	ATOM	651	O	PHE	K	54	-7.885	-12.404	15.497	1.00	0.00	O
	ATOM	652	CB	PHE	K	54	-10.875	-13.584	14.425	1.00	0.00	C
30	ATOM	653	CG	PHE	K	54	-11.049	-14.675	13.395	1.00	0.00	C
	ATOM	654	CD1	PHE	K	54	-10.674	-14.445	12.046	1.00	0.00	C
	ATOM	655	CD2	PHE	K	54	-11.619	-15.927	13.735	1.00	0.00	C
	ATOM	656	CE1	PHE	K	54	-10.872	-15.433	11.064	1.00	0.00	C
	ATOM	657	CE2	PHE	K	54	-11.815	-16.915	12.749	1.00	0.00	C
35	ATOM	658	CZ	PHE	K	54	-11.446	-16.668	11.415	1.00	0.00	C
	ATOM	668	N	ILE	K	55	-9.806	-11.654	16.535	1.00	0.00	N
	ATOM	669	CA	ILE	K	55	-9.312	-10.293	16.755	1.00	0.00	C
	ATOM	670	C	ILE	K	55	-8.091	-10.238	17.676	1.00	0.00	C
	ATOM	671	O	ILE	K	55	-7.254	-9.365	17.494	1.00	0.00	O
40	ATOM	672	CB	ILE	K	55	-10.389	-9.246	17.158	1.00	0.00	C
	ATOM	673	CG1	ILE	K	55	-11.082	-9.542	18.501	1.00	0.00	C
	ATOM	674	CG2	ILE	K	55	-11.412	-9.083	16.026	1.00	0.00	C
	ATOM	675	CD1	ILE	K	55	-11.891	-8.371	19.037	1.00	0.00	C
	ATOM	687	N	THR	K	56	-8.023	-11.158	18.719	1.00	0.00	N
45	ATOM	688	CA	THR	K	56	-6.895	-11.169	19.652	1.00	0.00	C
	ATOM	689	C	THR	K	56	-5.609	-11.585	18.936	1.00	0.00	C
	ATOM	690	O	THR	K	56	-4.563	-11.008	19.195	1.00	0.00	O
	ATOM	691	CB	THR	K	56	-7.163	-11.948	20.967	1.00	0.00	C
	ATOM	692	OG1	THR	K	56	-6.253	-11.504	21.975	1.00	0.00	O
50	ATOM	693	CG2	THR	K	56	-7.019	-13.463	20.88	1.00	0.00	C
	ATOM	701	N	VAL	K	57	-5.703	-12.634	18.023	1.00	0.00	N
	ATOM	702	CA	VAL	K	57	-4.544	-13.065	17.229	1.00	0.00	C
	ATOM	703	C	VAL	K	57	-4.032	-11.845	16.459	1.00	0.00	C
	ATOM	704	O	VAL	K	57	-2.852	-11.526	16.523	1.00	0.00	O
55	ATOM	705	CB	VAL	K	57	-4.84	-14.286	16.314	1.00	0.00	C
	ATOM	706	CG1	VAL	K	57	-3.727	-14.538	15.293	1.00	0.00	C
	ATOM	707	CG2	VAL	K	57	-5.023	-15.555	17.15	1.00	0.00	C
	ATOM	717	N	GLY	K	58	-4.99	-11.166	15.714	1.00	0.00	N
	ATOM	718	CA	GLY	K	58	-4.679	-9.985	14.925	1.00	0.00	C
60	ATOM	719	C	GLY	K	58	-3.929	-8.942	15.735	1.00	0.00	C
	ATOM	720	O	GLY	K	58	-2.85	-8.511	15.357	1.00	0.00	O
	ATOM	724	N	LEU	K	59	-4.583	-8.526	16.885	1.00	0.00	N

-66-

Table 6 - Continued

	ATOM	725	CA	LEU	K	59	-4.116	-7.424	17.724	1.00	0.00	C
	ATOM	726	C	LEU	K	59	-2.71	-7.721	18.236	1.00	0.00	C
5	ATOM	727	O	LEU	K	59	-1.8	-6.932	18.027	1.00	0.00	O
	ATOM	728	CB	LEU	K	59	-5.098	-7.132	18.879	1.00	0.00	C
	ATOM	729	CG	LEU	K	59	-4.681	-5.985	19.821	1.00	0.00	C
	ATOM	730	CD1	LEU	K	59	-4.63	-4.637	19.101	1.00	0.00	C
	ATOM	731	CD2	LEU	K	59	-5.655	-5.908	20.995	1.00	0.00	C
10	ATOM	743	N	VAL	K	60	-2.591	-8.892	18.977	1.00	0.00	N
	ATOM	744	CA	VAL	K	60	-1.393	-9.246	19.745	1.00	0.00	C
	ATOM	745	C	VAL	K	60	-0.188	-9.558	18.832	1.00	0.00	C
	ATOM	746	O	VAL	K	60	0.948	-9.523	19.287	1.00	0.00	O
	ATOM	747	CB	VAL	K	60	-1.685	-10.355	20.8	1.00	0.00	C
15	ATOM	748	CG1	VAL	K	60	-0.456	-10.725	21.631	1.00	0.00	C
	ATOM	749	CG2	VAL	K	60	-2.775	-9.905	21.784	1.00	0.00	C
	ATOM	759	N	GLU	K	61	-0.455	-9.815	17.489	1.00	0.00	N
	ATOM	760	CA	GLU	K	61	0.601	-9.873	16.474	1.00	0.00	C
	ATOM	761	C	GLU	K	61	1.585	-8.71	16.652	1.00	0.00	C
20	ATOM	762	O	GLU	K	61	2.791	-8.922	16.668	1.00	0.00	O
	ATOM	763	CB	GLU	K	61	0.034	-9.906	15.044	1.00	0.00	C
	ATOM	764	CG	GLU	K	61	1.102	-10.157	13.982	1.00	0.00	C
	ATOM	765	CD	GLU	K	61	0.467	-10.196	12.615	1.00	0.00	C
	ATOM	766	OE1	GLU	K	61	0.258	-9.216	11.914	1.00	0.00	O
25	ATOM	767	OE2	GLU	K	61	0.092	-11.457	12.285	1.00	0.00	O
	ATOM	775	N	ALA	K	62	1.013	-7.443	16.754	1.00	0.00	N
	ATOM	776	CA	ALA	K	62	1.826	-6.232	16.847	1.00	0.00	C
	ATOM	777	C	ALA	K	62	2.804	-6.324	18.027	1.00	0.00	C
	ATOM	778	O	ALA	K	62	4.001	-6.269	17.784	1.00	0.00	O
30	ATOM	779	CB	ALA	K	62	1.015	-4.938	16.813	1.00	0.00	C
	ATOM	785	N	TYR	K	64	4.126	-8.886	19.558	1.00	0.00	N
	ATOM	786	CA	TYR	K	64	5.22	-9.841	19.328	1.00	0.00	C
	ATOM	787	C	TYR	K	64	6.395	-9.131	18.644	1.00	0.00	C
	ATOM	788	O	TYR	K	64	7.533	-9.237	19.085	1.00	0.00	O
35	ATOM	789	CB	TYR	K	64	4.841	-11.101	18.517	1.00	0.00	C
	ATOM	790	CG	TYR	K	64	3.724	-11.949	19.079	1.00	0.00	C
	ATOM	791	CD1	TYR	K	64	3.57	-12.184	20.471	1.00	0.00	C
	ATOM	792	CD2	TYR	K	64	2.807	-12.559	18.186	1.00	0.00	C
	ATOM	793	CE1	TYR	K	64	2.502	-12.959	20.955	1.00	0.00	C
40	ATOM	794	CE2	TYR	K	64	1.734	-13.333	18.662	1.00	0.00	C
	ATOM	795	CZ	TYR	K	64	1.582	-13.517	20.051	1.00	0.00	C
	ATOM	796	OH	TYR	K	64	0.51	-14.228	20.567	1.00	0.00	O
	ATOM	806	N	PHE	K	65	6.078	-8.42	17.493	1.00	0.00	N
	ATOM	807	CA	PHE	K	65	7.098	-7.715	16.711	1.00	0.00	C
45	ATOM	808	C	PHE	K	65	7.688	-6.509	17.443	1.00	0.00	C
	ATOM	809	O	PHE	K	65	8.857	-6.2	17.252	1.00	0.00	O
	ATOM	810	CB	PHE	K	65	6.592	-7.299	15.317	1.00	0.00	C
	ATOM	811	CG	PHE	K	65	6.386	-8.506	14.431	1.00	0.00	C
	ATOM	812	CD1	PHE	K	65	7.499	-9.252	13.959	1.00	0.00	C
50	ATOM	813	CE1	PHE	K	65	7.307	-10.424	13.206	1.00	0.00	C
	ATOM	814	CZ	PHE	K	65	6.007	-10.858	12.9	1.00	0.00	C
	ATOM	815	CE2	PHE	K	65	4.898	-10.111	13.33	1.00	0.00	C
	ATOM	816	CD2	PHE	K	65	5.083	-8.939	14.087	1.00	0.00	C
	ATOM	826	N	ILE	K	66	6.836	-5.797	18.28	1.00	0.00	N
55	ATOM	827	CA	ILE	K	66	7.311	-4.68	19.108	1.00	0.00	C
	ATOM	828	C	ILE	K	66	8.423	-5.216	20.012	1.00	0.00	C
	ATOM	829	O	ILE	K	66	9.497	-4.635	20.061	1.00	0.00	O
	ATOM	830	CB	ILE	K	66	6.193	-3.949	19.908	1.00	0.00	C
	ATOM	831	CG1	ILE	K	66	5.183	-3.272	18.953	1.00	0.00	C
60	ATOM	832	CG2	ILE	K	66	6.784	-2.897	20.856	1.00	0.00	C
	ATOM	833	CD1	ILE	K	66	3.904	-2.827	19.648	1.00	0.00	C
	ATOM	845	N	ASN	K	67	8.12	-6.351	20.758	1.00	0.00	N

-67-

Table 6 - Continued

	ATOM	846	CA	ASN	K	67	9.084	-6.98	21.666	1.00	0.00	C
	ATOM	847	C	ASN	K	67	10.38	-7.338	20.946	1.00	0.00	C
5	ATOM	848	O	ASN	K	67	11.454	-7.126	21.491	1.00	0.00	O
	ATOM	849	CB	ASN	K	67	8.543	-8.23	22.385	1.00	0.00	C
	ATOM	850	CG	ASN	K	67	7.77	-7.843	23.631	1.00	0.00	C
	ATOM	851	OD1	ASN	K	67	6.567	-7.632	23.619	1.00	0.00	O
	ATOM	852	ND2	ASN	K	67	8.555	-7.711	24.756	1.00	0.00	N
10	ATOM	859	N	LEU	K	68	10.249	-7.945	19.702	1.00	0.00	N
	ATOM	860	CA	LEU	K	68	11.409	-8.36	18.903	1.00	0.00	C
	ATOM	861	C	LEU	K	68	12.342	-7.161	18.698	1.00	0.00	C
	ATOM	862	O	LEU	K	68	13.529	-7.233	18.988	1.00	0.00	O
	ATOM	863	CB	LEU	K	68	10.985	-9.036	17.579	1.00	0.00	C
15	ATOM	864	CG	LEU	K	68	12.09	-9.878	16.906	1.00	0.00	C
	ATOM	865	CD1	LEU	K	68	11.462	-10.985	16.058	1.00	0.00	C
	ATOM	866	CD2	LEU	K	68	13.006	-9.04	16.015	1.00	0.00	C
	ATOM	878	N	ALA	K	69	11.744	-6.024	18.167	1.00	0.00	N
	ATOM	879	CA	ALA	K	69	12.484	-4.781	17.934	1.00	0.00	C
20	ATOM	880	C	ALA	K	69	13.125	-4.241	19.216	1.00	0.00	C
	ATOM	881	O	ALA	K	69	14.252	-3.764	19.191	1.00	0.00	O
	ATOM	882	CB	ALA	K	69	11.606	-3.701	17.312	1.00	0.00	C
	ATOM	888	N	PHE	K	70	12.328	-4.3	20.354	1.00	0.00	N
	ATOM	889	CA	PHE	K	70	12.764	-3.853	21.679	1.00	0.00	C
25	ATOM	890	C	PHE	K	70	14.099	-4.515	22.02	1.00	0.00	C
	ATOM	891	O	PHE	K	70	15.029	-3.848	22.445	1.00	0.00	O
	ATOM	892	CB	PHE	K	70	11.724	-4.153	22.791	1.00	0.00	C
	ATOM	893	CG	PHE	K	70	11.511	-3.023	23.769	1.00	0.00	C
	ATOM	894	CD1	PHE	K	70	10.227	-2.434	23.901	1.00	0.00	C
30	ATOM	895	CE1	PHE	K	70	10.001	-1.403	24.831	1.00	0.00	C
	ATOM	896	CZ	PHE	K	70	11.054	-0.936	25.635	1.00	0.00	C
	ATOM	897	CE2	PHE	K	70	12.332	-1.512	25.521	1.00	0.00	C
	ATOM	898	CD2	PHE	K	70	12.559	-2.555	24.602	1.00	0.00	C
	ATOM	908	N	MET	K	71	14.144	-5.895	21.855	1.00	0.00	N
35	ATOM	909	CA	MET	K	71	15.311	-6.702	22.213	1.00	0.00	C
	ATOM	910	C	MET	K	71	16.54	-6.268	21.42	1.00	0.00	C
	ATOM	911	O	MET	K	71	17.617	-6.161	21.989	1.00	0.00	O
	ATOM	912	CB	MET	K	71	15.074	-8.211	22.043	1.00	0.00	C
	ATOM	913	CG	MET	K	71	14.1	-8.744	23.094	1.00	0.00	C
40	ATOM	914	SD	MET	K	71	13.617	-10.446	22.689	1.00	0.00	S
	ATOM	915	CE	MET	K	71	12.287	-10.632	23.901	1.00	0.00	C
	ATOM	925	N	ALA	K	72	16.354	-6.05	20.057	1.00	0.00	N
	ATOM	926	CA	ALA	K	72	17.447	-5.605	19.185	1.00	0.00	C
	ATOM	927	C	ALA	K	72	18.091	-4.323	19.72	1.00	0.00	C
45	ATOM	928	O	ALA	K	72	19.307	-4.229	19.831	1.00	0.00	O
	ATOM	929	CB	ALA	K	72	17.003	-5.411	17.736	1.00	0.00	C
	ATOM	935	N	LEU	K	73	17.199	-3.304	20.035	1.00	0.00	N
	ATOM	936	CA	LEU	K	73	17.624	-2.018	20.597	1.00	0.00	C
	ATOM	937	C	LEU	K	73	18.403	-2.272	21.888	1.00	0.00	C
50	ATOM	938	O	LEU	K	73	19.485	-1.735	22.075	1.00	0.00	O
	ATOM	939	CB	LEU	K	73	16.417	-1.069	20.8	1.00	0.00	C
	ATOM	940	CG	LEU	K	73	16.695	0.393	21.215	1.00	0.00	C
	ATOM	941	CD1	LEU	K	73	17.026	0.557	22.699	1.00	0.00	C
	ATOM	942	CD2	LEU	K	73	17.744	1.075	20.34	1.00	0.00	C
55	ATOM	954	N	PHE	K	74	17.774	-3.097	22.81	1.00	0.00	N
	ATOM	955	CA	PHE	K	74	18.26	-3.297	24.171	1.00	0.00	C
	ATOM	956	C	PHE	K	74	19.694	-3.832	24.176	1.00	0.00	C
	ATOM	957	O	PHE	K	74	20.534	-3.302	24.891	1.00	0.00	O
	ATOM	958	CB	PHE	K	74	17.307	-4.194	24.987	1.00	0.00	C
60	ATOM	959	CG	PHE	K	74	17.521	-4.114	26.478	1.00	0.00	C
	ATOM	960	CD1	PHE	K	74	17.967	-5.242	27.209	1.00	0.00	C
	ATOM	961	CE1	PHE	K	74	18.105	-5.172	28.609	1.00	0.00	C

-68-

Table 6 - Continued

5	ATOM	962	CZ	PHE	K	74	17.815	-3.979	29.293	1.00	0.00	C
	ATOM	963	CE2	PHE	K	74	17.377	-2.851	28.579	1.00	0.00	C
	ATOM	964	CD2	PHE	K	74	17.224	-2.918	27.182	1.00	0.00	C
	ATOM	974	N	VAL	K	75	19.946	-4.946	23.371	1.00	0.00	N
	ATOM	975	CA	VAL	K	75	21.272	-5.585	23.333	1.00	0.00	C
10	ATOM	976	C	VAL	K	75	22.348	-4.601	22.861	1.00	0.00	C
	ATOM	977	O	VAL	K	75	23.447	-4.59	23.401	1.00	0.00	O
	ATOM	978	CB	VAL	K	75	21.372	-6.94	22.573	1.00	0.00	C
	ATOM	979	CG1	VAL	K	75	20.544	-8.024	23.262	1.00	0.00	C
	ATOM	980	CG2	VAL	K	75	21.017	-6.882	21.086	1.00	0.00	C
15	ATOM	990	N	PHE	K	76	21.997	-3.787	21.789	1.00	0.00	N
	ATOM	991	CA	PHE	K	76	22.881	-2.742	21.272	1.00	0.00	C
	ATOM	992	C	PHE	K	76	23.25	-1.789	22.416	1.00	0.00	C
	ATOM	993	O	PHE	K	76	24.423	-1.544	22.664	1.00	0.00	O
	ATOM	994	CB	PHE	K	76	22.268	-2.031	20.042	1.00	0.00	C
20	ATOM	995	CG	PHE	K	76	22.877	-0.685	19.729	1.00	0.00	C
	ATOM	996	CD1	PHE	K	76	22.154	0.501	20.013	1.00	0.00	C
	ATOM	997	CD2	PHE	K	76	24.174	-0.578	19.171	1.00	0.00	C
	ATOM	998	CE1	PHE	K	76	22.718	1.764	19.756	1.00	0.00	C
	ATOM	999	CE2	PHE	K	76	24.736	0.689	18.92	1.00	0.00	C
25	ATOM	1000	CZ	PHE	K	76	24.01	1.858	19.211	1.00	0.00	C
	ATOM	1010	N	ALA	K	77	22.172	-1.217	23.081	1.00	0.00	N
	ATOM	1011	CA	ALA	K	77	22.328	-0.136	24.048	1.00	0.00	C
	ATOM	1012	C	ALA	K	77	23.234	-0.547	25.206	1.00	0.00	C
	ATOM	1013	O	ALA	K	77	24.165	0.171	25.545	1.00	0.00	O
30	ATOM	1014	CB	ALA	K	77	20.987	0.377	24.569	1.00	0.00	C
	ATOM	1020	N	THR	K	78	22.88	-1.727	25.855	1.00	0.00	N
	ATOM	1021	CA	THR	K	78	23.625	-2.223	27.009	1.00	0.00	C
	ATOM	1022	C	THR	K	78	24.987	-2.674	26.515	1.00	0.00	C
	ATOM	1023	O	THR	K	78	25.974	-2.7	27.236	1.00	0.00	O
35	ATOM	1024	CB	THR	K	78	22.881	-3.339	27.78	1.00	0.00	C
	ATOM	1025	OG1	THR	K	78	23.43	-3.473	29.094	1.00	0.00	O
	ATOM	1026	CG2	THR	K	78	22.894	-4.71	27.107	1.00	0.00	C
	ATOM	1035	N	PRO	K	63	2.314	-6.507	19.331	1.00	0.00	N
	ATOM	1036	CA	PRO	K	63	3.18	-6.771	20.468	1.00	0.00	C
40	ATOM	1038	C	PRO	K	63	4.349	-7.725	20.289	1.00	0.00	C
	ATOM	1039	O	PRO	K	63	5.423	-7.445	20.802	1.00	0.00	O
	ATOM	1040	CB	PRO	K	63	2.244	-7.213	21.576	1.00	0.00	C
	ATOM	1043	CG	PRO	K	63	0.981	-6.425	21.298	1.00	0.00	C
	ATOM	1046	CD	PRO	K	63	0.977	-6.194	19.795	1.00	0.00	C

-69-

Table 7

5	ATOM	1	N	ILE	K	5	28.121	-7.663	2.389	1.00	0.00	N
	ATOM	2	CA	ILE	K	5	27.537	-8.933	2.847	1.00	0.00	C
	ATOM	3	C	ILE	K	5	26.933	-8.728	4.240	1.00	0.00	C
	ATOM	4	O	ILE	K	5	25.896	-9.292	4.558	1.00	0.00	O
	ATOM	5	CB	ILE	K	5	28.544	-10.118	2.780	1.00	0.00	C
10	ATOM	6	CG1	ILE	K	5	27.845	-11.446	3.142	1.00	0.00	C
	ATOM	7	CG2	ILE	K	5	29.809	-9.894	3.618	1.00	0.00	C
	ATOM	8	CD1	ILE	K	5	28.630	-12.682	2.730	1.00	0.00	C
	ATOM	9	N	ALA	K	6	27.652	-7.885	5.078	1.00	0.00	N
	ATOM	10	CA	ALA	K	6	27.188	-7.544	6.421	1.00	0.00	C
15	ATOM	11	C	ALA	K	6	25.850	-6.821	6.317	1.00	0.00	C
	ATOM	12	O	ALA	K	6	24.876	-7.223	6.940	1.00	0.00	O
	ATOM	13	CB	ALA	K	6	28.205	-6.721	7.207	1.00	0.00	C
	ATOM	14	N	ALA	K	7	25.842	-5.715	5.472	1.00	0.00	N
	ATOM	15	CA	ALA	K	7	24.627	-4.946	5.207	1.00	0.00	C
20	ATOM	16	C	ALA	K	7	23.504	-5.870	4.742	1.00	0.00	C
	ATOM	17	O	ALA	K	7	22.387	-5.777	5.234	1.00	0.00	O
	ATOM	18	CB	ALA	K	7	24.850	-3.832	4.187	1.00	0.00	C
	ATOM	19	N	GLY	K	8	23.861	-6.771	3.743	1.00	0.00	N
	ATOM	20	CA	GLY	K	8	22.942	-7.733	3.159	1.00	0.00	C
25	ATOM	21	C	GLY	K	8	22.190	-8.547	4.197	1.00	0.00	C
	ATOM	22	O	GLY	K	8	20.981	-8.701	4.105	1.00	0.00	O
	ATOM	23	N	ALA	K	9	22.983	-9.120	5.181	1.00	0.00	N
	ATOM	24	CA	ALA	K	9	22.435	-9.985	6.224	1.00	0.00	C
	ATOM	25	C	ALA	K	9	21.368	-9.263	7.040	1.00	0.00	C
30	ATOM	26	O	ALA	K	9	20.289	-9.802	7.254	1.00	0.00	O
	ATOM	27	CB	ALA	K	9	23.515	-10.557	7.140	1.00	0.00	C
	ATOM	28	N	LEU	K	10	21.734	-8.017	7.538	1.00	0.00	N
	ATOM	29	CA	LEU	K	10	20.857	-7.260	8.435	1.00	0.00	C
	ATOM	30	C	LEU	K	10	19.538	-6.964	7.722	1.00	0.00	C
35	ATOM	31	O	LEU	K	10	18.472	-7.283	8.235	1.00	0.00	O
	ATOM	32	CB	LEU	K	10	21.475	-5.951	8.973	1.00	0.00	C
	ATOM	33	CG	LEU	K	10	22.328	-6.133	10.246	1.00	0.00	C
	ATOM	34	CD1	LEU	K	10	23.675	-6.796	9.973	1.00	0.00	C
	ATOM	35	CD2	LEU	K	10	22.563	-4.777	10.912	1.00	0.00	C
40	ATOM	36	N	ILE	K	11	19.650	-6.281	6.514	1.00	0.00	N
	ATOM	37	CA	ILE	K	11	18.467	-5.824	5.777	1.00	0.00	C
	ATOM	38	C	ILE	K	11	17.578	-7.005	5.372	1.00	0.00	C
	ATOM	39	O	ILE	K	11	16.360	-6.901	5.425	1.00	0.00	O
	ATOM	40	CB	ILE	K	11	18.795	-4.856	4.606	1.00	0.00	C
45	ATOM	41	CG1	ILE	K	11	17.524	-4.109	4.147	1.00	0.00	C
	ATOM	42	CG2	ILE	K	11	19.480	-5.544	3.421	1.00	0.00	C
	ATOM	43	CD1	ILE	K	11	17.822	-2.876	3.306	1.00	0.00	C
	ATOM	44	N	GLY	K	12	18.241	-8.146	4.933	1.00	0.00	N
	ATOM	45	CA	GLY	K	12	17.555	-9.364	4.535	1.00	0.00	C
50	ATOM	46	C	GLY	K	12	16.642	-9.865	5.635	1.00	0.00	C
	ATOM	47	O	GLY	K	12	15.472	-10.131	5.399	1.00	0.00	O
	ATOM	48	N	GLY	K	13	17.246	-10.004	6.877	1.00	0.00	N
	ATOM	49	CA	GLY	K	13	16.527	-10.463	8.054	1.00	0.00	C
	ATOM	50	C	GLY	K	13	15.268	-9.650	8.300	1.00	0.00	C
55	ATOM	51	O	GLY	K	13	14.189	-10.202	8.473	1.00	0.00	O
	ATOM	52	N	GLY	K	14	15.468	-8.276	8.332	1.00	0.00	N
	ATOM	53	CA	GLY	K	14	14.388	-7.324	8.544	1.00	0.00	C
	ATOM	54	C	GLY	K	14	13.234	-7.535	7.579	1.00	0.00	C
	ATOM	55	O	GLY	K	14	12.086	-7.620	7.992	1.00	0.00	O
60	ATOM	56	N	LEU	K	15	13.605	-7.585	6.240	1.00	0.00	N
	ATOM	57	CA	LEU	K	15	12.661	-7.745	5.129	1.00	0.00	C
	ATOM	58	C	LEU	K	15	11.777	-8.963	5.401	1.00	0.00	C

-70-

Table 7 - Continued

	ATOM	59	O	LEU	K	15	10.558	-8.853	5.398	1.00	0.00	O
	ATOM	60	CB	LEU	K	15	13.400	-7.824	3.771	1.00	0.00	C
5	ATOM	61	CG	LEU	K	15	12.529	-7.641	2.510	1.00	0.00	C
	ATOM	62	CD1	LEU	K	15	13.428	-7.309	1.318	1.00	0.00	C
	ATOM	63	CD2	LEU	K	15	11.700	-8.879	2.169	1.00	0.00	C
	ATOM	64	N	ILE	K	16	12.463	-10.153	5.628	1.00	0.00	N
	ATOM	65	CA	ILE	K	16	11.799	-11.454	5.776	1.00	0.00	C
10	ATOM	66	C	ILE	K	16	10.735	-11.338	6.868	1.00	0.00	C
	ATOM	67	O	ILE	K	16	9.582	-11.680	6.643	1.00	0.00	O
	ATOM	68	CB	ILE	K	16	12.803	-12.619	6.039	1.00	0.00	C
	ATOM	69	CG1	ILE	K	16	13.659	-12.895	4.782	1.00	0.00	C
	ATOM	70	CG2	ILE	K	16	12.086	-13.909	6.458	1.00	0.00	C
15	ATOM	71	CD1	ILE	K	16	14.930	-13.674	5.089	1.00	0.00	C
	ATOM	72	N	MET	K	17	11.186	-10.883	8.101	1.00	0.00	N
	ATOM	73	CA	MET	K	17	10.325	-10.873	9.285	1.00	0.00	C
	ATOM	74	C	MET	K	17	9.112	-9.969	9.083	1.00	0.00	C
	ATOM	75	O	MET	K	17	7.992	-10.376	9.358	1.00	0.00	O
20	ATOM	76	CB	MET	K	17	11.072	-10.480	10.569	1.00	0.00	C
	ATOM	77	CG	MET	K	17	11.965	-11.617	11.063	1.00	0.00	C
	ATOM	78	SD	MET	K	17	12.781	-11.152	12.622	1.00	0.00	S
	ATOM	79	CE	MET	K	17	14.229	-10.299	11.947	1.00	0.00	C
	ATOM	80	N	ALA	K	18	9.381	-8.681	8.641	1.00	0.00	N
25	ATOM	81	CA	ALA	K	18	8.335	-7.661	8.530	1.00	0.00	C
	ATOM	82	C	ALA	K	18	7.251	-8.073	7.536	1.00	0.00	C
	ATOM	83	O	ALA	K	18	6.066	-7.978	7.829	1.00	0.00	O
	ATOM	84	CB	ALA	K	18	8.898	-6.297	8.153	1.00	0.00	C
	ATOM	85	N	GLY	K	19	7.717	-8.515	6.304	1.00	0.00	N
30	ATOM	86	CA	GLY	K	19	6.829	-9.005	5.260	1.00	0.00	C
	ATOM	87	C	GLY	K	19	5.987	-10.160	5.767	1.00	0.00	C
	ATOM	88	O	GLY	K	19	4.781	-10.204	5.565	1.00	0.00	O
	ATOM	89	N	GLY	K	20	6.707	-11.134	6.437	1.00	0.00	N
	ATOM	90	CA	GLY	K	20	6.099	-12.302	7.039	1.00	0.00	C
35	ATOM	91	C	GLY	K	20	4.913	-11.965	7.916	1.00	0.00	C
	ATOM	92	O	GLY	K	20	3.864	-12.584	7.803	1.00	0.00	O
	ATOM	93	N	ALA	K	21	5.151	-10.963	8.844	1.00	0.00	N
	ATOM	94	CA	ALA	K	21	4.174	-10.565	9.849	1.00	0.00	C
	ATOM	95	C	ALA	K	21	2.837	-10.204	9.219	1.00	0.00	C
40	ATOM	96	O	ALA	K	21	1.807	-10.745	9.602	1.00	0.00	O
	ATOM	97	CB	ALA	K	21	4.669	-9.411	10.713	1.00	0.00	C
	ATOM	98	N	ILE	K	22	2.887	-9.210	8.246	1.00	0.00	N
	ATOM	99	CA	ILE	K	22	1.657	-8.691	7.639	1.00	0.00	C
	ATOM	100	C	ILE	K	22	0.932	-9.798	6.872	1.00	0.00	C
45	ATOM	101	O	ILE	K	22	-0.288	-9.878	6.917	1.00	0.00	O
	ATOM	102	CB	ILE	K	22	1.811	-7.360	6.845	1.00	0.00	C
	ATOM	103	CG1	ILE	K	22	2.660	-7.427	5.557	1.00	0.00	C
	ATOM	104	CG2	ILE	K	22	2.377	-6.274	7.765	1.00	0.00	C
	ATOM	105	CD1	ILE	K	22	1.848	-7.745	4.310	1.00	0.00	C
50	ATOM	106	N	GLY	K	23	1.741	-10.663	6.142	1.00	0.00	N
	ATOM	107	CA	GLY	K	23	1.204	-11.765	5.363	1.00	0.00	C
	ATOM	108	C	GLY	K	23	0.376	-12.709	6.211	1.00	0.00	C
	ATOM	109	O	GLY	K	23	-0.767	-13.004	5.889	1.00	0.00	O
	ATOM	110	N	ALA	K	24	1.042	-13.206	7.322	1.00	0.00	N
55	ATOM	111	CA	ALA	K	24	0.432	-14.149	8.256	1.00	0.00	C
	ATOM	112	C	ALA	K	24	-0.867	-13.592	8.834	1.00	0.00	C
	ATOM	113	O	ALA	K	24	-1.841	-14.320	8.961	1.00	0.00	O
	ATOM	114	CB	ALA	K	24	1.385	-14.552	9.378	1.00	0.00	C
	ATOM	115	N	GLY	K	25	-0.837	-12.253	9.209	1.00	0.00	N
60	ATOM	116	CA	GLY	K	25	-1.989	-11.554	9.762	1.00	0.00	C
	ATOM	117	C	GLY	K	25	-3.224	-11.712	8.896	1.00	0.00	C
	ATOM	118	O	GLY	K	25	-4.270	-12.142	9.367	1.00	0.00	O

-71-

Table 7 - Continued

	ATOM	119	N	ILE	K	26	-3.049	-11.314	7.575	1.00	0.00	N
	ATOM	120	CA	ILE	K	26	-4.123	-11.406	6.580	1.00	0.00	C
5	ATOM	121	C	ILE	K	26	-4.608	-12.856	6.541	1.00	0.00	C
	ATOM	122	O	ILE	K	26	-5.800	-13.101	6.670	1.00	0.00	O
	ATOM	123	CB	ILE	K	26	-3.723	-10.885	5.167	1.00	0.00	C
	ATOM	124	CG1	ILE	K	26	-3.329	-9.390	5.154	1.00	0.00	C
	ATOM	125	CG2	ILE	K	26	-4.818	-11.147	4.125	1.00	0.00	C
10	ATOM	126	CD1	ILE	K	26	-4.410	-8.423	5.617	1.00	0.00	C
	ATOM	127	N	GLY	K	27	-3.622	-13.815	6.331	1.00	0.00	N
	ATOM	128	CA	GLY	K	27	-3.902	-15.227	6.118	1.00	0.00	C
	ATOM	129	C	GLY	K	27	-4.862	-15.800	7.143	1.00	0.00	C
	ATOM	130	O	GLY	K	27	-5.885	-16.369	6.784	1.00	0.00	O
15	ATOM	131	N	ASP	K	28	-4.461	-15.632	8.465	1.00	0.00	N
	ATOM	132	CA	ASP	K	28	-5.235	-16.133	9.607	1.00	0.00	C
	ATOM	133	C	ASP	K	28	-6.691	-15.707	9.464	1.00	0.00	C
	ATOM	134	O	ASP	K	28	-7.587	-16.541	9.509	1.00	0.00	O
	ATOM	135	CB	ASP	K	28	-4.707	-15.657	10.975	1.00	0.00	C
20	ATOM	136	CG	ASP	K	28	-3.539	-16.488	11.442	1.00	0.00	C
	ATOM	137	OD1	ASP	K	28	-2.373	-16.308	11.122	1.00	0.00	O
	ATOM	138	OD2	ASP	K	28	-3.957	-17.506	12.234	1.00	0.00	O
	ATOM	139	N	GLY	K	29	-6.886	-14.338	9.315	1.00	0.00	N
	ATOM	140	CA	GLY	K	29	-8.205	-13.736	9.279	1.00	0.00	C
25	ATOM	141	C	GLY	K	29	-9.036	-14.339	8.166	1.00	0.00	C
	ATOM	142	O	GLY	K	29	-10.008	-15.041	8.410	1.00	0.00	O
	ATOM	143	N	VAL	K	30	-8.603	-14.009	6.889	1.00	0.00	N
	ATOM	144	CA	VAL	K	30	-9.444	-14.243	5.714	1.00	0.00	C
	ATOM	145	C	VAL	K	30	-9.809	-15.722	5.590	1.00	0.00	C
30	ATOM	146	O	VAL	K	30	-10.974	-16.055	5.423	1.00	0.00	O
	ATOM	147	CB	VAL	K	30	-8.921	-13.639	4.378	1.00	0.00	C
	ATOM	148	CG1	VAL	K	30	-8.803	-12.116	4.474	1.00	0.00	C
	ATOM	149	CG2	VAL	K	30	-7.604	-14.230	3.864	1.00	0.00	C
	ATOM	150	N	ALA	K	31	-8.745	-16.616	5.628	1.00	0.00	N
35	ATOM	151	CA	ALA	K	31	-8.927	-18.027	5.299	1.00	0.00	C
	ATOM	152	C	ALA	K	31	-9.775	-18.719	6.360	1.00	0.00	C
	ATOM	153	O	ALA	K	31	-10.740	-19.402	6.043	1.00	0.00	O
	ATOM	154	CB	ALA	K	31	-7.605	-18.761	5.097	1.00	0.00	C
	ATOM	155	N	GLY	K	32	-9.344	-18.541	7.669	1.00	0.00	N
40	ATOM	156	CA	GLY	K	32	-9.973	-19.223	8.786	1.00	0.00	C
	ATOM	157	C	GLY	K	32	-11.448	-18.886	8.852	1.00	0.00	C
	ATOM	158	O	GLY	K	32	-12.311	-19.748	8.739	1.00	0.00	O
	ATOM	159	N	ASN	K	33	-11.697	-17.540	9.067	1.00	0.00	N
	ATOM	160	CA	ASN	K	33	-13.041	-17.042	9.353	1.00	0.00	C
45	ATOM	161	C	ASN	K	33	-14.030	-17.338	8.237	1.00	0.00	C
	ATOM	162	O	ASN	K	33	-15.195	-17.586	8.518	1.00	0.00	O
	ATOM	163	CB	ASN	K	33	-13.082	-15.548	9.682	1.00	0.00	C
	ATOM	164	CG	ASN	K	33	-12.429	-15.313	11.027	1.00	0.00	C
	ATOM	165	OD1	ASN	K	33	-11.228	-15.123	11.150	1.00	0.00	O
50	ATOM	166	ND2	ASN	K	33	-13.304	-15.391	12.084	1.00	0.00	N
	ATOM	167	N	ALA	K	34	-13.550	-17.251	6.936	1.00	0.00	N
	ATOM	168	CA	ALA	K	34	-14.421	-17.507	5.790	1.00	0.00	C
	ATOM	169	C	ALA	K	34	-15.122	-18.859	5.907	1.00	0.00	C
	ATOM	170	O	ALA	K	34	-16.319	-18.947	5.666	1.00	0.00	O
55	ATOM	171	CB	ALA	K	34	-13.694	-17.415	4.452	1.00	0.00	C
	ATOM	172	N	LEU	K	35	-14.314	-19.944	6.241	1.00	0.00	N
	ATOM	173	CA	LEU	K	35	-14.846	-21.307	6.228	1.00	0.00	C
	ATOM	174	C	LEU	K	35	-15.971	-21.436	7.251	1.00	0.00	C
	ATOM	175	O	LEU	K	35	-17.069	-21.845	6.903	1.00	0.00	O
60	ATOM	176	CB	LEU	K	35	-13.772	-22.394	6.421	1.00	0.00	C
	ATOM	177	CG	LEU	K	35	-14.300	-23.840	6.297	1.00	0.00	C
	ATOM	178	CD1	LEU	K	35	-15.047	-24.085	4.985	1.00	0.00	C

-72-

Table 7 - Continued

	ATOM	179	CD2	LEU	K	35	-13.141	-24.824	6.390	1.00	0.00	C
	ATOM	180	N	ILE	K	36	-15.638	-21.099	8.558	1.00	0.00	N
5	ATOM	181	CA	ILE	K	36	-16.600	-21.255	9.659	1.00	0.00	C
	ATOM	182	C	ILE	K	36	-17.882	-20.429	9.441	1.00	0.00	C
	ATOM	183	O	ILE	K	36	-18.949	-20.824	9.886	1.00	0.00	O
	ATOM	184	CB	ILE	K	36	-15.962	-21.030	11.062	1.00	0.00	C
	ATOM	185	CG1	ILE	K	36	-16.871	-21.445	12.238	1.00	0.00	C
10	ATOM	186	CG2	ILE	K	36	-15.510	-19.587	11.273	1.00	0.00	C
	ATOM	187	CD1	ILE	K	36	-17.169	-22.935	12.277	1.00	0.00	C
	ATOM	188	N	SER	K	37	-17.738	-19.213	8.783	1.00	0.00	N
	ATOM	189	CA	SER	K	37	-18.885	-18.361	8.470	1.00	0.00	C
	ATOM	190	C	SER	K	37	-19.842	-19.064	7.503	1.00	0.00	C
15	ATOM	191	O	SER	K	37	-21.048	-19.060	7.714	1.00	0.00	O
	ATOM	192	CB	SER	K	37	-18.468	-16.998	7.904	1.00	0.00	C
	ATOM	193	OG	SER	K	37	-17.726	-16.273	8.882	1.00	0.00	O
	ATOM	194	N	GLY	K	38	-19.250	-19.608	6.368	1.00	0.00	N
	ATOM	195	CA	GLY	K	38	-20.018	-20.200	5.286	1.00	0.00	C
20	ATOM	196	C	GLY	K	38	-20.674	-21.495	5.719	1.00	0.00	C
	ATOM	197	O	GLY	K	38	-21.892	-21.595	5.801	1.00	0.00	O
	ATOM	198	N	VAL	K	39	-19.771	-22.524	5.962	1.00	0.00	N
	ATOM	199	CA	VAL	K	39	-20.202	-23.854	6.388	1.00	0.00	C
	ATOM	200	C	VAL	K	39	-20.585	-23.634	7.851	1.00	0.00	C
25	ATOM	201	O	VAL	K	39	-19.755	-23.371	8.710	1.00	0.00	O
	ATOM	202	CB	VAL	K	39	-19.109	-24.938	6.216	1.00	0.00	C
	ATOM	203	CG1	VAL	K	39	-19.600	-26.295	6.726	1.00	0.00	C
	ATOM	204	CG2	VAL	K	39	-18.706	-25.084	4.746	1.00	0.00	C
	ATOM	205	N	ALA	K	40	-21.950	-23.720	8.052	1.00	0.00	N
30	ATOM	206	CA	ALA	K	40	-22.661	-23.216	9.225	1.00	0.00	C
	ATOM	207	C	ALA	K	40	-24.147	-23.511	9.031	1.00	0.00	C
	ATOM	208	O	ALA	K	40	-24.767	-24.137	9.880	1.00	0.00	O
	ATOM	209	CB	ALA	K	40	-22.458	-21.723	9.480	1.00	0.00	C
	ATOM	210	N	ARG	K	41	-24.700	-23.008	7.852	1.00	0.00	N
35	ATOM	211	CA	ARG	K	41	-26.085	-23.274	7.460	1.00	0.00	C
	ATOM	212	C	ARG	K	41	-26.211	-24.778	7.215	1.00	0.00	C
	ATOM	213	O	ARG	K	41	-27.000	-25.451	7.864	1.00	0.00	O
	ATOM	214	CB	ARG	K	41	-26.570	-22.473	6.234	1.00	0.00	C
	ATOM	215	CG	ARG	K	41	-26.713	-20.966	6.485	1.00	0.00	C
40	ATOM	216	CD	ARG	K	41	-25.452	-20.174	6.135	1.00	0.00	C
	ATOM	217	NE	ARG	K	41	-25.678	-18.741	6.386	1.00	0.00	N
	ATOM	218	CZ	ARG	K	41	-25.452	-18.101	7.583	1.00	0.00	C
	ATOM	219	NH1	ARG	K	41	-25.060	-18.741	8.738	1.00	0.00	N
	ATOM	220	NH2	ARG	K	41	-25.621	-16.742	7.672	1.00	0.00	N
45	ATOM	221	N	GLN	K	42	-25.370	-25.293	6.231	1.00	0.00	N
	ATOM	222	CA	GLN	K	42	-25.068	-26.723	6.170	1.00	0.00	C
	ATOM	223	C	GLN	K	42	-24.106	-26.908	7.346	1.00	0.00	C
	ATOM	224	O	GLN	K	42	-23.120	-26.187	7.425	1.00	0.00	O
	ATOM	225	CB	GLN	K	42	-24.378	-27.132	4.861	1.00	0.00	C
50	ATOM	226	CG	GLN	K	42	-25.309	-26.988	3.656	1.00	0.00	C
	ATOM	227	CD	GLN	K	42	-24.569	-27.351	2.387	1.00	0.00	C
	ATOM	228	OE1	GLN	K	42	-23.890	-26.535	1.781	1.00	0.00	O
	ATOM	229	NE2	GLN	K	42	-24.697	-28.671	2.018	1.00	0.00	N
	ATOM	230	N	PRO	K	43	-24.423	-27.890	8.291	1.00	0.00	N
55	ATOM	231	CA	PRO	K	43	-23.884	-27.878	9.642	1.00	0.00	C
	ATOM	232	C	PRO	K	43	-22.377	-27.648	9.717	1.00	0.00	C
	ATOM	233	O	PRO	K	43	-21.587	-28.264	9.010	1.00	0.00	O
	ATOM	234	CB	PRO	K	43	-24.244	-29.240	10.215	1.00	0.00	C
	ATOM	235	CG	PRO	K	43	-25.513	-29.627	9.485	1.00	0.00	C
60	ATOM	236	CD	PRO	K	43	-25.436	-28.920	8.145	1.00	0.00	C
	ATOM	237	N	GLU	K	44	-22.018	-26.729	10.698	1.00	0.00	N
	ATOM	238	CA	GLU	K	44	-20.630	-26.532	11.109	1.00	0.00	C

-73-

Table 7 - Continued

	ATOM	239	C	GLU	K	44	-20.263	-27.787	11.901	1.00	0.00	C
	ATOM	240	O	GLU	K	44	-20.648	-27.973	13.047	1.00	0.00	O
5	ATOM	241	CB	GLU	K	44	-20.357	-25.222	11.885	1.00	0.00	C
	ATOM	242	CG	GLU	K	44	-21.282	-24.897	13.065	1.00	0.00	C
	ATOM	243	CD	GLU	K	44	-20.874	-23.584	13.689	1.00	0.00	C
	ATOM	244	OE1	GLU	K	44	-21.169	-22.482	13.249	1.00	0.00	O
	ATOM	245	OE2	GLU	K	44	-20.084	-23.772	14.778	1.00	0.00	O
10	ATOM	246	N	ALA	K	45	-19.503	-28.690	11.171	1.00	0.00	N
	ATOM	247	CA	ALA	K	45	-19.111	-29.993	11.700	1.00	0.00	C
	ATOM	248	C	ALA	K	45	-17.820	-30.392	10.992	1.00	0.00	C
	ATOM	249	O	ALA	K	45	-16.751	-30.343	11.586	1.00	0.00	O
	ATOM	250	CB	ALA	K	45	-20.221	-31.038	11.595	1.00	0.00	C
15	ATOM	251	N	GLN	K	46	-17.945	-30.742	9.651	1.00	0.00	N
	ATOM	252	CA	GLN	K	46	-16.777	-31.025	8.812	1.00	0.00	C
	ATOM	253	C	GLN	K	46	-15.948	-29.747	8.696	1.00	0.00	C
	ATOM	254	O	GLN	K	46	-14.745	-29.762	8.923	1.00	0.00	O
	ATOM	255	CB	GLN	K	46	-17.123	-31.555	7.408	1.00	0.00	C
20	ATOM	256	CG	GLN	K	46	-17.621	-33.004	7.392	1.00	0.00	C
	ATOM	257	CD	GLN	K	46	-19.006	-33.186	7.986	1.00	0.00	C
	ATOM	258	OE1	GLN	K	46	-19.859	-32.308	7.971	1.00	0.00	O
	ATOM	259	NE2	GLN	K	46	-19.226	-34.446	8.491	1.00	0.00	N
	ATOM	260	N	GLY	K	47	-16.657	-28.614	8.311	1.00	0.00	N
25	ATOM	261	CA	GLY	K	47	-16.039	-27.303	8.201	1.00	0.00	C
	ATOM	262	C	GLY	K	47	-15.338	-26.879	9.479	1.00	0.00	C
	ATOM	263	O	GLY	K	47	-14.240	-26.342	9.441	1.00	0.00	O
	ATOM	264	N	ARG	K	48	-16.061	-27.090	10.644	1.00	0.00	N
	ATOM	265	CA	ARG	K	48	-15.555	-26.706	11.960	1.00	0.00	C
30	ATOM	266	C	ARG	K	48	-14.231	-27.405	12.262	1.00	0.00	C
	ATOM	267	O	ARG	K	48	-13.287	-26.756	12.689	1.00	0.00	O
	ATOM	268	CB	ARG	K	48	-16.597	-26.944	13.061	1.00	0.00	C
	ATOM	269	CG	ARG	K	48	-16.186	-26.354	14.413	1.00	0.00	C
	ATOM	270	CD	ARG	K	48	-17.369	-26.238	15.367	1.00	0.00	C
35	ATOM	271	NE	ARG	K	48	-17.915	-27.575	15.655	1.00	0.00	N
	ATOM	272	CZ	ARG	K	48	-19.183	-27.822	16.126	1.00	0.00	C
	ATOM	273	NH1	ARG	K	48	-20.102	-26.840	16.422	1.00	0.00	N
	ATOM	274	NH2	ARG	K	48	-19.592	-29.116	16.330	1.00	0.00	N
	ATOM	275	N	LEU	K	49	-14.204	-28.779	12.049	1.00	0.00	N
40	ATOM	276	CA	LEU	K	49	-13.005	-29.597	12.271	1.00	0.00	C
	ATOM	277	C	LEU	K	49	-11.827	-29.081	11.437	1.00	0.00	C
	ATOM	278	O	LEU	K	49	-10.702	-29.027	11.916	1.00	0.00	O
	ATOM	279	CB	LEU	K	49	-13.275	-31.090	11.982	1.00	0.00	C
	ATOM	280	CG	LEU	K	49	-12.083	-32.036	12.236	1.00	0.00	C
45	ATOM	281	CD1	LEU	K	49	-11.677	-32.080	13.709	1.00	0.00	C
	ATOM	282	CD2	LEU	K	49	-12.425	-33.444	11.754	1.00	0.00	C
	ATOM	283	N	PHE	K	50	-12.130	-28.759	10.121	1.00	0.00	N
	ATOM	284	CA	PHE	K	50	-11.132	-28.301	9.155	1.00	0.00	C
	ATOM	285	C	PHE	K	50	-10.455	-27.011	9.641	1.00	0.00	C
50	ATOM	286	O	PHE	K	50	-9.236	-26.909	9.608	1.00	0.00	O
	ATOM	287	CB	PHE	K	50	-11.767	-28.116	7.763	1.00	0.00	C
	ATOM	288	CG	PHE	K	50	-10.777	-28.053	6.628	1.00	0.00	C
	ATOM	289	CD1	PHE	K	50	-10.020	-26.882	6.371	1.00	0.00	C
	ATOM	290	CE1	PHE	K	50	-9.135	-26.833	5.279	1.00	0.00	C
55	ATOM	291	CZ	PHE	K	50	-9.016	-27.936	4.421	1.00	0.00	C
	ATOM	292	CE2	PHE	K	50	-9.753	-29.103	4.664	1.00	0.00	C
	ATOM	293	CD2	PHE	K	50	-10.628	-29.162	5.761	1.00	0.00	C
	ATOM	294	N	THR	K	51	-11.316	-25.991	10.042	1.00	0.00	N
	ATOM	295	CA	THR	K	51	-10.914	-24.586	10.190	1.00	0.00	C
60	ATOM	296	C	THR	K	51	-9.594	-24.387	10.960	1.00	0.00	C
	ATOM	297	O	THR	K	51	-8.750	-23.638	10.482	1.00	0.00	O
	ATOM	298	CB	THR	K	51	-12.056	-23.684	10.725	1.00	0.00	C

-74-

Table 7 - Continued

	ATOM	299	OG1	THR	K	51	-13.156	-23.711	9.813	1.00	0.00	O
	ATOM	300	CG2	THR	K	51	-11.641	-22.223	10.839	1.00	0.00	C
5	ATOM	301	N	PRO	K	52	-9.405	-25.041	12.190	1.00	0.00	N
	ATOM	302	CA	PRO	K	52	-8.158	-24.960	12.932	1.00	0.00	C
	ATOM	303	C	PRO	K	52	-6.858	-25.075	12.146	1.00	0.00	C
	ATOM	304	O	PRO	K	52	-5.885	-24.428	12.506	1.00	0.00	O
	ATOM	305	CB	PRO	K	52	-8.261	-26.043	13.991	1.00	0.00	C
10	ATOM	306	CG	PRO	K	52	-9.743	-26.108	14.284	1.00	0.00	C
	ATOM	307	CD	PRO	K	52	-10.411	-25.728	12.977	1.00	0.00	C
	ATOM	308	N	PHE	K	53	-6.854	-25.955	11.068	1.00	0.00	N
	ATOM	309	CA	PHE	K	53	-5.670	-26.171	10.235	1.00	0.00	C
	ATOM	310	C	PHE	K	53	-5.125	-24.829	9.739	1.00	0.00	C
15	ATOM	311	O	PHE	K	53	-3.942	-24.556	9.891	1.00	0.00	O
	ATOM	312	CB	PHE	K	53	-5.936	-27.142	9.069	1.00	0.00	C
	ATOM	313	CG	PHE	K	53	-4.673	-27.523	8.331	1.00	0.00	C
	ATOM	314	CD1	PHE	K	53	-4.287	-26.835	7.153	1.00	0.00	C
	ATOM	315	CD2	PHE	K	53	-3.860	-28.588	8.795	1.00	0.00	C
20	ATOM	316	CE1	PHE	K	53	-3.117	-27.201	6.460	1.00	0.00	C
	ATOM	317	CE2	PHE	K	53	-2.693	-28.953	8.097	1.00	0.00	C
	ATOM	318	CZ	PHE	K	53	-2.322	-28.262	6.930	1.00	0.00	C
	ATOM	319	N	PHE	K	54	-6.042	-23.989	9.109	1.00	0.00	N
	ATOM	320	CA	PHE	K	54	-5.632	-22.714	8.512	1.00	0.00	C
25	ATOM	321	C	PHE	K	54	-4.879	-21.890	9.557	1.00	0.00	C
	ATOM	322	O	PHE	K	54	-3.748	-21.476	9.337	1.00	0.00	O
	ATOM	323	CB	PHE	K	54	-6.794	-21.857	7.962	1.00	0.00	C
	ATOM	324	CG	PHE	K	54	-7.478	-22.388	6.726	1.00	0.00	C
	ATOM	325	CD1	PHE	K	54	-6.776	-22.516	5.501	1.00	0.00	C
30	ATOM	326	CD2	PHE	K	54	-8.868	-22.667	6.744	1.00	0.00	C
	ATOM	327	CE1	PHE	K	54	-7.453	-22.895	4.325	1.00	0.00	C
	ATOM	328	CE2	PHE	K	54	-9.540	-23.037	5.565	1.00	0.00	C
	ATOM	329	CZ	PHE	K	54	-8.835	-23.146	4.354	1.00	0.00	C
	ATOM	330	N	ILE	K	55	-5.602	-21.616	10.711	1.00	0.00	N
35	ATOM	331	CA	ILE	K	55	-5.139	-20.632	11.690	1.00	0.00	C
	ATOM	332	C	ILE	K	55	-3.881	-21.077	12.435	1.00	0.00	C
	ATOM	333	O	ILE	K	55	-3.018	-20.252	12.706	1.00	0.00	O
	ATOM	334	CB	ILE	K	55	-6.240	-20.109	12.653	1.00	0.00	C
	ATOM	335	CG1	ILE	K	55	-6.944	-21.221	13.459	1.00	0.00	C
40	ATOM	336	CG2	ILE	K	55	-7.249	-19.271	11.863	1.00	0.00	C
	ATOM	337	CD1	ILE	K	55	-7.916	-20.694	14.499	1.00	0.00	C
	ATOM	338	N	THR	K	56	-3.815	-22.415	12.811	1.00	0.00	N
	ATOM	339	CA	THR	K	56	-2.675	-22.938	13.561	1.00	0.00	C
	ATOM	340	C	THR	K	56	-1.407	-22.838	12.711	1.00	0.00	C
45	ATOM	341	O	THR	K	56	-0.371	-22.417	13.208	1.00	0.00	O
	ATOM	342	CB	THR	K	56	-2.921	-24.337	14.185	1.00	0.00	C
	ATOM	343	OG1	THR	K	56	-1.991	-24.550	15.248	1.00	0.00	O
	ATOM	344	CG2	THR	K	56	-2.789	-25.522	13.234	1.00	0.00	C
	ATOM	345	N	VAL	K	57	-1.512	-23.258	11.387	1.00	0.00	N
50	ATOM	346	CA	VAL	K	57	-0.372	-23.191	10.471	1.00	0.00	C
	ATOM	347	C	VAL	K	57	0.068	-21.732	10.327	1.00	0.00	C
	ATOM	348	O	VAL	K	57	1.259	-21.469	10.285	1.00	0.00	O
	ATOM	349	CB	VAL	K	57	-0.628	-23.887	9.109	1.00	0.00	C
	ATOM	350	CG1	VAL	K	57	0.515	-23.659	8.115	1.00	0.00	C
55	ATOM	351	CG2	VAL	K	57	-0.791	-25.399	9.300	1.00	0.00	C
	ATOM	352	N	GLY	K	58	-0.931	-20.773	10.232	1.00	0.00	N
	ATOM	353	CA	GLY	K	58	-0.646	-19.343	10.177	1.00	0.00	C
	ATOM	354	C	GLY	K	58	0.245	-18.856	11.314	1.00	0.00	C
	ATOM	355	O	GLY	K	58	1.223	-18.154	11.094	1.00	0.00	O
60	ATOM	356	N	LEU	K	59	-0.170	-19.229	12.585	1.00	0.00	N
	ATOM	357	CA	LEU	K	59	0.563	-18.847	13.797	1.00	0.00	C
	ATOM	358	C	LEU	K	59	1.995	-19.390	13.755	1.00	0.00	C

-75-

Table 7 - Continued

	ATOM	359	O	LEU	K	59	2.950	-18.680	14.037	1.00	0.00	O
	ATOM	360	CB	LEU	K	59	-0.175	-19.306	15.071	1.00	0.00	C
5	ATOM	361	CG	LEU	K	59	0.460	-18.836	16.396	1.00	0.00	C
	ATOM	362	CD1	LEU	K	59	0.454	-17.314	16.532	1.00	0.00	C
	ATOM	363	CD2	LEU	K	59	-0.280	-19.457	17.578	1.00	0.00	C
	ATOM	364	N	VAL	K	60	2.103	-20.735	13.437	1.00	0.00	N
	ATOM	365	CA	VAL	K	60	3.383	-21.445	13.401	1.00	0.00	C
10	ATOM	366	C	VAL	K	60	4.304	-20.826	12.329	1.00	0.00	C
	ATOM	367	O	VAL	K	60	5.497	-20.677	12.556	1.00	0.00	O
	ATOM	368	CB	VAL	K	60	3.168	-22.974	13.243	1.00	0.00	C
	ATOM	369	CG1	VAL	K	60	4.467	-23.717	12.973	1.00	0.00	C
	ATOM	370	CG2	VAL	K	60	2.530	-23.575	14.502	1.00	0.00	C
15	ATOM	371	N	GLU	K	61	3.707	-20.485	11.121	1.00	0.00	N
	ATOM	372	CA	GLU	K	61	4.409	-19.828	10.011	1.00	0.00	C
	ATOM	373	C	GLU	K	61	5.144	-18.585	10.515	1.00	0.00	C
	ATOM	374	O	GLU	K	61	6.304	-18.381	10.182	1.00	0.00	O
	ATOM	375	CB	GLU	K	61	3.458	-19.496	8.840	1.00	0.00	C
20	ATOM	376	CG	GLU	K	61	4.128	-18.695	7.725	1.00	0.00	C
	ATOM	377	CD	GLU	K	61	3.185	-18.379	6.589	1.00	0.00	C
	ATOM	378	OE1	GLU	K	61	1.978	-18.211	6.690	1.00	0.00	O
	ATOM	379	OE2	GLU	K	61	3.875	-18.199	5.434	1.00	0.00	O
	ATOM	380	N	ALA	K	62	4.398	-17.723	11.310	1.00	0.00	N
25	ATOM	381	CA	ALA	K	62	4.961	-16.490	11.858	1.00	0.00	C
	ATOM	382	C	ALA	K	62	6.272	-16.759	12.595	1.00	0.00	C
	ATOM	383	O	ALA	K	62	7.268	-16.086	12.362	1.00	0.00	O
	ATOM	384	CB	ALA	K	62	3.985	-15.755	12.765	1.00	0.00	C
	ATOM	385	N	ALA	K	63	6.222	-17.786	13.532	1.00	0.00	N
30	ATOM	386	CA	ALA	K	63	7.397	-18.184	14.304	1.00	0.00	C
	ATOM	387	C	ALA	K	63	8.559	-18.562	13.385	1.00	0.00	C
	ATOM	388	O	ALA	K	63	9.683	-18.139	13.615	1.00	0.00	O
	ATOM	389	CB	ALA	K	63	7.109	-19.317	15.286	1.00	0.00	C
	ATOM	390	N	TYR	K	64	8.256	-19.413	12.328	1.00	0.00	N
35	ATOM	391	CA	TYR	K	64	9.285	-19.912	11.410	1.00	0.00	C
	ATOM	392	C	TYR	K	64	10.073	-18.796	10.731	1.00	0.00	C
	ATOM	393	O	TYR	K	64	11.269	-18.949	10.526	1.00	0.00	O
	ATOM	394	CB	TYR	K	64	8.751	-20.857	10.318	1.00	0.00	C
	ATOM	395	CG	TYR	K	64	8.211	-22.195	10.773	1.00	0.00	C
40	ATOM	396	CD1	TYR	K	64	8.685	-22.868	11.933	1.00	0.00	C
	ATOM	397	CD2	TYR	K	64	7.247	-22.847	9.964	1.00	0.00	C
	ATOM	398	CE1	TYR	K	64	8.206	-24.146	12.270	1.00	0.00	C
	ATOM	399	CE2	TYR	K	64	6.796	-24.141	10.271	1.00	0.00	C
	ATOM	400	CZ	TYR	K	64	7.279	-24.784	11.431	1.00	0.00	C
45	ATOM	401	OH	TYR	K	64	6.844	-26.049	11.786	1.00	0.00	O
	ATOM	402	N	PHE	K	65	9.364	-17.669	10.325	1.00	0.00	N
	ATOM	403	CA	PHE	K	65	10.059	-16.531	9.710	1.00	0.00	C
	ATOM	404	C	PHE	K	65	11.164	-16.015	10.631	1.00	0.00	C
	ATOM	405	O	PHE	K	65	12.265	-15.736	10.172	1.00	0.00	O
50	ATOM	406	CB	PHE	K	65	9.145	-15.353	9.328	1.00	0.00	C
	ATOM	407	CG	PHE	K	65	8.256	-15.625	8.140	1.00	0.00	C
	ATOM	408	CD1	PHE	K	65	6.850	-15.558	8.269	1.00	0.00	C
	ATOM	409	CE1	PHE	K	65	6.019	-15.722	7.147	1.00	0.00	C
	ATOM	410	CZ	PHE	K	65	6.578	-15.970	5.883	1.00	0.00	C
55	ATOM	411	CE2	PHE	K	65	7.973	-16.052	5.738	1.00	0.00	C
	ATOM	412	CD2	PHE	K	65	8.808	-15.877	6.858	1.00	0.00	C
	ATOM	413	N	ILE	K	66	10.810	-15.851	11.967	1.00	0.00	N
	ATOM	414	CA	ILE	K	66	11.764	-15.375	12.973	1.00	0.00	C
	ATOM	415	C	ILE	K	66	12.951	-16.337	13.006	1.00	0.00	C
60	ATOM	416	O	ILE	K	66	14.086	-15.893	12.915	1.00	0.00	O
	ATOM	417	CB	ILE	K	66	11.140	-15.149	14.379	1.00	0.00	C
	ATOM	418	CG1	ILE	K	66	10.099	-14.011	14.323	1.00	0.00	C

-76-

Table 7 - Continued

	ATOM	419	CG2	ILE	K	66	12.227	-14.831	15.415	1.00	0.00	C
	ATOM	420	CD1	ILE	K	66	9.228	-13.930	15.564	1.00	0.00	C
5	ATOM	421	N	ASN	K	67	12.652	-17.685	13.180	1.00	0.00	N
	ATOM	422	CA	ASN	K	67	13.703	-18.702	13.320	1.00	0.00	C
	ATOM	423	C	ASN	K	67	14.701	-18.596	12.170	1.00	0.00	C
	ATOM	424	O	ASN	K	67	15.900	-18.535	12.401	1.00	0.00	O
	ATOM	425	CB	ASN	K	67	13.186	-20.151	13.395	1.00	0.00	C
10	ATOM	426	CG	ASN	K	67	12.499	-20.446	14.713	1.00	0.00	C
	ATOM	427	OD1	ASN	K	67	11.286	-20.373	14.846	1.00	0.00	O
	ATOM	428	ND2	ASN	K	67	13.361	-20.767	15.738	1.00	0.00	N
	ATOM	429	N	LEU	K	68	14.148	-18.617	10.895	1.00	0.00	N
	ATOM	430	CA	LEU	K	68	14.952	-18.648	9.672	1.00	0.00	C
15	ATOM	431	C	LEU	K	68	15.897	-17.447	9.657	1.00	0.00	C
	ATOM	432	O	LEU	K	68	17.102	-17.606	9.507	1.00	0.00	O
	ATOM	433	CB	LEU	K	68	14.060	-18.741	8.415	1.00	0.00	C
	ATOM	434	CG	LEU	K	68	14.812	-19.062	7.106	1.00	0.00	C
	ATOM	435	CD1	LEU	K	68	13.884	-19.801	6.142	1.00	0.00	C
20	ATOM	436	CD2	LEU	K	68	15.348	-17.806	6.416	1.00	0.00	C
	ATOM	437	N	ALA	K	69	15.280	-16.209	9.799	1.00	0.00	N
	ATOM	438	CA	ALA	K	69	16.020	-14.950	9.727	1.00	0.00	C
	ATOM	439	C	ALA	K	69	17.139	-14.903	10.766	1.00	0.00	C
	ATOM	440	O	ALA	K	69	18.266	-14.546	10.449	1.00	0.00	O
25	ATOM	441	CB	ALA	K	69	15.107	-13.737	9.887	1.00	0.00	C
	ATOM	442	N	PHE	K	70	16.758	-15.243	12.059	1.00	0.00	N
	ATOM	443	CA	PHE	K	70	17.670	-15.188	13.199	1.00	0.00	C
	ATOM	444	C	PHE	K	70	18.884	-16.072	12.927	1.00	0.00	C
	ATOM	445	O	PHE	K	70	20.011	-15.631	13.104	1.00	0.00	O
30	ATOM	446	CB	PHE	K	70	16.975	-15.568	14.523	1.00	0.00	C
	ATOM	447	CG	PHE	K	70	17.885	-15.411	15.718	1.00	0.00	C
	ATOM	448	CD1	PHE	K	70	18.073	-14.141	16.317	1.00	0.00	C
	ATOM	449	CE1	PHE	K	70	18.941	-13.990	17.415	1.00	0.00	C
	ATOM	450	CZ	PHE	K	70	19.631	-15.104	17.928	1.00	0.00	C
35	ATOM	451	CE2	PHE	K	70	19.449	-16.372	17.346	1.00	0.00	C
	ATOM	452	CD2	PHE	K	70	18.578	-16.527	16.251	1.00	0.00	C
	ATOM	453	N	MET	K	71	18.608	-17.374	12.522	1.00	0.00	N
	ATOM	454	CA	MET	K	71	19.663	-18.364	12.302	1.00	0.00	C
	ATOM	455	C	MET	K	71	20.669	-17.820	11.295	1.00	0.00	C
40	ATOM	456	O	MET	K	71	21.861	-17.837	11.565	1.00	0.00	O
	ATOM	457	CB	MET	K	71	19.144	-19.738	11.845	1.00	0.00	C
	ATOM	458	CG	MET	K	71	18.539	-20.532	13.001	1.00	0.00	C
	ATOM	459	SD	MET	K	71	17.840	-22.089	12.369	1.00	0.00	S
	ATOM	460	CE	MET	K	71	17.151	-22.720	13.919	1.00	0.00	C
45	ATOM	461	N	ALA	K	72	20.140	-17.350	10.096	1.00	0.00	N
	ATOM	462	CA	ALA	K	72	20.987	-16.868	9.002	1.00	0.00	C
	ATOM	463	C	ALA	K	72	21.948	-15.778	9.479	1.00	0.00	C
	ATOM	464	O	ALA	K	72	23.143	-15.836	9.214	1.00	0.00	O
	ATOM	465	CB	ALA	K	72	20.171	-16.371	7.810	1.00	0.00	C
50	ATOM	466	N	LEU	K	73	21.352	-14.740	10.188	1.00	0.00	N
	ATOM	467	CA	LEU	K	73	22.105	-13.603	10.723	1.00	0.00	C
	ATOM	468	C	LEU	K	73	23.219	-14.134	11.625	1.00	0.00	C
	ATOM	469	O	LEU	K	73	24.380	-13.793	11.445	1.00	0.00	O
	ATOM	470	CB	LEU	K	73	21.168	-12.597	11.435	1.00	0.00	C
55	ATOM	471	CG	LEU	K	73	21.770	-11.268	11.940	1.00	0.00	C
	ATOM	472	CD1	LEU	K	73	22.598	-11.416	13.216	1.00	0.00	C
	ATOM	473	CD2	LEU	K	73	22.551	-10.518	10.865	1.00	0.00	C
	ATOM	474	N	PHE	K	74	22.798	-14.976	12.647	1.00	0.00	N
	ATOM	475	CA	PHE	K	74	23.673	-15.420	13.728	1.00	0.00	C
60	ATOM	476	C	PHE	K	74	24.905	-16.131	13.168	1.00	0.00	C
	ATOM	477	O	PHE	K	74	26.020	-15.816	13.560	1.00	0.00	O
	ATOM	478	CB	PHE	K	74	22.924	-16.299	14.751	1.00	0.00	C

-77-

Table 7 - Continued

5	ATOM	479	CG	PHE	K	74	23.732	-16.543	16.002	1.00	0.00	C
	ATOM	480	CD1	PHE	K	74	24.581	-17.672	16.106	1.00	0.00	C
	ATOM	481	CE1	PHE	K	74	25.344	-17.887	17.269	1.00	0.00	C
	ATOM	482	CZ	PHE	K	74	25.264	-16.982	18.342	1.00	0.00	C
	ATOM	483	CE2	PHE	K	74	24.421	-15.860	18.254	1.00	0.00	C
10	ATOM	484	CD2	PHE	K	74	23.658	-15.640	17.091	1.00	0.00	C
	ATOM	485	N	VAL	K	75	24.659	-17.162	12.265	1.00	0.00	N
	ATOM	486	CA	VAL	K	75	25.740	-18.022	11.768	1.00	0.00	C
	ATOM	487	C	VAL	K	75	26.806	-17.217	11.023	1.00	0.00	C
	ATOM	488	O	VAL	K	75	27.988	-17.509	11.151	1.00	0.00	O
15	ATOM	489	CB	VAL	K	75	25.296	-19.270	10.961	1.00	0.00	C
	ATOM	490	CG1	VAL	K	75	24.498	-20.225	11.849	1.00	0.00	C
	ATOM	491	CG2	VAL	K	75	24.524	-18.965	9.677	1.00	0.00	C
	ATOM	492	N	PHE	K	76	26.338	-16.197	10.199	1.00	0.00	N
	ATOM	493	CA	PHE	K	76	27.254	-15.284	9.518	1.00	0.00	C
20	ATOM	494	C	PHE	K	76	28.106	-14.562	10.570	1.00	0.00	C
	ATOM	495	O	PHE	K	76	29.327	-14.567	10.485	1.00	0.00	O
	ATOM	496	CB	PHE	K	76	26.514	-14.307	8.577	1.00	0.00	C
	ATOM	497	CG	PHE	K	76	27.428	-13.236	8.034	1.00	0.00	C
	ATOM	498	CD1	PHE	K	76	27.372	-11.920	8.557	1.00	0.00	C
25	ATOM	499	CD2	PHE	K	76	28.398	-13.540	7.048	1.00	0.00	C
	ATOM	500	CE1	PHE	K	76	28.293	-10.945	8.136	1.00	0.00	C
	ATOM	501	CE2	PHE	K	76	29.317	-12.561	6.628	1.00	0.00	C
	ATOM	502	CZ	PHE	K	76	29.271	-11.268	7.180	1.00	0.00	C
	ATOM	503	N	ALA	K	77	27.390	-13.889	11.554	1.00	0.00	N
30	ATOM	504	CA	ALA	K	77	28.022	-12.981	12.509	1.00	0.00	C
	ATOM	505	C	ALA	K	77	29.158	-13.664	13.265	1.00	0.00	C
	ATOM	506	O	ALA	K	77	30.255	-13.126	13.348	1.00	0.00	O
	ATOM	507	CB	ALA	K	77	27.020	-12.372	13.488	1.00	0.00	C
	ATOM	508	N	THR	K	78	28.833	-14.872	13.873	1.00	0.00	N
35	ATOM	509	CA	THR	K	78	29.831	-15.665	14.586	1.00	0.00	C
	ATOM	510	C	THR	K	78	30.768	-16.240	13.544	1.00	0.00	C
	ATOM	511	O	THR	K	78	31.932	-16.523	13.791	1.00	0.00	O
	ATOM	512	CB	THR	K	78	29.211	-16.756	15.490	1.00	0.00	C
	ATOM	513	OG1	THR	K	78	30.185	-17.218	16.432	1.00	0.00	O
	ATOM	514	CG2	THR	K	78	28.636	-17.966	14.756	1.00	0.00	C

40

WHAT IS CLAIMED IS:

1. A binding site in the F₀ part of an ATPase characterised in that it comprises the resistance-conferring mutation sites of an atpE protein.
5
2. A binding site according to claim 1 wherein the resistance-conferring mutation sites refer to amino acids 14 to 34 and to amino acids 53 to 69 of an atpE protein, taking the numbering of Mtb_S (SEQ ID No.1) or of Mtb_R (SEQ ID No.2) as a reference.
10
3. A binding site according to claim 1 comprising at least the amino acids Ala²⁴, Gly²⁷, Phe⁵³, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴ and Phe⁶⁵ of one C subunit and the amino acids Ser¹⁸², Leu¹⁸³, Leu¹⁸⁵, Arg¹⁸⁶ of one A subunit.
15
4. A binding site according to claim 4 wherein said amino acids have the atomic coordinates of any of Tables 3, 4 or 5 or homologous structure coordinates comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5Å.
20
5. Use of a binding site according to any one of claims 1 to 4 in a method to identify compounds that interact with the F₀ part of an ATPase and to their potential as anti-microbial compounds.
25
6. A method to evaluate the potential of a test compound to interact with an atpE protein, said method comprising;
- molecular modeling techniques to generate the three-dimensional structure of a binding site according to any of claims 1 to 4;
- employing computational means to perform a fitting operation between the test compound and the three-dimensional structure of the binding site; and
30 - analyzing the results of said fitting operation to quantify the association of the test compound with the three-dimensional structure of the binding site.

7. A method according to claim 6 wherein the three dimensional structure is generated with at least the amino acids Ala²⁴, Gly²⁷, Phe⁵³, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴ and Phe⁶⁵ of one C subunit and the amino acids Ser¹⁸², Leu¹⁸³, Leu¹⁸⁵, and Arg¹⁸⁶ of one A subunit, using the atomic coordinates of any of Tables 3, 4 or 5 or homologous structure coordinates comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5Å.
8. A method according to claim 6 wherein the three-dimensional structure is generated using the atomic coordinates of the amino acids Ala²¹, Gly²⁵ of the A Chain of any of Tables 3, 4 or 5; the amino acids Ala²⁴, Gly²⁷, Phe⁵³, Phe⁵⁴, Val⁵⁷, Gly⁵⁸, Glu⁶¹, Tyr⁶⁴, Phe⁶⁵ of the K Chain of any of Tables 3, 4 or 5; the amino acids Met¹⁷, Gly¹⁹, Gly²⁰, Ala²¹, Ile²², Gly²³, Ala²⁴, Gly²⁵, Ile²⁶, Gly²⁷, Asp²⁸, Gly²⁹, Ala³¹, Phe⁵³, Thr⁵⁶, Val⁵⁷, Gly⁵⁸, Leu⁵⁹, Val⁶⁰, Glu⁶¹, Ala⁶², Ala⁶³/Pro⁶³, Tyr⁶⁴, Phe⁶⁵ of the L Chain of any of Tables 3, 4 or 5; and of the amino acids Ser¹⁸², Leu¹⁸³, Leu¹⁸⁵, and Arg¹⁸⁶ of the M Chain of any of Tables 3, 4 or 5.
9. A method of treating a subject with a microbially-based infection, comprising administering to the subject a compound that interacts with an atpE protein at the resistance-conferring mutation sites.
10. A method according to claim 9, wherein the resistance-conferring mutation sites refer to amino acids 14 to 34 and to amino acids 53 to 69 of an atpE protein, taking the numbering of Mtb_S (SEQ ID No.1) or of Mtb_R (SEQ ID No.2) as a reference.
11. A method of treating a subject with a microbially-based infection, comprising administering to the subject a compound that interacts with the binding site according to any one of claims 1 to 4.
12. Use of compounds identified using any of the aforementioned screening methods in a method of treating a subject with a microbially-based infection.

13. Use according to claim 12 to treat infections caused by Gram-positive bacteria, more particular mycobacteria, and most particular against infections caused by *M. africanum*, *M. avium*, *M. bovis*, *M. bovis-BCG*, *M. chelonae*, *M. fortuitum*, *M. gordonae*, *M. intracellulare*, *M. kansasii*, *M. microti*, *M. scrofulaceum*, *M. paratuberculosis*, *M. leprea*, *M. tuberculosis*, *M. ulcerans* and *M. ranae*.
14. Use according to claim 12 to treat central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients.
15. Use of DARQ J in the manufacture of a medicament for treating a bacterial infection provided that said infection is other than a mycobacterial infection.
16. An isolated mutant atpE protein wherein the mutation consists of at least one point mutation located in any one of amino acids 20 to 40, in particular 30 to 40 or of amino acids 60 to 75, in particular 62 to 73 as shown in the sequence alignment of Fig.2.
17. An isolated mutant atpE protein according to claim 16 wherein the mutation consists of at least one point mutation, in amino acid 34 or amino acid 69 as shown in the sequence alignment of Fig.2
18. An isolated mutant atpE protein according to claim 17, selected from Mtb_R (SEQ ID No. 2), Msm_R09 (SEQ ID No.4), Msm_R10 (SEQ ID No.5) and an amino acid sequence having at least 70, 80, 90, 95, 97 or 98% sequence identity to Mtb_R, Msm_R09 or Msm_R10.

19. An isolated nucleic acid sequence encoding an isolated mutant atpE protein according to any one of claims 16 to 18.
20. A vector comprising the nucleic acid sequence according to claim 19
- 5 21. A host cell carrying the vector according to claim 20
22. A method for identifying an anti-microbial compound, said method comprising
- 10 a) contacting cells expressing an atpE protein with a test compound under physiological conditions, and
- b) determining whether the test compound interacts with the atpE protein
23. A method according to claim 22, wherein the atpE protein is selected from the group consisting of;
- 15 SwissProt entry Q10598 or a protein having at least 70, 80, 90, 95, 97 or 98% sequence identity to SwissProt entry Q10598; and
- a mutant atpE protein according to any one of claims 1 to 3.
24. A method to identify whether a test compound binds to an isolated atpE protein, said method comprising;
- 20 a) contacting cells expressing an atpE protein wherein such cells do not normally express said atpE protein, with the test compound in the presence and absence of a compound known to bind the atpE protein,
- b) determine the binding of the test compound to the atpE protein using the compound known to bind to the atpE protein as a reference.
- 25 25. A method according to claim 24 wherein the atpE protein is selected from the group consisting of;
- 30 SwissProt entry Q10598 or a protein having at least 70, 80, 90, 95, 97 or 98% sequence identity to SwissProt entry Q10598; and
- a mutant atpE protein according to any one of claims 16 to 18.

26. A method according to claim 24, wherein the compound known to bind to the atpE protein is detectably labeled, and consists of (J).
27. A method according to claim 24 wherein step a) consists of contacting a cellular composition comprising an atpE protein, with the test compound in the presence and absence of a compound known to bind the atpE protein
28. A method according to claim 27 wherein the cellular composition consists of a membrane preparation obtained from the cell according to claim 21.
29. A method for evaluating the potential of a test compound to interact with an atpE protein, said method comprising;
- a) using molecular modeling techniques to formulate a three-dimensional structure of the atpE protein,
- b) employing computational means to perform a fitting operation between the test compound and the three-dimensional structure of the atpE protein, and
- c) analyzing the results of said fitting operation to quantify the association of the test compound with the three-dimensional structure of the atpE protein.
30. A method according to claim 29 wherein the three-dimensional structure of the atpE protein is generated using the atomic coordinates of the Ile28, Glu61 and Ile63 of *E. coli* (Protein Database 1Q01) +/- a root mean square deviation of the backbone atoms of said amino acids of not more than 10Å.
31. A method according to claim 29 wherein the three-dimensional structure of the atpE protein is generated using the atomic coordinates according to tables 6 or 7 +/- a root mean square deviation of the backbone atoms of said amino acids of not more than 1.5Å.

-1/2-

Fig 1





Fig 2

		*	20	*	40	*	60	*	80
Mtb_S	:	MDE---	TIATGALICGGLIMAGGAIGAG	ICDCVAGNALISGVARQPEAQGR	LFTPEFFITVGLVEA	YFINLAFMALFVFATPVK			
Mtb_R	:	MDE---	TIATGALICGGLIMAGGAIGAG	ICDCVAGNALISGVARQPEAQGR	LFTPEFFITVGLVEA	YFINLAFMALFVFATPVK			
Msm_S	:	MDLDPNAITTAGAL	ICGGLIMCGGAIGAGIC	CIACNALISGVARQPEAQGR	LFTPEFFITVGLVEA	YAYFINLAFMALFVFATPGLO			
Msm_R09	:	MDLDPNAITTAGAL	ICGGLIMCGGAIGAGIC	CIACNALISGVARQPEAQGR	LFTPEFFITVGLVEA	YAYFINLAFMALFVFATPGLO			
Msm_R10	:	MDLDPNAITTAGAL	ICGGLIMCGGAIGAGIC	CIACNALISGVARQPEAQGR	LFTPEFFITVGLVEA	YAYFINLAFMALFVFATPGLO			
Human	:	SRD---	DDTAAKFICACAATVGV	A-GSCAGICTVFGSLITGYARN	PSLKQOLFSTYATLGFAL	SEAMGLFCLMVAFLLIFAM			
		70	*	90	*	110	*	130	*

-2/2-

Fig 3**Fig 4**